BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
benign male breast tumor 2005:2010[pubdate] *count=100
202 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
benign male breast tumor
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 202
1.
Yanik B, Tur BS, Kutlay S:
Metastatic vertebral tumor misdiagnosed in magnetic resonance imaging as benign degenerative bone marrow changes: a case report.
Rheumatol Int
; 2005 Jun;25(5):384-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metastatic vertebral
tumor
misdiagnosed in magnetic resonance imaging as
benign
degenerative bone marrow changes: a case report.
We report a man with low back and right groin pain as a result of metastatic
breast
carcinoma which was misdiagnosed in magnetic resonance imaging as
benign
degenerative changes.
[MeSH-major]
Adenocarcinoma / secondary. Bone Marrow / pathology. Bone Neoplasms / secondary.
Breast
Neoplasms,
Male
/ pathology. Diagnostic Errors. Lumbar Vertebrae / pathology. Magnetic Resonance Imaging
[MeSH-minor]
Humans. Low Back Pain / etiology.
Male
. Middle Aged. Radiography. Radionuclide Imaging
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Radiology. 1985 Oct;157(1):157-66
[
3875878.001
]
[Cites]
Clin Nucl Med. 2000 Aug;25(8):647-9
[
10944033.001
]
[Cites]
Radiology. 1988 Jan;166(1 Pt 1):193-9
[
3336678.001
]
[Cites]
Ann Intern Med. 2002 Oct 15;137(8):678-87
[
12379069.001
]
[Cites]
Cancer. 1987 Mar 15;59(6):1112-6
[
3815285.001
]
[Cites]
Nihon Igaku Hoshasen Gakkai Zasshi. 1992 Dec 25;52(12):1611-9
[
1488288.001
]
[Cites]
AJR Am J Roentgenol. 1990 Jul;155(1):85-8
[
2112871.001
]
(PMID = 15449024.001).
[ISSN]
0172-8172
[Journal-full-title]
Rheumatology international
[ISO-abbreviation]
Rheumatol. Int.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Germany
2.
Chung EM, Cube R, Hall GJ, González C, Stocker JT, Glassman LM:
From the archives of the AFIP: breast masses in children and adolescents: radiologic-pathologic correlation.
Radiographics
; 2009 May-Jun;29(3):907-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
From the archives of the AFIP:
breast
masses in children and adolescents: radiologic-pathologic correlation.
The spectrum of
breast
lesions in children and adolescents varies markedly from that for adults, with the former lesions being overwhelmingly
benign
.
A
breast
mass in a young boy or girl may arise from normal and abnormal
breast
development.
After onset of puberty, most cases of
breast
enlargement arise from
benign
fibroadenoma in girls and gynecomastia in boys.
These conditions have specific imaging appearances, although juvenile (often giant) fibroadenoma cannot be distinguished from phyllodes
tumor
, which can be
benign
or malignant.
A
diagnosis of
juvenile papillomatosis (a
benign
lesion) portends later development of
breast
cancer, and patients with this condition should be closely monitored.
Malignant lesions of the
breast
in children are rare.
The most common primary
breast
malignancy is malignant phyllodes
tumor
.
Primary
breast
carcinoma is exceedingly rare in the pediatric age group, but its imaging appearance in children is the same as seen in adults and is different from that of almost all
benign
lesions.
In girls, diagnostic interventions may injure the developing
breast
and cause subsequent disfigurement.
Given this risk and the low prevalence of malignant disease in this population, a prudent course should be followed in
the diagnosis
of
breast
lesions.
[MeSH-major]
Breast
Diseases / radiography
[MeSH-minor]
Adolescent.
Breast
/ abnormalities.
Breast
/ anatomy & histology.
Breast
/ growth & development.
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms / pathology.
Breast
Neoplasms / radiography.
Breast
Neoplasms,
Male
/
diagnosis
.
Breast
Neoplasms,
Male
/ pathology.
Breast
Neoplasms,
Male
/ radiography.
Breast
Neoplasms,
Male
/ secondary. Carcinoma, Ductal,
Breast
/
diagnosis
. Carcinoma, Ductal,
Breast
/ pathology. Carcinoma, Ductal,
Breast
/ radiography. Carcinoma, Ductal,
Breast
/ ultrasonography. Child. Child, Preschool. Female. Fibroadenoma /
diagnosis
. Fibroadenoma / pathology. Fibroadenoma / radiography. Granular Cell
Tumor
/
diagnosis
. Granular Cell
Tumor
/ pathology. Granular Cell
Tumor
/ radiography. Gynecomastia / pathology. Gynecomastia / radiography. Humans. Infant. Infant, Newborn.
Male
. Nipples / abnormalities. Papilloma /
diagnosis
. Papilloma / pathology. Papilloma / radiography. Phyllodes
Tumor
/
diagnosis
. Phyllodes
Tumor
/ pathology. Phyllodes
Tumor
/ radiography. Puberty. Puberty, Precocious /
diagnosis
. Young Adult
MedlinePlus Health Information.
consumer health - Breast Diseases
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19448124.001).
[ISSN]
1527-1323
[Journal-full-title]
Radiographics : a review publication of the Radiological Society of North America, Inc
[ISO-abbreviation]
Radiographics
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
90
3.
Bianco C, Strizzi L, Mancino M, Rehman A, Hamada S, Watanabe K, De Luca A, Jones B, Balogh G, Russo J, Mailo D, Palaia R, D'Aiuto G, Botti G, Perrone F, Salomon DS, Normanno N:
Identification of cripto-1 as a novel serologic marker for breast and colon cancer.
Clin Cancer Res
; 2006 Sep 1;12(17):5158-64
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Identification of cripto-1 as a novel serologic marker for
breast
and colon cancer.
We evaluated whether CR-1 is present in the plasma of patients with
breast
and colon cancer, and if it can represent a new biomarker for these malignancies.
EXPERIMENTAL DESIGN: We determined CR-1 plasma levels using a sandwich-type ELISA in 21 healthy volunteers, 54 patients with
breast
cancer, 33 patients with colon carcinoma, and 21 patients with
benign breast
lesions.
A statistically significant increase in the levels of plasma CR-1 was found in patients with colon carcinoma (4.68+/-3.5 ng/mL) and in patients with
breast
carcinoma (2.97+/-1.48 ng/mL; P<0.001).
Although moderate levels of plasma CR-1 were found in women with
benign
lesions of the
breast
(1.7+/-0.99 ng/mL), these levels were significantly lower than in patients with
breast
cancer (P<0.001).
Finally, immunohistochemical analysis and real-time reverse transcription-PCR confirmed strong positivity for CR-1 in colon and/or
breast tumor
tissues.
CONCLUSION: This study suggests that plasma CR-1 might represent a novel biomarker for the detection of
breast
and colon carcinomas.
[MeSH-major]
Biomarkers,
Tumor
/ blood.
Breast
Neoplasms / blood.
Breast
Neoplasms /
diagnosis
. Colonic Neoplasms / blood. Colonic Neoplasms /
diagnosis
. Epidermal Growth Factor / blood. Membrane Glycoproteins / blood.
Neoplasm
Proteins / blood
[MeSH-minor]
Animals. Enzyme-Linked Immunosorbent Assay / methods. Female. GPI-Linked Proteins. Humans. Immunohistochemistry / methods. Intercellular Signaling Peptides and Proteins.
Male
. Mice. Mice, Transgenic.
Neoplasm
Staging. Reverse Transcriptase Polymerase Chain Reaction / methods. Sensitivity and Specificity
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16951234.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / Intramural NIH HHS / /
[Publication-type]
Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins; 0 / TDGF1 protein, human; 62229-50-9 / Epidermal Growth Factor
Advertisement
4.
Lan Y, Zhang Y, Wang J, Lin C, Ittmann MM, Wang F:
Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death.
Int J Cancer
; 2008 Aug 1;123(3):543-51
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Forced expression of Cks1 and Cks2 in
benign
prostate
tumor
epithelial cells promoted cell population growth.
Knockdown of Cks1 expression in malignant prostate
tumor
cells inhibited proliferation, anchorage-independent growth, and migration activities, whereas knockdown of Cks2 expression induced programmed cell death and inhibited the tumorigenicity.
Collectively, the data suggest that elevated expression of Cks1 contributes to the tumorigenicity of prostate
tumor
cells by promoting cell growth and elevated expression of Cks2 protects the cells from apoptosis.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oral Oncol. 2005 Feb;41(2):105-16
[
15695111.001
]
[Cites]
Mol Gen Genet. 1986 Feb;202(2):291-3
[
3010051.001
]
[Cites]
Mol Cell Biol. 1989 May;9(5):2034-41
[
2664468.001
]
[Cites]
Genes Dev. 1990 Aug;4(8):1332-44
[
2227411.001
]
[Cites]
Cancer Res. 1997 Aug 15;57(16):3325-30
[
9269988.001
]
[Cites]
Cancer Res. 1997 Dec 1;57(23):5369-78
[
9393762.001
]
[Cites]
Prog Nucleic Acid Res Mol Biol. 1998;59:135-76
[
9427842.001
]
[Cites]
Int J Cancer. 1999 Jul 2;82(1):98-104
[
10360827.001
]
[Cites]
Am J Pathol. 2004 Dec;165(6):2147-55
[
15579456.001
]
[Cites]
J Biol Chem. 2004 Dec 31;279(53):55348-54
[
15513912.001
]
[Cites]
Cancer Cell. 2005 Jan;7(1):51-63
[
15652749.001
]
[Cites]
Oncogene. 2006 Jan 12;25(2):310-6
[
16116475.001
]
[Cites]
Int J Cancer. 2006 May 15;118(10):2461-9
[
16353136.001
]
[Cites]
Int J Cancer. 2006 Aug 1;119(3):599-607
[
16572426.001
]
[Cites]
Genes Dev. 2006 Jun 1;20(11):1511-24
[
16705040.001
]
[Cites]
Oncol Rep. 2006 Sep;16(3):521-31
[
16865252.001
]
[Cites]
Cancer. 2006 Aug 15;107(4):668-75
[
16826582.001
]
[Cites]
Cancer Res. 2006 Oct 15;66(20):9986-94
[
17047061.001
]
[Cites]
J Urol. 2006 Nov;176(5):2285-9
[
17070313.001
]
[Cites]
Int J Oncol. 2006 Dec;29(6):1337-47
[
17088971.001
]
[Cites]
J Biol Chem. 2007 Jan 5;282(1):390-6
[
17092932.001
]
[Cites]
Development. 2007 Feb;134(4):723-34
[
17215304.001
]
[Cites]
FEBS Lett. 2007 Mar 20;581(6):1166-72
[
17336302.001
]
[Cites]
Mod Pathol. 2007 Apr;20(4):497-507
[
17384652.001
]
[Cites]
Breast Cancer Res. 2007;9(2):R25
[
17428314.001
]
[Cites]
Cancer. 2005 Apr 1;103(7):1336-46
[
15717322.001
]
[Cites]
J Biol Chem. 2007 Aug 10;282(32):23716-24
[
17569667.001
]
[Cites]
Br J Cancer. 2005 Jun 20;92(12):2249-61
[
15900300.001
]
[Cites]
Oncogene. 2005 Jul 7;24(29):4672-87
[
15940270.001
]
[Cites]
Oncogene. 2005 Aug 4;24(33):5246-51
[
15897880.001
]
[Cites]
Breast Cancer Res. 2005;7(5):R737-44
[
16168119.001
]
[Cites]
Nat Cell Biol. 2006 Jan;8(1):17-26
[
16341208.001
]
[Cites]
Exp Cell Res. 2001 Mar 10;264(1):148-68
[
11237531.001
]
[Cites]
Nat Cell Biol. 2001 Mar;3(3):321-4
[
11231585.001
]
[Cites]
Mol Cell. 2001 Mar;7(3):639-50
[
11463388.001
]
[Cites]
Semin Cancer Biol. 2003 Feb;13(1):41-7
[
12507555.001
]
[Cites]
Prostate. 2003 May 15;55(3):219-37
[
12692788.001
]
[Cites]
Cell Cycle. 2003 Jan-Feb;2(1):59-63
[
12695690.001
]
[Cites]
Science. 2003 Apr 25;300(5619):647-50
[
12714746.001
]
[Cites]
Cancer Res. 2003 Aug 15;63(16):4936-44
[
12941818.001
]
[Cites]
Cancer Res. 2003 Dec 15;63(24):8784-90
[
14695195.001
]
[Cites]
Nat Rev Cancer. 2003 Dec;3(12):921-30
[
14737122.001
]
[Cites]
Lab Invest. 2004 May;84(5):588-96
[
15064772.001
]
[Cites]
Genes Dev. 2004 Apr 15;18(8):862-76
[
15078817.001
]
[Cites]
EMBO J. 1987 Nov;6(11):3507-14
[
3322810.001
]
(PMID = 18498131.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA096824-01A1; United States / NCI NIH HHS / CA / R01 CA096824-01A1; United States / NCI NIH HHS / CA / CA096824-05; United States / NCI NIH HHS / CA / R01 CA096824-05; United States / NCI NIH HHS / CA / R56 CA096824; United States / NCI NIH HHS / CA / CA096824; United States / NCI NIH HHS / CA / R01 CA096824
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / CKS1B protein, human; 0 / CKS2 protein, human; 0 / Carrier Proteins; 0 / Cell Cycle Proteins; 0 / DNA, Complementary; 0 / RNA, Messenger; EC 2.7.- / Protein Kinases; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / CDC28 Protein Kinase, S cerevisiae; EC 2.7.11.22 / Cks1 protein, mouse; EC 2.7.11.22 / Cks2 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinases
[Other-IDs]
NLM/ NIHMS93124; NLM/ PMC3262990
5.
Jung EM, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F:
Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: a prospective controlled two-center study.
World J Gastroenterol
; 2007 Dec 21;13(47):6356-64
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: One hundred patients with histologically confirmed malignant or
benign
hepatic
tumor
(maximum size 5 cm) were analyzed.
The cut-off of the gray value differences between
tumor
and normal liver tissue was established using Receiver Operating Characteristic (ROC) analysis 64-line multi-slice computed tomography served as reference method in all cases.
RESULTS: One hundred patients with 59 malignant (43 colon, 5
breast
, 2 endocrine metastases, 7 hepatocellular carcinomas and 2 kidney cancers) and 41
benign
(15 hemangiomas, 7 focal nodular hyperplasias, 5 complicated cysts, 2 abscesses and 12 circumscribed fatty changes) tumors were included.
The late venous phase proved to be the most sensitive for classification of the
tumor
type.
Of the 41
benign
tumors, 37 were classified as true negative and 4 as false negative, which corresponds to a specificity of 90.2%.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Germany. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Angiography.
Male
. Middle Aged. Observer Variation. Predictive Value of Tests. Prospective Studies. ROC Curve. Reproducibility of Results. Sensitivity and Specificity. Time Factors. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - Liver Cancer
.
Hazardous Substances Data Bank.
SULFUR HEXAFLUORIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18081224.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Controlled Clinical Trial; Evaluation Studies; Journal Article; Multicenter Study
[Publication-country]
China
[Chemical-registry-number]
0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
[Other-IDs]
NLM/ PMC4205454
6.
Pruthi RS, Lentz AC, Sand M, Kouba E, Wallen EM:
Impact of marital status in patients undergoing radical cystectomy for bladder cancer.
World J Urol
; 2009 Aug;27(4):573-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PURPOSE: Married (vs. unmarried) individuals have improved health status and longer life expectancies in a variety of
benign
and malignant disease states, including prostate,
breast
, head/neck, and lung cancers.
Married individuals (vs. unmarried) were more often
male
(84 vs. 62%) and had a higher BMI (28.1 vs. 25.9).
These findings may support the evidence (observed in other
tumor
types and other disease states) that married persons present earlier than unmarried individuals, and this may help explain the improved survival outcomes that have been observed in married patients with bladder cancer.
[MeSH-major]
Carcinoma, Transitional Cell /
diagnosis
. Carcinoma, Transitional Cell / surgery. Cystectomy. Marital Status. Urinary Bladder Neoplasms /
diagnosis
. Urinary Bladder Neoplasms / surgery
[MeSH-minor]
Aged. Cohort Studies. Creatinine / blood. Female. Follow-Up Studies. Hematocrit. Humans. Length of Stay.
Male
. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome
Genetic Alliance.
consumer health - Bladder cancer
.
MedlinePlus Health Information.
consumer health - Bladder Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer. 2005 Sep 15;104(6):1188-94
[
16078264.001
]
[Cites]
Soc Sci Med. 2003 Dec;57(11):2137-47
[
14512244.001
]
[Cites]
Psychooncology. 2008 Sep;17(9):869-76
[
18033697.001
]
[Cites]
J Urol. 1996 Nov;156(5):1696-70
[
8863573.001
]
[Cites]
Ann Epidemiol. 2000 May;10(4):224-38
[
10854957.001
]
[Cites]
Health Psychol. 1988;7(3):269-97
[
3289916.001
]
[Cites]
Lancet. 1989 Oct 14;2(8668):888-91
[
2571815.001
]
[Cites]
JAMA. 1987 Dec 4;258(21):3125-30
[
3669259.001
]
[Cites]
World J Surg. 2003 Mar;27(3):304-8
[
12607056.001
]
[Cites]
Am J Epidemiol. 1982 Jul;116(1):123-40
[
7102648.001
]
(PMID = 19219612.001).
[ISSN]
1433-8726
[Journal-full-title]
World journal of urology
[ISO-abbreviation]
World J Urol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
AYI8EX34EU / Creatinine
7.
Alemán C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF:
Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions.
Med Clin (Barc)
; 2009 Oct 3;133(12):449-53
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Pleural fluid mesothelin for the differential
diagnosis of
exudative pleural effusions.
BACKGROUND: Malignant mesothelioma (MM) is a highly aggressive
tumor
that can be difficult to diagnose, resulting in a delayed
diagnosis
in some cases.
Recent studies have reported that determination of soluble mesothelin-related peptides (SMRP) in pleural fluid may be a promising marker for use in
the diagnosis
of MM.
PATIENTS AND METHODS: Pleural fluid SMRP concentration was measured in 68 patients: 47 had malignant pleural effusions (18 MM and 29 metastatic effusion) and 21 had
benign
pleural effusion (8 infectious disease and 13 idiopathic effusion).
Mann
-Whitney analysis was used to compare SMRP values according to the etiology of the effusion.
RESULTS: Pleural fluid SMRP concentration was significantly higher in patients with malignant pleural effusion than in those with
benign
effusion (P=0.02).
CONCLUSIONS: Soluble mesothelin-related peptide measurement in pleural fluid may aid in
the diagnosis
of patients presenting with pleural effusion.
[MeSH-major]
Adenocarcinoma /
diagnosis
.
Breast
Neoplasms /
diagnosis
. Carcinoma, Small Cell /
diagnosis
. Hematologic Neoplasms /
diagnosis
. Lung Neoplasms /
diagnosis
. Membrane Glycoproteins / analysis. Mesothelioma /
diagnosis
. Ovarian Neoplasms /
diagnosis
. Pancreatic Neoplasms /
diagnosis
. Pleural Effusion /
diagnosis
. Pleural Effusion, Malignant /
diagnosis
[MeSH-minor]
Biomarkers.
Diagnosis
, Differential. Female. GPI-Linked Proteins. Humans.
Male
. Prospective Studies. Sensitivity and Specificity. Statistics, Nonparametric
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Mesothelioma
.
MedlinePlus Health Information.
consumer health - Ovarian Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19783262.001).
[ISSN]
0025-7753
[Journal-full-title]
Medicina clínica
[ISO-abbreviation]
Med Clin (Barc)
[Language]
eng
[Publication-type]
Comparative Study; Evaluation Studies; Journal Article
[Publication-country]
Spain
[Chemical-registry-number]
0 / Biomarkers; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
8.
Dupuis C, Coard KC:
A review of granular cell tumours at the University Hospital of the West Indies: 1965-2006.
West Indian Med J
; 2009 Mar;58(2):138-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
They are usually
benign
, but as they are infrequently diagnosed preoperatively, they may be confused clinically with malignant lesions.
Of these, 99patients were female and 23
male
, providing a
male
:female ratio of l to 4.3.
Lesions ranged in size from 0.2 cm to 10 cm in greatest dimension, the average size being 1.85 cm and were found in a diverse array of anatomic locations, the most common being the vulva,
breast
and tongue.
The correct clinical
diagnosis
was proffered preoperatively in only one case.
In contrast, a malignant
diagnosis
was suggested in 19 cases.
In particular lesions of the tongue accounted for fewer than expected, while lesions of the
breast
and vulva were considerably increased.
[MeSH-major]
Granular Cell
Tumor
/ epidemiology. Granular Cell
Tumor
/ pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over.
Breast
Neoplasms / epidemiology. Child. Child, Preschool. Female. Hospitals, University. Humans. Infant. Infant, Newborn.
Male
. Middle Aged. Tongue Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology. West Indies / epidemiology. Young Adult
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21866599.001).
[ISSN]
0043-3144
[Journal-full-title]
The West Indian medical journal
[ISO-abbreviation]
West Indian Med J
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Jamaica
9.
Behera MA, Dai Q, Garde R, Saner C, Jungheim E, Price TM:
Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells.
Am J Physiol Endocrinol Metab
; 2009 Nov;297(5):E1089-96
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A
benign breast
epithelial cells.
The effects of progesterone on
breast
epithelial cells remain poorly defined with observations showing both proliferative and antiproliferative effects.
The release of paracrine growth factors from nuclear receptor-positive cells has been postulated as a mechanism, since in vitro studies show a lack of growth effect by progesterone in
breast
epithelial cells lacking nuclear receptors.
This study examined possible nongenomic effects of progesterone in
breast
epithelia by using MCF-10A cells known to lack nuclear progesterone receptor expression.
Our study demonstrates a nongenomic action of progesterone on
benign breast
epithelial cells, resulting in enhanced cellular respiration and protection from apoptosis.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
Hazardous Substances Data Bank.
PROGESTERONE
.
Hazardous Substances Data Bank.
CYCLOHEXIMIDE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Mol Cell Cardiol. 1995 Oct;27(10):2167-76
[
8576933.001
]
[Cites]
Genes Dev. 1995 Sep 15;9(18):2266-78
[
7557380.001
]
[Cites]
Breast Cancer Res Treat. 1997 Sep;45(2):121-33
[
9342437.001
]
[Cites]
Exp Cell Res. 1997 Oct 10;236(1):223-30
[
9344602.001
]
[Cites]
Cancer Res. 1997 Nov 15;57(22):4987-91
[
9371488.001
]
[Cites]
J Biol Chem. 1999 Apr 30;274(18):12567-75
[
10212235.001
]
[Cites]
Breast Cancer Res Treat. 1999 Feb;53(3):217-27
[
10369068.001
]
[Cites]
J Steroid Biochem Mol Biol. 2005 Nov;97(3):278-88
[
16154741.001
]
[Cites]
Dev Cell. 2005 Dec;9(6):843-54
[
16326395.001
]
[Cites]
J Steroid Biochem Mol Biol. 2006 Feb;98(2-3):174-8
[
16413775.001
]
[Cites]
J Biol Chem. 2006 Mar 3;281(9):5837-44
[
16407197.001
]
[Cites]
J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27
[
16466914.001
]
[Cites]
Carcinogenesis. 2006 May;27(5):925-35
[
16361271.001
]
[Cites]
Apoptosis. 2006 Apr;11(4):473-85
[
16532373.001
]
[Cites]
Biochim Biophys Acta. 2006 May-Jun;1757(5-6):509-17
[
16829228.001
]
[Cites]
Maturitas. 2006 Jul 20;54(4):327-34
[
16806749.001
]
[Cites]
Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83
[
16460873.001
]
[Cites]
Mol Endocrinol. 2006 Dec;20(12):3146-64
[
16959873.001
]
[Cites]
FEBS J. 2007 Mar;274(6):1393-418
[
17302740.001
]
[Cites]
Endocrinology. 2007 Jun;148(6):2723-36
[
17332059.001
]
[Cites]
Cell Prolif. 2007 Oct;40(5):721-40
[
17877612.001
]
[Cites]
Biol Chem. 2007 Oct;388(10):1113-9
[
17937626.001
]
[Cites]
Mitochondrion. 2007 Dec;7(6):399-401
[
17881297.001
]
[Cites]
Methods. 2008 Mar;44(3):222-8
[
18314052.001
]
[Cites]
Breast. 2008 Apr;17(2):172-9
[
17928227.001
]
[Cites]
Cell Res. 2009 Jan;19(1):140-8
[
19079362.001
]
[Cites]
J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65
[
10599719.001
]
[Cites]
Cancer Res. 2000 Feb 15;60(4):867-72
[
10706096.001
]
[Cites]
Cancer Res. 2000 Feb 15;60(4):936-43
[
10706108.001
]
[Cites]
Oncology. 2000;59 Suppl 1:39-44
[
11096355.001
]
[Cites]
Mol Endocrinol. 2001 Feb;15(2):255-70
[
11158332.001
]
[Cites]
Mol Cell Endocrinol. 2001 Jun 20;179(1-2):97-103
[
11420134.001
]
[Cites]
Endocrinology. 2002 Aug;143(8):3071-82
[
12130573.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2002 Jan;7(1):93-105
[
12160089.001
]
[Cites]
Nat Rev Cancer. 2002 Jun;2(6):420-30
[
12189384.001
]
[Cites]
Breast Cancer Res. 2002;4(5):187-90
[
12223122.001
]
[Cites]
Mol Endocrinol. 2003 Jan;17(1):117-27
[
12511611.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2231-6
[
12574519.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2237-42
[
12601167.001
]
[Cites]
Mol Cell Endocrinol. 2003 Feb 28;200(1-2):155-63
[
12644308.001
]
[Cites]
J Steroid Biochem Mol Biol. 2002 Dec;83(1-5):25-30
[
12650698.001
]
[Cites]
Biochim Biophys Acta. 2004 Jul 23;1658(1-2):141-7
[
15282185.001
]
[Cites]
Proc Natl Acad Sci U S A. 1974 Aug;71(8):2942-5
[
4528490.001
]
[Cites]
Nature. 1975 Feb 27;253(5494):746-7
[
1113869.001
]
[Cites]
Cancer Res. 1978 Aug;38(8):2434-7
[
667841.001
]
[Cites]
Exp Cell Res. 1988 Sep;178(1):143-53
[
3409975.001
]
[Cites]
Cancer Res. 1990 Sep 15;50(18):6075-86
[
1975513.001
]
[Cites]
Mol Endocrinol. 1990 Dec;4(12):1833-40
[
2082185.001
]
[Cites]
Cancer Res. 1994 Jan 15;54(2):340-3
[
8275464.001
]
[Cites]
Cancer Res. 1994 Jul 15;54(14):3868-77
[
8033109.001
]
[Cites]
J Exp Med. 1994 Sep 1;180(3):917-23
[
8064240.001
]
[Cites]
Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8
[
9024102.001
]
(PMID = 19690070.001).
[ISSN]
1522-1555
[Journal-full-title]
American journal of physiology. Endocrinology and metabolism
[ISO-abbreviation]
Am. J. Physiol. Endocrinol. Metab.
[Language]
ENG
[Grant]
United States / NICHD NIH HHS / HD / 1R03HD-052770-01
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD95; 0 / Inhibitor of Differentiation Protein 1; 0 / Protein Synthesis Inhibitors; 0 / Receptors, Progesterone; 0 / Transforming Growth Factor beta1; 4G7DS2Q64Y / Progesterone; 8L70Q75FXE / Adenosine Triphosphate; 98600C0908 / Cycloheximide; EC 3.4.21.- / Kallikreins; EC 3.4.22.- / Caspases; EC 3.4.24.- / Matrix Metalloproteinases
10.
Hossain D, Meiers I, Qian J, MacLennan GT, Bostwick DG:
Prostatic stromal hyperplasia with atypia: follow-up study of 18 cases.
Arch Pathol Lab Med
; 2008 Nov;132(11):1729-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: Prostatic stromal hyperplasia with atypia consists of 1 or more ill-defined, uncircumscribed, hyperplastic stromal nodules, with variable numbers of atypical, bizarre giant cells, with vacuolated nuclei, smudged chromatin, and frequent multinucleation infiltrating around
benign
acini.
CONCLUSIONS: Prostatic stromal hyperplasia with atypia is a rare,
benign
lesion, composed of degenerative myocytes with atypia that is histologically and clinically reminiscent of
benign
counterparts in the myometrium,
breast
, vulva, vagina, and elsewhere.
Recognition of this distinctive entity should allow separation from phyllodes
tumor
and sarcoma of the prostate.
The phrase stromal
tumor
of uncertain malignant potential is inappropriate for this
benign tumor
, and its use is discouraged.
[MeSH-major]
Prostatic Hyperplasia /
diagnosis
. Prostatic Hyperplasia / pathology. Stromal Cells / pathology
[MeSH-minor]
Aged. Aged, 80 and over. Cell Nucleus / pathology.
Diagnosis
, Differential. Follow-Up Studies. Humans.
Male
. Middle Aged. Muscle Cells / metabolism. Muscle Cells / pathology. Receptors, Androgen / metabolism. Retrospective Studies. Vimentin / metabolism
MedlinePlus Health Information.
consumer health - Enlarged Prostate (BPH)
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18976007.001).
[ISSN]
1543-2165
[Journal-full-title]
Archives of pathology & laboratory medicine
[ISO-abbreviation]
Arch. Pathol. Lab. Med.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, Androgen; 0 / Vimentin
11.
Lauwers K, Bestman TJ, Bergmans G, Molderez C:
Granular cell tumour of the male breast.
Acta Chir Belg
; 2008 Jan-Feb;108(1):112-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Granular cell tumour of the
male breast
.
Granular cell tumour (GCT) is a rare
neoplasm
that can be found in multiple sites throughout the body.
Occasionally GCT is located in the
breast
.
In general, it appears as a singular
benign
lesion, although it can be multi-focal and rare cases with malignant behaviour have been reported.
We report a rare case of granular cell tumour of the nipple in the
male breast
, treated by wide local excision.
[MeSH-major]
Breast
Neoplasms,
Male
/ surgery. Granular Cell
Tumor
/ surgery
[MeSH-minor]
Aged. Humans. Immunohistochemistry.
Male
. Nipples
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18411585.001).
[ISSN]
0001-5458
[Journal-full-title]
Acta chirurgica Belgica
[ISO-abbreviation]
Acta Chir. Belg.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Belgium
12.
Abaffy T, Duncan R, Riemer DD, Tietje O, Elgart G, Milikowski C, DeFazio RA:
Differential volatile signatures from skin, naevi and melanoma: a novel approach to detect a pathological process.
PLoS One
; 2010 Nov 04;5(11):e13813
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Discovering new melanoma biomarkers would improve early detection and
diagnosis
.
Volatiles released from fresh biopsy tissue of melanoma and
benign
naevus were compared based on their difference in frequency distribution and their expression level.
MedlinePlus Health Information.
consumer health - Birthmarks
.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Moles
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Anal Chem. 2000 Feb 15;72(4):747-56
[
10701259.001
]
[Cites]
J Am Chem Soc. 2010 Mar 24;132(11):3642-3
[
20196537.001
]
[Cites]
Philos Trans R Soc Lond B Biol Sci. 2002 Jan 29;357(1417):17-23
[
11839178.001
]
[Cites]
Breast J. 2003 May-Jun;9(3):184-91
[
12752626.001
]
[Cites]
Trends Biochem Sci. 2003 Jun;28(6):329-35
[
12826405.001
]
[Cites]
Cancer Treat Rev. 2003 Dec;29(6):489-99
[
14585259.001
]
[Cites]
Lancet. 2004 Feb 28;363(9410):728-30
[
15005091.001
]
[Cites]
Prev Med. 2004 Apr;38(4):382-7
[
15020171.001
]
[Cites]
Environ Health Perspect. 2004 May;112(7):A396-7
[
15159211.001
]
[Cites]
Nat Rev Cancer. 2004 Jul;4(7):551-61
[
15229480.001
]
[Cites]
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 5;808(2):269-77
[
15261821.001
]
[Cites]
Nature. 1966 Nov 26;212(5065):933-5
[
4306794.001
]
[Cites]
J Biol Chem. 1980 Nov 10;255(21):10493-501
[
7430132.001
]
[Cites]
Anticancer Res. 1985 Jan-Feb;5(1):1-30
[
3888043.001
]
[Cites]
Mutat Res. 1989 Jan;219(1):71-9
[
2911273.001
]
[Cites]
Biochem Pharmacol. 1995 Dec 22;50(12):1955-62
[
8849320.001
]
[Cites]
Science. 1996 Jul 5;273(5271):59-63
[
8658196.001
]
[Cites]
J Biol Chem. 1997 May 2;272(18):11895-901
[
9115250.001
]
[Cites]
Nucleic Acids Res. 1999 Jun 1;27(11):2291-8
[
10325416.001
]
[Cites]
Cancer Res. 1999 Aug 15;59(16):3855-60
[
10463569.001
]
[Cites]
J Invest Dermatol. 1964 Aug;43:111-3
[
14196302.001
]
[Cites]
Biochemistry. 2004 Nov 16;43(45):14332-9
[
15533037.001
]
[Cites]
Nature. 2005 Aug 4;436(7051):720-4
[
16079850.001
]
[Cites]
J Invest Dermatol. 2006 Dec;126(12):2565-75
[
17108903.001
]
[Cites]
Mass Spectrom Rev. 2007 Jan-Feb;26(1):51-78
[
16921475.001
]
[Cites]
Nature. 2007 Feb 22;445(7130):843-50
[
17314970.001
]
[Cites]
Am J Clin Nutr. 2007 Apr;85(4):946-9
[
17413090.001
]
[Cites]
Cancer Biomark. 2007;3(2):95-109
[
17522431.001
]
[Cites]
Int J Epidemiol. 2008 Apr;37 Suppl 1:i23-30
[
18381390.001
]
[Cites]
Skin Res Technol. 2008 May;14(2):226-36
[
18412567.001
]
[Cites]
PLoS Med. 2008 Jun 3;5(6):e120
[
18532874.001
]
[Cites]
J Thorac Oncol. 2008 Jul;3(7):774-80
[
18594325.001
]
[Cites]
Int J Cancer. 2008 Nov 15;123(10):2446-55
[
18729182.001
]
[Cites]
Br J Dermatol. 2008 Sep;159(4):780-91
[
18637798.001
]
[Cites]
J Am Chem Soc. 2008 Oct 29;130(43):14111-3
[
18831549.001
]
[Cites]
Nature. 2008 Oct 23;455(7216):1054-6
[
18948945.001
]
[Cites]
Lung Cancer. 2009 Feb;63(2):164-8
[
18599152.001
]
[Cites]
Can Fam Physician. 2009 Jan;55(1):24; autor reply 24
[
19155361.001
]
[Cites]
Anal Bioanal Chem. 2009 Feb;393(3):781-95
[
18836706.001
]
[Cites]
Nature. 2009 Feb 12;457(7231):910-4
[
19212411.001
]
[Cites]
J Am Soc Mass Spectrom. 2009 Mar;20(3):464-8
[
19070510.001
]
[Cites]
Am J Pathol. 2009 Apr;174(4):1524-33
[
19342374.001
]
[Cites]
Nat Rev Genet. 2009 May;10(5):295-304
[
19308066.001
]
[Cites]
Cancer Control. 2009 Jul;16(3):200-18
[
19556960.001
]
[Cites]
Eur Respir J. 2009 Jul;34(1):261-75
[
19567608.001
]
[Cites]
BMC Cancer. 2009;9:348
[
19788722.001
]
[Cites]
Pigment Cell Melanoma Res. 2009 Dec;22(6):750-60
[
19735457.001
]
[Cites]
Pigment Cell Melanoma Res. 2010 Feb;23(1):64-71
[
19788535.001
]
[Cites]
Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):613-20
[
20143319.001
]
[Cites]
J Invest Dermatol. 2001 Apr;116(4):520-4
[
11286617.001
]
(PMID = 21079799.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA132046-02; United States / NCI NIH HHS / CA / R21 CA132046; United States / NCI NIH HHS / CA / R21CA 132046; United States / NCI NIH HHS / CA / R21 CA132046-01A1; United States / NCI NIH HHS / CA / R21 CA132046-02
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Volatile Organic Compounds
[Other-IDs]
NLM/ PMC2973952
13.
Karam M, Roberts-Klein S, Shet N, Chang J, Feustel P:
Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with benign and malignant etiology.
J Nucl Med
; 2008 Sep;49(9):1429-36
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Bilateral hilar foci on 18F-FDG PET scan in patients without lung cancer: variables associated with
benign
and malignant etiology.
Our objective was to evaluate features of these foci associated with
benign
or malignant etiology.
Variables evaluated were maximum standard uptake values (SUV max), purity (absence of (18)F-FDG-avid foci in nonhilar mediastinal nodes), symmetry (difference between left and right side SUV max), the primary
tumor
, node size determined by CT, and, in those who participated in 2 studies, stability of uptake over time.
The gold standard was histologic
diagnosis
or long-term clinical follow-up (range, 19-41 mo; mean, 25 mo).
On univariate analysis, variables associated with malignancy were SUV max (6.6+/-4.1 vs. 3.5+/-1.0 for
benign
, P<0.001; t test); impurity (P<0.001; chi(2) test), with 79% of impure scans versus 18% of pure scans being malignant; node size determined by CT (P=0.027); and change in uptake between scans 1 and 2 (change in SUV=2.7+/-2.1 vs. 0.73+/-1.1 for
benign
, P < 0.01; t test).
Variables associated with
benign
etiology were: symmetry (difference between left and right sides=0.57+/-0.54 for
benign
vs. 1.8+/-1.7 for malignant, P<0.01), purity, and colorectal primary (75% of colorectal were
benign
vs. 34% of
breast
, 49% of lymphoma, and 37% of other, P=0.030; chi(2) test).
CONCLUSION: In patients with nonlung cancer, in particular colorectal, foci of symmetric and mild uptake limited to the hilar regions that are stable on 2 sequential PET studies despite intervening anticancer therapy are likely related to a
benign
etiology.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans.
Male
. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity
Genetic Alliance.
consumer health - Lung Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Nucl Med. 2009 Mar;50(3):489-90
[
19223415.001
]
(PMID = 18765585.001).
[ISSN]
0161-5505
[Journal-full-title]
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
[ISO-abbreviation]
J. Nucl. Med.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
14.
Jeryong K, Jinsun L, Hyegyong K, Eilsung C, Jiyoung S, Insang S, Moonsang A, Jiyeon K, Jaeeun H:
Total endoscopic thyroidectomy with bilateral breast areola and ipsilateral axillary (BBIA) approach.
World J Surg
; 2008 Nov;32(11):2488-93
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Total endoscopic thyroidectomy with bilateral
breast
areola and ipsilateral axillary (BBIA) approach.
The present study reviews our experiences with endoscopic thyroidectomy using bilateral
breast
areola and ipsilateral axillary (BBIA) approach to evaluate its safety and feasibility.
METHODS: From June 2003 through November 2007, the study group was comprised of 68 consecutive patients with
benign
thyroid nodules (66 women; mean age, 33.28 +/- 10.3 (range, 15-72) years).
RESULTS: The mean maximum diameter of the
tumor
was 3.14 +/- 1.61 (range, 1-10.7) cm.
[MeSH-minor]
Adolescent. Adult. Aged. Cohort Studies. Feasibility Studies. Female. Humans. Length of Stay.
Male
. Middle Aged. Nipples. Retrospective Studies. Treatment Outcome. Young Adult
MedlinePlus Health Information.
consumer health - Endoscopy
.
MedlinePlus Health Information.
consumer health - Thyroid Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Laryngoscope. 2006 Oct;116(10):1745-8
[
17003721.001
]
[Cites]
Thyroid. 2002 Aug;12(8):703-6
[
12225638.001
]
[Cites]
Am J Surg. 2001 Jun;181(6):567-70
[
11513788.001
]
[Cites]
J Surg Oncol. 1998 Nov;69(3):178-80
[
9846506.001
]
[Cites]
Surg Endosc. 2002 Dec;16(12 ):1741-5
[
12140635.001
]
[Cites]
Am J Surg. 2000 Aug;180(2):82-5
[
11044518.001
]
[Cites]
Anesth Analg. 1997 May;84(5):1154-6
[
9141952.001
]
[Cites]
Biomed Pharmacother. 2002;56 Suppl 1:68s-71s
[
12487256.001
]
[Cites]
World J Surg. 2004 Nov;28(11):1075-8
[
15490052.001
]
[Cites]
J Am Coll Surg. 2003 Feb;196(2):189-95
[
12595044.001
]
[Cites]
Anesth Analg. 2000 Mar;90(3):760-2
[
10702471.001
]
[Cites]
Br J Surg. 1996 Jun;83(6):875
[
8696772.001
]
[Cites]
Surg Laparosc Endosc. 1994 Apr;4(2):92-9
[
8180774.001
]
[Cites]
Biomed Pharmacother. 2002;56 Suppl 1:64s-67s
[
12487255.001
]
[Cites]
Surgery. 2000 Dec;128(6):1035-42
[
11114640.001
]
[Cites]
J Am Coll Surg. 2000 Sep;191(3):336-40
[
10989910.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4
[
10872517.001
]
(PMID = 18668282.001).
[ISSN]
0364-2313
[Journal-full-title]
World journal of surgery
[ISO-abbreviation]
World J Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
15.
Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D'Amico C, Leto G:
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C.
Med Oncol
; 2009;26(1):10-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The clinical significance of serum interleukin-6 (IL-6) and its correlation with cystatin C (Cyst C), an endogenous inhibitor of cysteine proteinase cathepsin K, was investigated by immunoassays in patients with bone metastasis from
breast
cancer (BCa) or prostate cancer (PCa).
Mean IL-6 levels were also higher in PCa patients and in patients with
benign
prostatic hyperplasia (BPH) than in HS while Cyst C resulted significantly higher in PCa but not in BPH patients as compared to HS.
[MeSH-major]
Bone Neoplasms / blood. Bone Neoplasms / secondary.
Breast
Neoplasms / pathology. Cystatin C / blood. Interleukin-6 / blood. Prostatic Neoplasms / pathology
[MeSH-minor]
Aged. Aged, 80 and over. Biomarkers,
Tumor
/ blood. Bone Density Conservation Agents / therapeutic use. Diphosphonates / therapeutic use. Female. Humans. Imidazoles / therapeutic use.
Male
. Middle Aged. Osteoporosis / blood. Osteoporosis / complications. Prostate-Specific Antigen / blood. ROC Curve
MedlinePlus Health Information.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Bone. 2005 Nov;37(5):601-6
[
16112634.001
]
[Cites]
Breast Cancer Res Treat. 2007 Apr;102(2):129-35
[
16927176.001
]
[Cites]
Arthritis Res Ther. 2007;9 Suppl 1:S5
[
17634144.001
]
[Cites]
Anticancer Res. 2006 Jan-Feb;26(1A):23-6
[
16475674.001
]
[Cites]
Pathol Res Pract. 2005;200(11-12):753-62
[
15792117.001
]
[Cites]
Radiology. 1983 Sep;148(3):839-43
[
6878708.001
]
[Cites]
Urology. 2001 Dec;58(6):1008-15
[
11744478.001
]
[Cites]
Bone. 2004 Sep;35(3):689-96
[
15336605.001
]
[Cites]
J Clin Endocrinol Metab. 2001 May;86(5):2032-42
[
11344203.001
]
[Cites]
Int J Biol Markers. 2000 Jan-Mar;15(1):84-9
[
10763147.001
]
[Cites]
Cancer Lett. 2006 Apr 28;235(2):159-76
[
15893421.001
]
[Cites]
Biochimie. 2008 Feb;90(2):208-26
[
17935853.001
]
[Cites]
Oncology. 2005;69(1):35-43
[
16088233.001
]
[Cites]
Br J Cancer. 2004 Jun 14;90(12):2312-6
[
15150588.001
]
[Cites]
Palliat Med. 2003 Sep;17(6):539-53
[
14526888.001
]
[Cites]
Acta Physiol Scand. 1997 Sep;161(1):81-92
[
9381954.001
]
[Cites]
Oncologist. 2004;9(6):687-95
[
15561812.001
]
[Cites]
Radiology. 1982 Apr;143(1):29-36
[
7063747.001
]
[Cites]
Cancer. 2007 Nov 1;110(9):1911-28
[
17849470.001
]
[Cites]
Eur Urol. 2007 May;51(5):1202-16
[
17182170.001
]
[Cites]
Clin Biochem. 2007 Mar;40(5-6):383-91
[
17316593.001
]
[Cites]
Bull World Health Organ. 2001;79(4):373-4
[
11357217.001
]
[Cites]
J Clin Pharmacol. 2002 Nov;42(11):1228-36
[
12412821.001
]
[Cites]
J Chemother. 2005 Oct;17(5):555-9
[
16323446.001
]
[Cites]
BJU Int. 2006 Jul;98(1):189-96
[
16831167.001
]
[Cites]
Bone. 2004 Mar;34(3):412-24
[
15003789.001
]
[Cites]
J Cell Biochem. 2004 Mar 1;91(4):718-29
[
14991763.001
]
[Cites]
Ann Oncol. 2006 Jun;17(6):986-9
[
16533874.001
]
[Cites]
Biochem Biophys Res Commun. 2007 Aug 17;360(1):199-204
[
17592728.001
]
[Cites]
Int J Cancer. 2003 Feb 20;103(5):642-6
[
12494472.001
]
[Cites]
J Cell Biochem. 2005 Jun 1;95(3):497-505
[
15838876.001
]
[Cites]
Prostate. 1999 Jun 1;39(4):246-61
[
10344214.001
]
[Cites]
J Pathol. 2004 Jan;202(1):41-9
[
14694520.001
]
[Cites]
J Endocrinol Invest. 2002 Jun;25(6):539-46
[
12109626.001
]
[Cites]
Cancer Treat Rev. 2008 Apr;34(2):183-92
[
18061356.001
]
[Cites]
Cytokine Growth Factor Rev. 2004 Feb;15(1):49-60
[
14746813.001
]
(PMID = 18461289.001).
[ISSN]
1357-0560
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / Cystatin C; 0 / Diphosphonates; 0 / Imidazoles; 0 / Interleukin-6; 6XC1PAD3KF / zoledronic acid; EC 3.4.21.77 / Prostate-Specific Antigen
16.
Ismail MF, Aly MS, Khaled HM, Mohamed HM:
Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with breast cancer.
Ger Med Sci
; 2009;7:Doc03
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of HER-2/neu, c-myc amplification and p53 inactivation by FISH in Egyptian patients with
breast
cancer.
Breast
cancer is a leading cause of cancer-related deaths in women worldwide.
Amplification of the two oncogenes HER-2/neu and c-myc and inactivation of the
tumor
suppressor gene p53 are frequently encountered in
breast
carcinomas.
The study was conducted on 34 tissue samples obtained from 33 females and 1
male
with
breast
carcinomas and 17 samples obtained from 16 females and 1
male
with
benign breast
lesions.
Results revealed that the level of HER-2/neu, c-myc and p53 in the malignant group was significantly increased as compared to the
benign
group.
The sensitivity of the investigated markers significantly increased with larger
tumor
size.
Concerning
tumor
grade, HER-2/neu and p53 showed a significant increase in low-grade tumors whereas c-myc showed a highly significant increase in high-grade tumors.
[MeSH-major]
Breast
Neoplasms / genetics. In Situ Hybridization, Fluorescence / methods. Proto-Oncogene Proteins c-myc / analysis. Receptor, ErbB-2 / analysis.
Tumor
Suppressor Protein p53 / analysis
[MeSH-minor]
Adolescent. Adult. Aged. Biomarkers,
Tumor
/ analysis. Biopsy.
Breast
Neoplasms,
Male
/
diagnosis
.
Breast
Neoplasms,
Male
/ epidemiology.
Breast
Neoplasms,
Male
/ genetics. Egypt / epidemiology. Female. Humans.
Male
. Middle Aged.
Neoplasm
Staging / methods. Nucleic Acid Amplification Techniques / methods. Prevalence. Young Adult
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Pathol. 2000 Jan;156(1):183-91
[
10623666.001
]
[Cites]
Diagn Mol Pathol. 2007 Dec;16(4):207-10
[
18043283.001
]
[Cites]
Breast Cancer Res Treat. 2000 Feb;59(3):211-21
[
10832591.001
]
[Cites]
Indian J Exp Biol. 2000 Mar;38(3):225-30
[
10927863.001
]
[Cites]
Ann Oncol. 2000 Jun;11(6):647-63
[
10942052.001
]
[Cites]
Acta Oncol. 2000;39(3):327-33
[
10987229.001
]
[Cites]
Endocr Relat Cancer. 2000 Sep;7(3):143-64
[
11021963.001
]
[Cites]
Oncogene. 2000 Dec 11;19(53):6093-101
[
11156522.001
]
[Cites]
Oncogene. 2000 Dec 11;19(53):6102-14
[
11156523.001
]
[Cites]
Int J Cancer. 2001 Jul 20;95(4):266-70
[
11400121.001
]
[Cites]
Tumour Biol. 2001 Sep-Oct;22(5):337-44
[
11553865.001
]
[Cites]
Cancer Res. 2002 Mar 1;62(5):1481-8
[
11888924.001
]
[Cites]
Breast Cancer Res Treat. 2002 Jul;74(1):25-31
[
12150449.001
]
[Cites]
Cancer. 2003 Feb 1;97(3):690-4
[
12548612.001
]
[Cites]
Br J Cancer. 2004 Apr 19;90(8):1612-9
[
15083194.001
]
[Cites]
J Pathol. 2004 Aug;203(4):918-26
[
15258994.001
]
[Cites]
Am J Clin Pathol. 2004 Aug;122(2):246-55
[
15323142.001
]
[Cites]
Nature. 1986 Feb 27-Mar 5;319(6056):783-4
[
3005871.001
]
[Cites]
Science. 1987 Jan 9;235(4785):177-82
[
3798106.001
]
[Cites]
Histopathology. 1991 Nov;19(5):403-10
[
1757079.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5
[
1351679.001
]
[Cites]
Nature. 1992 Jul 2;358(6381):15-6
[
1614522.001
]
[Cites]
Cell Growth Differ. 1993 Jan;4(1):41-7
[
8424905.001
]
[Cites]
Curr Opin Genet Dev. 1995 Feb;5(1):97-104
[
7749333.001
]
[Cites]
J Pathol. 1995 Nov;177(3):225-32
[
8551383.001
]
[Cites]
Oncogene. 1996 Jul 4;13(1):63-72
[
8700555.001
]
[Cites]
Hum Pathol. 1998 Apr;29(4):323-9
[
9563780.001
]
[Cites]
Breast Cancer Res Treat. 1998 May;49(1):35-9
[
9694609.001
]
[Cites]
J Natl Cancer Inst. 1998 Sep 2;90(17):1262-9
[
9731732.001
]
[Cites]
Genes Chromosomes Cancer. 1998 Oct;23(2):100-8
[
9739012.001
]
[Cites]
Oncogene. 1999 May 13;18(19):3004-16
[
10378696.001
]
[Cites]
Am J Clin Pathol. 1999 Oct;112(4):459-69
[
10510669.001
]
[Cites]
Cancer. 2005 Mar 1;103(5):900-5
[
15643600.001
]
[Cites]
Cancer Res. 2005 Mar 1;65(5):1909-17
[
15753390.001
]
[Cites]
Oncol Rep. 2005 Apr;13(4):633-41
[
15756435.001
]
[Cites]
Histopathology. 2005 Apr;46(4):431-41
[
15810955.001
]
[Cites]
Rev Med Chir Soc Med Nat Iasi. 2004 Jul-Sep;108(3):657-61
[
15832994.001
]
[Cites]
Hum Pathol. 2005 Jun;36(6):634-9
[
16021569.001
]
[Cites]
Breast Cancer Res. 2005;7(5):R598-604
[
16168103.001
]
[Cites]
Indian J Pathol Microbiol. 2004 Jul;47(3):340-2
[
16295419.001
]
[Cites]
Breast J. 2005 Nov-Dec;11(6):433-9
[
16297088.001
]
[Cites]
Clin Exp Metastasis. 2005;22(6):495-502
[
16320112.001
]
[Cites]
Breast Cancer Res. 2005;7(6):R1058-79
[
16457687.001
]
[Cites]
J Clin Pathol. 2006 Apr;59(4):424-8
[
16497871.001
]
[Cites]
Cancer Res. 2006 May 15;66(10):5330-7
[
16707459.001
]
[Cites]
Oncologist. 2006 Sep;11(8):857-67
[
16951389.001
]
[Cites]
Int J Oncol. 2006 Oct;29(4):973-80
[
16964393.001
]
[Cites]
Int J Biol Markers. 2006 Jul-Sep;21(3):131-40
[
17013794.001
]
[Cites]
Hua Xi Yi Ke Da Xue Xue Bao. 1998 Dec;29(4):399-401
[
10743237.001
]
(PMID = 19675743.001).
[ISSN]
1612-3174
[Journal-full-title]
German medical science : GMS e-journal
[ISO-abbreviation]
Ger Med Sci
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
[Other-IDs]
NLM/ PMC2716551
[Keywords]
NOTNLM ; HER-2/neu / breast cancer / c-myc / fluorescent in situ hybridization (FISH) / genetic alterations / p53
17.
Drees R, Hünigen H, Wagner S, Schnorr J, Plendl J, Taupitz M:
Peripheral washout phenomenon in an animal tumour model: comparison of dynamic magnetic resonance imaging using a small molecular contrast medium with histology.
Vet Comp Oncol
; 2008 Sep;6(3):151-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The peripheral washout sign was first described in delayed dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) using a small molecular contrast medium in solid lesions of the human
breast
and liver.
It was found to be 100% specific for malignant lesions and could therefore potentially be used as an additional noninvasive diagnostic tool differentiating malignant from
benign
lesions.
[MeSH-minor]
Animals. Cell Line,
Tumor
.
Male
. Rats. Rats, Inbred Strains. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - MRI Scans
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19178675.001).
[ISSN]
1476-5829
[Journal-full-title]
Veterinary and comparative oncology
[ISO-abbreviation]
Vet Comp Oncol
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Contrast Media
18.
Mouton WG, Kienle Y, Muggli B, Naef M, Wagner HE:
Tumors associated with superficial thrombophlebitis.
Vasa
; 2009 May;38(2):167-70
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: To assess the incidence of malignant tumors in patients with thrombophlebitis of the leg with regard to potential early
tumor
detection.
RESULTS: There were 18 patients (12.9%) suffering from thrombophlebitis in association with a malignant
tumor
:
breast
cancer in seven patients, colon carcinoma and haematologic cancer in four, skin cancer in three patients and one case each of oesophageal, prostatic, kidney and neck cancer .
In two patients thrombophlebitis preceded
the diagnosis
of the malignancy.
Superficial thrombophlebitis may have been associated in four cases (2.9%) with a
benign tumor
.
CONCLUSIONS:
Breast
, colonic, haematological and skin cancer were mainly associated with superficial thrombophlebitis in our patients.
In case of a thrombophlebitis without a known malignancy a thorough clinical examination with special regard to skin,
breast
and abdomen is mandatory.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Comorbidity. Cross-Sectional Studies. Early
Diagnosis
. Female. Follow-Up Studies. Humans. Incidence.
Male
. Middle Aged. Retrospective Studies. Ultrasonography, Doppler, Duplex. Venous Insufficiency / complications. Venous Insufficiency / epidemiology. Venous Insufficiency / ultrasonography
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19588305.001).
[ISSN]
0301-1526
[Journal-full-title]
VASA. Zeitschrift für Gefässkrankheiten
[ISO-abbreviation]
VASA
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
19.
Kim TY, Kim WB, Ryu JS, Gong G, Hong SJ, Shong YK:
18F-fluorodeoxyglucose uptake in thyroid from positron emission tomogram (PET) for evaluation in cancer patients: high prevalence of malignancy in thyroid PET incidentaloma.
Laryngoscope
; 2005 Jun;115(6):1074-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVES: To investigate the prevalence of incidental thyroid F-fluorodeoxyglucose (FDG) uptake in positron emission tomogram (PET) scan for evaluation in cancer patients and the role of standard uptake value (SUV) measurement in differentiation of thyroid malignancy from
benign
disease.
Cytologic
diagnosis
was available in 32 of 45 focal thyroid FDG uptakes.
In 16 (50%) patients, the
tumor
was found to be malignant; 14 were papillary thyroid carcinoma (surgically confirmed in 7 cases), 2 were metastatic
tumor
from
breast
and esophagus.
Sixteen were cytologically diagnosed as follicular cell lesions: follicular
neoplasm
(n = 2), nodular hyperplasia (n = 7), indeterminate follicular lesion (n = 7).
There was no significant difference in maximum SUV between
benign
and malignant nodules.
From 45 patients with diffuse thyroid FDG uptake, presumptive
diagnosis of
chronic thyroiditis was possible in 34 patients by clinical and laboratory findings.
CONCLUSION: Our data suggest that a cytologic
diagnosis of
focal thyroid FDG-PET incidentaloma regardless of SUV is mandatory considering the very high prevalence of thyroid malignancy.
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Needle. Carcinoma, Papillary / pathology. Carcinoma, Papillary / radionuclide imaging. Child. Child, Preschool. Female. Humans.
Male
. Middle Aged.
Neoplasm
Metastasis. Retrospective Studies. Thyroid Nodule / radionuclide imaging. Thyroiditis
Genetic Alliance.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15933524.001).
[ISSN]
0023-852X
[Journal-full-title]
The Laryngoscope
[ISO-abbreviation]
Laryngoscope
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0Z5B2CJX4D / Fluorodeoxyglucose F18
20.
Moon HJ, Kim MJ, Kwak JY, Yoon JH, Kim SJ, Sohn YM, Kim EK:
Malignant lesions initially categorized as probably benign breast lesions: retrospective review of ultrasonographic, clinical and pathologic characteristics.
Ultrasound Med Biol
; 2010 Apr;36(4):551-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Malignant lesions initially categorized as probably
benign breast
lesions: retrospective review of ultrasonographic, clinical and pathologic characteristics.
The primary objective of this study was to review the ultrasonographic features of BI-RADS category 3 ("probably
benign
") lesions that eventually proved to be malignant.
Thirty-two (0.8%) of 4000 women with lesions that were initially classified as "probably
benign
" proved to be malignant and formed the study group.
There was no statistical difference in the mean age, mean size of lesions, or
tumor
stage between patients who underwent early biopsy (n = 19) or biopsy after 6 months (n = 13).
[MeSH-major]
Biopsy / statistics & numerical data.
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms / epidemiology. Ultrasonography, Mammary / statistics & numerical data
[MeSH-minor]
Adult. Aged. Female. Humans. Korea / epidemiology.
Male
. Middle Aged. Prevalence. Reproducibility of Results. Retrospective Studies. Risk Assessment. Risk Factors. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Biopsy
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.
(PMID = 20350681.001).
[ISSN]
1879-291X
[Journal-full-title]
Ultrasound in medicine & biology
[ISO-abbreviation]
Ultrasound Med Biol
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
21.
Hafner C, Schmiemann V, Ruetten A, Coras B, Landthaler M, Reifenberger J, Vogt T:
PTCH mutations are not mainly involved in the pathogenesis of sporadic trichoblastomas.
Hum Pathol
; 2007 Oct;38(10):1496-500
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Trichoblastomas are rare,
benign
tumors of the appendix in human skin.
This mutation at codon 1,315 represents an already described PTCH germline polymorphism and results in a heterozygous Pro to Leu substitution in the
tumor
.
The Pro/Leu polymorphism in germline is associated with a higher risk for
breast
cancer, but a potential contribution to the tumorigenesis of trichoblastoma is unknown.
The genetic basis of this rare appendageal
tumor
remains elusive.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Female. Humans.
Male
. Middle Aged. Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17597182.001).
[ISSN]
0046-8177
[Journal-full-title]
Human pathology
[ISO-abbreviation]
Hum. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, Cell Surface; 0 / patched receptors
22.
Markushin Y, Gaikwad N, Zhang H, Kapke P, Rogan EG, Cavalieri EL, Trock BJ, Pavlovich C, Jankowiak R:
Potential biomarker for early risk assessment of prostate cancer.
Prostate
; 2006 Oct 1;66(14):1565-71
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This damage leads to mutations that can initiate
breast
and prostate cancer.
To determine whether this damage occurs in humans, urine samples from men with prostate cancer and
benign
urological conditions, and healthy controls were analyzed.
RESULTS: 4-OHE1-1-N3Ade was detected at higher levels in samples from subjects with prostate cancer (n = 7) and
benign
urological conditions (n = 4) compared to healthy males (n = 5).
[MeSH-major]
Biomarkers,
Tumor
/ urine. DNA Adducts / urine. Prostatic Neoplasms /
diagnosis
. Prostatic Neoplasms / urine
[MeSH-minor]
Antibodies, Monoclonal. Early
Diagnosis
. Electrophoresis, Capillary. Estradiol / analogs & derivatives. Estradiol / chemistry. Estradiol / immunology. Estradiol / urine. Estrogens, Catechol. Humans. Hydroxyestrones / chemistry. Hydroxyestrones / immunology. Hydroxyestrones / urine.
Male
. Risk Factors
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ESTRADIOL
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2006 Wiley-Liss, Inc.
(PMID = 16894534.001).
[ISSN]
0270-4137
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
eng
[Grant]
United States / PHS HHS / / 1 P20 RP15563; United States / NCI NIH HHS / CA / 2P01 CA49210-12
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / DNA Adducts; 0 / Estrogens, Catechol; 0 / Hydroxyestrones; 3131-23-5 / 4-hydroxyestrone; 4TI98Z838E / Estradiol; C3ZO03450E / 4-hydroxyestradiol
23.
Tumminello FM, Flandina C, Crescimanno M, Leto G:
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Biomed Pharmacother
; 2008 Feb;62(2):130-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The clinical significance of serum cathepsin K and cystatin C was assessed in patients with
breast
cancer (BCa) or prostate cancer (PCa) with confined disease (M0) or bone metastasis (BM).
In PCa patients, cathepsin K concentrations did not significantly differ from those measured in sex matched HS or in patients with
benign
prostatic hyperplasia (BPH).
[MeSH-major]
Biomarkers,
Tumor
/ blood. Bone Neoplasms / secondary. Cathepsins / blood. Cystatins / blood
[MeSH-minor]
Aged. Aged, 80 and over. Bone Density Conservation Agents / pharmacology.
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms / pathology. Case-Control Studies. Cathepsin K. Cystatin C. Diphosphonates / pharmacology. Disease Progression. Drug Monitoring / methods. Enzyme-Linked Immunosorbent Assay. Female. Humans. Imidazoles / pharmacology.
Male
. Middle Aged. Osteoporosis / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Neoplasms /
diagnosis
. Prostatic Neoplasms / pathology. ROC Curve
Genetic Alliance.
consumer health - Bone Cancer
.
MedlinePlus Health Information.
consumer health - Bone Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17728092.001).
[ISSN]
0753-3322
[Journal-full-title]
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie
[ISO-abbreviation]
Biomed. Pharmacother.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
France
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / CST3 protein, human; 0 / Cystatin C; 0 / Cystatins; 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; EC 3.4.- / Cathepsins; EC 3.4.22.38 / CTSK protein, human; EC 3.4.22.38 / Cathepsin K
24.
Gunasekera RS, Sewgobind K, Desai S, Dunn L, Black HS, McKeehan WL, Patil B:
Lycopene and lutein inhibit proliferation in rat prostate carcinoma cells.
Nutr Cancer
; 2007;58(2):171-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Consumption of lycopene, a carotenoid without provitamin A activity, has been associated with a lower risk of prostate and
breast
cancer.
The effects of grapefruit-derived and commercial lycopene and lutein preparations on androgen independent cultured malignant type II
tumor
cells [Dunning R3327AT3 or AT3 cells (androgen-responsive, slow-growing
tumor
cells with well developed epithelium and stroma)] were compared to their
benign
parent type I
tumor
epithelial cells (DTE).
No such effect was observed when
benign
DTE cells were examined, demonstrating selective inhibition of extremely malignant AT3 prostate cancer cells relative to their
benign
parent.
[MeSH-minor]
Animals. Chromatography, High Pressure Liquid. Citrus paradisi. Dose-Response Relationship, Drug. Humans.
Male
. Rats. Time Factors.
Tumor
Cells, Cultured
MedlinePlus Health Information.
consumer health - Antioxidants
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17640163.001).
[ISSN]
0163-5581
[Journal-full-title]
Nutrition and cancer
[ISO-abbreviation]
Nutr Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Antioxidants; 36-88-4 / Carotenoids; SB0N2N0WV6 / lycopene; X72A60C9MT / Lutein
25.
Neves Cde O, Soares AB, Costa AF, de Araujo VC, Furuse C, Juliano PB, Altemani A:
CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms.
Appl Immunohistochem Mol Morphol
; 2010 Mar;18(2):172-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
CD10 is a cell surface peptidase expressed in a wide variety of normal and neoplastic tissues, including
breast
myoepithelial cells.
In neoplastic myoepithelial cells, CD10 expression was found in 25.71% of
benign
and 32.43% of malignant neoplasms.
The high expression of CD10 by this carcinoma can be a valuable tool to separate EMEC from the tubular variant of adenoid cystic carcinomas in small incisional biopsies, where the precise
diagnosis
may be impossible.
MedlinePlus Health Information.
consumer health - Salivary Gland Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19752720.001).
[ISSN]
1533-4058
[Journal-full-title]
Applied immunohistochemistry & molecular morphology : AIMM
[ISO-abbreviation]
Appl. Immunohistochem. Mol. Morphol.
[Language]
ENG
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
26.
Kondi-Pafitis A, Kairi-Vassilatou E, Grapsa D, Kalkounou I, Vassilikostas G, Psichogios I:
A large benign vascular neoplasm of the male breast. A case report and review of the literature.
Eur J Gynaecol Oncol
; 2005;26(4):454-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
A large
benign
vascular
neoplasm of
the
male breast
. A case report and review of the literature.
Breast
hemangiomas are extremely rare neoplasms in the
male
population.
We report a case of a 77-year old man with a
breast
hemangioma which was detected in physical examination as a small nodule ten years after a chest injury.
The final histological
diagnosis
was hemangioma of the
breast
, 6 cm in the largest diameter.
To our knowledge, this is the largest
benign
vascular
breast
neoplasm
in a
male
patient reported up to date.
The rarity of the lesion and its differential
diagnosis
from angiosarcoma are discussed while the problems encountered in the correct
diagnosis
and classification of this
tumor
are also presented.
The need for extreme caution in the interpretation of the histological characteristics of all palpable vascular tumors of the
breast
is emphasized.
[MeSH-major]
Breast
Neoplasms,
Male
/
diagnosis
. Hemangioma /
diagnosis
[MeSH-minor]
Aged. Humans.
Male
. Mastectomy, Segmental
MedlinePlus Health Information.
consumer health - Birthmarks
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Eur J Gynaecol Oncol. 2005;26(6):667; author reply 667-8
[
16398236.001
]
(PMID = 16122203.001).
[ISSN]
0392-2936
[Journal-full-title]
European journal of gynaecological oncology
[ISO-abbreviation]
Eur. J. Gynaecol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Italy
[Number-of-references]
10
27.
Porcel JM, Salud A, Vives M, Esquerda A, Rodríguez-Panadero F:
Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions.
Clin Biochem
; 2005 Nov;38(11):1031-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVES: To investigate whether pleural levels of the soluble oncoprotein 185 HER-2 (sp185(HER-2)), individually or in combination with CEA and CA 15-3, were useful for
the diagnosis
of malignant effusions.
DESIGN AND METHODS: Levels of CEA, CA 15-3, and sp185(HER-2) were measured in the pleural fluid from 135 malignant and 103
benign
effusions.
Thresholds of these
tumor
markers were chosen for a diagnostic specificity of >or=99%.
RESULTS: Pleural sp185(HER-2) levels greater than 25 ng/mL were observed in 20% of
breast
and 10% of lung adenocarcinomas, and predicted a malignant effusion with a sensitivity of 7% and a likelihood ratio of 7.6.
Only 1 patient with
breast
adenocarcinoma among 45 cytology-negative malignant effusions had sp185(HER-2) above the diagnostic cutoff point.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Pleural Effusion, Malignant /
diagnosis
. Receptor, ErbB-2 / analysis
[MeSH-minor]
Adenocarcinoma /
diagnosis
. Aged.
Breast
Neoplasms /
diagnosis
. Carcinoembryonic Antigen / analysis. False Negative Reactions. Humans. Likelihood Functions. Lung Neoplasms /
diagnosis
.
Male
. Middle Aged. Mucin-1 / analysis. Pleural Effusion / chemistry. Pleural Effusion /
diagnosis
. Sensitivity and Specificity
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15925354.001).
[ISSN]
0009-9120
[Journal-full-title]
Clinical biochemistry
[ISO-abbreviation]
Clin. Biochem.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; EC 2.7.10.1 / Receptor, ErbB-2
28.
Castillo OA, Vitagliano G, Kerkebe M, Parma P, Pinto I, Diaz M:
Laparoscopic adrenalectomy for suspected metastasis of adrenal glands: our experience.
Urology
; 2007 Apr;69(4):637-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: A total of 34 adrenalectomies were performed in 32 patients for incidental adrenal masses discovered at primary
tumor
diagnosis
or during follow-up.
The primary tumors diagnosed were 13 cases of lung carcinoma, 9 of renal cell carcinoma, 2 of colorectal carcinoma, 2 of bladder carcinoma, and 1 each of ovarian carcinoma,
breast
cancer, gastric cancer, and melanoma.
Two patients had no history of a primary
tumor
.
The
male
/female ratio was 1.9:1.
The mean
tumor
size was 4.3 cm (range 1.5 to 9).
The microscopic analysis revealed 22 malign lesions (64.7%) and 12 cases of
benign
pathologic features (35.3%).
[MeSH-minor]
Adult. Female. Humans. Incidental Findings.
Male
. Middle Aged
MedlinePlus Health Information.
consumer health - Adrenal Gland Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17445640.001).
[ISSN]
1527-9995
[Journal-full-title]
Urology
[ISO-abbreviation]
Urology
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
29.
McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ:
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
Clin Chem
; 2008 Jan;54(1):44-52
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Analytical validation of serum proteomic profiling for
diagnosis of
prostate cancer: sources of sample bias.
METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and
benign
prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220).
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
Biospecimen Research Database.
Biospecimen Research Database
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8
[
12381711.001
]
[Cites]
Clin Breast Cancer. 2003 Aug;4(3):203-9
[
14499014.001
]
[Cites]
BMC Bioinformatics. 2003 Jun 9;4:24
[
12795817.001
]
[Cites]
J Natl Cancer Inst. 2004 Mar 3;96(5):353-6
[
14996856.001
]
[Cites]
Bioinformatics. 2004 Mar 22;20(5):777-85
[
14751995.001
]
[Cites]
N Engl J Med. 2004 May 27;350(22):2239-46
[
15163773.001
]
[Cites]
Dis Markers. 2003-2004;19(4-5):185-95
[
15258333.001
]
[Cites]
Clin Chem. 2004 Dec;50(12):2398-401
[
15563493.001
]
[Cites]
Clin Chem. 2005 Jan;51(1):102-12
[
15613711.001
]
[Cites]
Nat Rev Cancer. 2005 Feb;5(2):142-9
[
15685197.001
]
[Cites]
Clin Chem. 2005 Aug;51(8):1525-8
[
15951319.001
]
[Cites]
Clin Chem. 2005 Sep;51(9):1637-49
[
16002455.001
]
[Cites]
Proteomics. 2006 Mar;6(5):1676-80
[
16447157.001
]
[Cites]
Clin Chem. 2006 Apr;52(4):771-2; author reply 772
[
16595832.001
]
[Cites]
Proteomics. 2006 May;6(10):3189-98
[
16586434.001
]
[Cites]
Clin Chem. 2006 Jul;52(7):1218-22
[
16675505.001
]
[Cites]
Biometrics. 2006 Jun;62(2):589-97
[
16918924.001
]
[Cites]
J Proteome Res. 2006 Sep;5(9):2079-82
[
16944917.001
]
[Cites]
Nat Clin Pract Rheumatol. 2007 Feb;3(2):96-103
[
17299447.001
]
[Cites]
Clin Chem. 2007 Apr;53(4):645-56
[
17303688.001
]
[Cites]
Anal Chem. 2005 Aug 15;77(16):5114-23
[
16097747.001
]
[Cites]
Proteomics. 2005 Aug;5(13):3262-77
[
16052621.001
]
[Cites]
Am J Pathol. 2001 Apr;158(4):1491-502
[
11290567.001
]
[Cites]
Lancet. 2002 Feb 16;359(9306):572-7
[
11867112.001
]
[Cites]
Cancer Res. 2002 Mar 15;62(6):1868-75
[
11912167.001
]
[Cites]
Cancer Res. 2002 Jul 1;62(13):3609-14
[
12097261.001
]
[Cites]
Clin Chem. 2002 Aug;48(8):1296-304
[
12142387.001
]
[Cites]
Clin Chem. 2002 Oct;48(10):1835-43
[
12324514.001
]
[CommentIn]
Clin Chem. 2008 Jan;54(1):3-5
[
18160722.001
]
[CommentIn]
Clin Chem. 2008 Jan;54(1):6-7
[
18160723.001
]
(PMID = 17981926.001).
[ISSN]
0009-9147
[Journal-full-title]
Clinical chemistry
[ISO-abbreviation]
Clin. Chem.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / CA 084986; United States / NCI NIH HHS / CA / CA 84968; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / CA 86368; United States / NCI NIH HHS / CA / U01 CA086402; United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA086323; United States / NCI NIH HHS / CA / U24 CA086368; United States / NCI NIH HHS / CA / U01 CA086368; United States / NCI NIH HHS / CA / CA 86359; United States / NCI NIH HHS / CA / CA 86402; United States / NCI NIH HHS / CA / U24 CA086359; United States / NCI NIH HHS / CA / CA 86323; United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / CA 85067; United States / NCI NIH HHS / CA / U01 CA084986
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
[Other-IDs]
NLM/ NIHMS371877; NLM/ PMC3354530
30.
Blumenthal GM, Dennis PA:
PTEN hamartoma tumor syndromes.
Eur J Hum Genet
; 2008 Nov;16(11):1289-300
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
PTEN hamartoma
tumor
syndromes.
The PTEN hamartoma
tumor
syndromes (PHTS) are a collection of rare clinical syndromes characterized by germline mutations of the
tumor
suppressor PTEN.
These syndromes are driven by cellular overgrowth, leading to
benign
hamartomas in virtually any organ.
Cowden syndrome (CS), the prototypic PHTS syndrome, is associated with increased susceptibility to
breast
, thyroid, and endometrial cancer.
[MeSH-minor]
Cell Movement. Cell Proliferation. Cell Survival. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 10 / metabolism. Female. Humans.
Male
. Phosphatidylinositol 3-Kinases / genetics. Phosphatidylinositol 3-Kinases / metabolism. Protein Kinases / genetics. Protein Kinases / metabolism. Proto-Oncogene Proteins c-akt / genetics. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction. TOR Serine-Threonine Kinases
Genetics Home Reference.
consumer health - Bannayan-Riley-Ruvalcaba syndrome
.
Genetics Home Reference.
consumer health - Cowden syndrome
.
Genetics Home Reference.
consumer health - PTEN gene
.
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
SciCrunch.
OMIM: Data: Gene Annotation
.
SciCrunch.
Clinical Genomic Database: Data: Gene Annotation
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18781191.001).
[ISSN]
1018-4813
[Journal-full-title]
European journal of human genetics : EJHG
[ISO-abbreviation]
Eur. J. Hum. Genet.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Antineoplastic Agents; EC 2.7.- / Protein Kinases; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
[Number-of-references]
77
31.
Suzuki H, Graziano DF, McKolanis J, Finn OJ:
T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease.
Clin Cancer Res
; 2005 Feb 15;11(4):1521-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
PURPOSE: Cyclin B1-derived peptides were shown by us to be targets of
tumor
-specific CD8(+) T cells in patients with
breast
and head and neck cancer.
We obtained further evidence of cyclin B1 immunogenicity and its potential to serve as a
tumor
-specific antigen by analyzing its ability to elicit T cell-dependent humoral immune responses in vivo in patients with different types of tumors.
EXPERIMENTAL DESIGN: Recombinant cyclin B1 protein from two different sources was purified and used as antigen in ELISA assays to test sera from patients with
breast
, pancreatic, colon, and lung cancer for the presence of anti-cyclin B1 antibody.
We also analyzed patients with
benign
lung disease, premalignant disease, and a known history of heavy smoking.
Antibodies in patients with
breast
and colon cancer are primarily of the IgG isotype whereas patients with pancreatic and lung cancer have in addition anti-cyclin B1 IgA.
[MeSH-minor]
Breast
Neoplasms / blood.
Breast
Neoplasms / immunology.
Breast
Neoplasms / metabolism. Colonic Neoplasms / blood. Colonic Neoplasms / immunology. Colonic Neoplasms / metabolism. Cyclin B1. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoglobulin A / blood. Immunoglobulin G / blood. Immunohistochemistry. Lung Neoplasms / blood. Lung Neoplasms / immunology. Lung Neoplasms / metabolism.
Male
. Pancreatic Neoplasms / blood. Pancreatic Neoplasms / immunology. Pancreatic Neoplasms / metabolism. Smoking / immunology
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15746055.001).
[ISSN]
1078-0432
[Journal-full-title]
Clinical cancer research : an official journal of the American Association for Cancer Research
[ISO-abbreviation]
Clin. Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / P50 CA 090440
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / CCNB1 protein, human; 0 / Cyclin B; 0 / Cyclin B1; 0 / Immunoglobulin A; 0 / Immunoglobulin G
32.
He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T, Skog S:
Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
Oncol Rep
; 2005 Oct;14(4):1013-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We investigate thymidine kinase 1 concentration in serum (S-TK1) as a potential
tumor
marker.
S-TK1 concentration and STK activity levels were determined in 9 human malignant diseases (
breast
, gastric, rectal, colorectal, lung, brain cancer, hepatoma, lymphoma, leukaemia) and in
benign
and non-cancerous diseases, representing 850 preoperative cases.
S-TK1 concentrations and STK activity levels in preoperative malignant patients were significantly higher than in healthy individuals, in patients with
benign
tumors and in those with non-cancerous diseases.
Significant correlations between concentration and activity level were only found in healthy individuals, in patients with
benign
tumors, and in some patients with malignancies, i.e. leukaemia, and
breast
and gastric cancers.
We conclude that S-TK1 concentration is a more sensitive
tumor
marker in solid malignancies than is STK activity.
[MeSH-major]
Biomarkers,
Tumor
. Neoplasms / blood. Neoplasms /
diagnosis
. Thymidine Kinase / blood
[MeSH-minor]
Breast
Neoplasms / pathology. Cell Line,
Tumor
. Cell Proliferation. Dose-Response Relationship, Drug. Female. Humans.
Male
.
Neoplasm
Staging. Radioimmunoassay / methods. Stomach Neoplasms / pathology
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16142366.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1
33.
Li BJ, Huang XP, Wei WD, Wang JY, Su XD, Zhang X, Hong WS, Tang J, Zhang LJ, Long H, Yang MT, Rong TH:
[Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer].
Ai Zheng
; 2005 Jun;24(6):735-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Expression and clinical significance of cytokeratin 19 in bone marrow of patients with
breast
cancer].
BACKGROUND & OBJECTIVE:
Breast
cancer may undergo metastasis in early phase.
Distant metastasis, especially bone metastasis, may influence prognosis of
breast
cancer patients.
This study was designed to evaluate expression and clinical significance of cytokeratin 19 (CK19) in bone marrow of patients with
breast
cancer.
METHODS: Expression of CK19 mRNA in bone marrows of 65
breast
cancer patients, 15
benign breast
disease patients, and 8 healthy volunteers was detected by reverse transcription-polymerase chain reaction (RT-PCR).
Correlation of CK19 mRNA expression to clinicopathologic features of the 65
breast
cancer patients was analyzed.
RESULTS: Positive rate of CK19 mRNA was 33.8% in the 65
breast
cancer patients, and 0 in both
benign breast
disease patients and healthy volunteers.
Expression of CK19 mRNA was positively correlated with
tumor
size and clinical stage (P < 0.05), but was not related to age and lymph node status (P > 0.05).
CONCLUSIONS: CK19 mRNA may be used as a molecular marker to detect bone marrow micrometastasis in patients with
breast
cancer.
The detection may help to select proper therapy and predict prognosis of
breast
cancer patients.
[MeSH-major]
Bone Marrow / metabolism.
Breast
Neoplasms / metabolism. Carcinoma, Ductal,
Breast
/ metabolism. Keratin-19 / biosynthesis
[MeSH-minor]
Adult. Aged.
Breast
Neoplasms,
Male
/ metabolism.
Breast
Neoplasms,
Male
/ pathology. Carcinoembryonic Antigen / blood. Female. Fibroadenoma / blood. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Lymphatic Metastasis.
Male
. Middle Aged.
Neoplasm
Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics
Genetic Alliance.
consumer health - Bone Cancer
.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15946491.001).
[Journal-full-title]
Ai zheng = Aizheng = Chinese journal of cancer
[ISO-abbreviation]
Ai Zheng
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
34.
Di Carlo A, Terracciano D, Mariano A, Macchia V:
Matrix metalloproteinase-2 and matrix metalloproteinase-9 type IV collagenases in serum of patients with pleural effusions.
Int J Oncol
; 2005 May;26(5):1363-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Recently, several MMPs were implicated in creating an environment that supports the initiation and maintenance of
tumor
growth.
Of these patients, 22 had malignant pleural effusion, consisting of 11
breast
carcinomas and 11 lung carcinomas (7 squamous cell carcinomas and 4 adenocarcinomas), and 8 patients had
benign
effusions.
The MMP-9/MMP-2 ratio was enhanced in cancer patients compared with
benign
diseases and healthy individuals.
[MeSH-major]
Biomarkers,
Tumor
/ blood.
Breast
Neoplasms / enzymology.
Breast
Neoplasms / pathology. Carcinoma, Non-Small-Cell Lung / enzymology. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / enzymology. Lung Neoplasms / pathology. Matrix Metalloproteinase 2 / blood. Matrix Metalloproteinase 9 / blood. Pleural Effusion / enzymology. Pleural Effusion / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Case-Control Studies. Female. Humans.
Male
. Middle Aged
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15809729.001).
[ISSN]
1019-6439
[Journal-full-title]
International journal of oncology
[ISO-abbreviation]
Int. J. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
35.
Nassar A, Amin MB, Sexton DG, Cohen C:
Utility of alpha-methylacyl coenzyme A racemase (p504s antibody) as a diagnostic immunohistochemical marker for cancer.
Appl Immunohistochem Mol Morphol
; 2005 Sep;13(3):252-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Recently, AMACR has been demonstrated to be overexpressed in localized and metastatic prostate cancer and in high-grade prostatic intraepithelial
neoplasia
but not in normal prostatic glands, suggesting that it may be an important
tumor
marker.
This study examines AMACR expression in a variety of human cancers to assess its viability as a
tumor
marker in the clinical setting.
Cancers studied included
breast
(94 cases), prostate (38), lung (28), endometrium (27), colon (29), ovary (26), and melanoma (21).
A section of prostate cancer and prostatic intraepithelial
neoplasia
was used as positive control.
AMACR protein overexpression was found in several cancers, including prostate (34/38 [89.5%]), colon (13/29 [44.8%]), lung (4/28 [14.3%]), melanoma (2/21 [9.5%]), endometrium (2/27 [7.4%]), and
breast
(3/94 [3.2%]).
AMACR expression was not present in any of the normal tissues nor in
benign
prostatic tissue associated with prostate carcinomas.
This study suggests that AMACR is potentially an important
tumor
marker, particularly for prostate and colon cancer.
It may be a useful adjunct to an immunohistochemical panel employed in the differential
diagnosis of
colon versus ovarian and
breast
carcinoma; the latter two infrequently express AMACR.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16082251.001).
[ISSN]
1541-2016
[Journal-full-title]
Applied immunohistochemistry & molecular morphology : AIMM
[ISO-abbreviation]
Appl. Immunohistochem. Mol. Morphol.
[Language]
ENG
[Publication-type]
Evaluation Studies; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
36.
Shah SN:
Giant myofibroblastoma of breast: a case report.
Indian J Pathol Microbiol
; 2007 Jul;50(3):583-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Giant myofibroblastoma of
breast
: a case report.
Myofibroblastoma of the
breast
is a very rare
benign
neoplasm
usually seen in elderly
male
and is of very small size.
A 40 year old nulliparous woman was admitted with chief complain of massive enlargement of left
breast
.
The case was clinically diagnosed as Phyllodes
tumor
Left mastectomy was done.
The
tumor
was histopathologically and immunohistochemically diagnosed as Myofibroblastoma.
[MeSH-major]
Breast
Neoplasms /
diagnosis
. Neoplasms, Muscle Tissue /
diagnosis
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17883145.001).
[ISSN]
0377-4929
[Journal-full-title]
Indian journal of pathology & microbiology
[ISO-abbreviation]
Indian J Pathol Microbiol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
India
37.
Shams TM, Samaka RM, Shams ME:
Maspin protein expression: a special feature of papillary thyroid carcinoma.
J Egypt Natl Canc Inst
; 2006 Sep;18(3):274-80
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND AND AIM: Mammary serine protease inhibitor (Maspin) is down regulated in
breast
and prostate cancers and is considered as a
tumor
suppressor gene.
On the contrary, it is over expressed in pancreatic and ovarian carcinomas and is reported to be an oncogene rather than a
tumor
suppressor gene.
The studies of maspin expression in thyroid
neoplasia
, the focus of this study, are limited.
We, therefore, carried out this work in order to detect the frequency and pattern of maspin expression in thyroid
neoplasia
.
MATERIAL & METHODS: An immunohistochemical approach was performed on 63 thyroid specimens showing different
benign
and malignant thyroid lesions.
There was no statistically significant relation between maspin positive cases and the studied clinicopathological parameters including patient's age, sex and
tumor
stage.
On the other hand, it was statistically significant as regards
tumor
multicentricity, vascular and lymphatic invasion, as well as lymph node metastasis.
[MeSH-major]
Carcinoma, Papillary /
diagnosis
. Serpins / analysis. Thyroid Neoplasms /
diagnosis
[MeSH-minor]
Adult. Female. Humans. Immunohistochemistry.
Male
. Middle Aged. Prognosis. Thyroid Gland / chemistry
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17671538.001).
[ISSN]
1110-0362
[Journal-full-title]
Journal of the Egyptian National Cancer Institute
[ISO-abbreviation]
J Egypt Natl Canc Inst
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Egypt
[Chemical-registry-number]
0 / SERPIN-B5; 0 / Serpins
38.
Leinweber B, Chott A, Kerl H, Cerroni L:
Epidermotropic precursor T-cell lymphoma with highly aggressive clinical behavior simulating localized pagetoid reticulosis.
Am J Dermatopathol
; 2007 Aug;29(4):392-4
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The
tumor
cells expressed a T-phenotype (CD3+, CD20-) and were CD30-, CD4-, and CD8-negative.
A
diagnosis of
localized pagetoid reticulosis (Woringer-Kolopp disease) with possible large cell transformation was proposed.
Reevaluation of the skin lesion and of a tonsil specimen previously interpreted as
benign
hyperplasia showed features consistent with those observed in the lymph node.
[MeSH-major]
Breast
Neoplasms,
Male
/ pathology. Lymphatic Diseases / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Nipples / pathology. Paget's Disease, Mammary / pathology
[MeSH-minor]
Adult. Antigens, CD3 / analysis. Antigens, CD43 / analysis. Antigens, CD7 / analysis. Fatal Outcome. Humans. Hyperplasia. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / pathology.
Male
. Palatine Tonsil / pathology. T-Lymphocytes / pathology
MedlinePlus Health Information.
consumer health - Lymphatic Diseases
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17667175.001).
[ISSN]
0193-1091
[Journal-full-title]
The American Journal of dermatopathology
[ISO-abbreviation]
Am J Dermatopathol
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD3; 0 / Antigens, CD43; 0 / Antigens, CD7
39.
Rekhi B, Jambhekar NA:
Morphologic spectrum, immunohistochemical analysis, and clinical features of a series of granular cell tumors of soft tissues: a study from a tertiary referral cancer center.
Ann Diagn Pathol
; 2010 Jun;14(3):162-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A granular cell
tumor
(GCT) is relatively uncommon and objectively diagnosed with neural markers on immunohistochemistry (IHC).
Herein, we present morphologic spectrum of 12 GCTs of soft tissues and skin, including 10
benign
and 2 malignant subtypes with an optimal diagnostic IHC panel.
Six cases occurred in soft tissues and skin of extremities, 4 in the
breast
soft tissues, and 1 case each in the back and preauricular region, respectively.
On histopathology, all cases invariably revealed a nonencapsulated infiltrating
tumor
comprising groups and nests of granular cells with vesicular nuclei.
Immunohistochemistry in 10 cases (83.3%) showed diffuse S-100 positivity in all 7
benign
and 2 malignant cases: cytoplasmic CD68 positivity (all 10 cases) and membranous vimentin staining (all 4 cases).
A GCT is a discrete
tumor
entity and can be identified from other granular lesions by its proximity to nerves and objective identification with diffuse S-100 positivity, CD68 positivity, and membranous vimentin positivity that form an optimal IHC panel in limited resource settings, irrespective of
benign
or malignant types.
[MeSH-major]
Cancer Care Facilities. Granular Cell
Tumor
/ pathology. Referral and Consultation. Skin Neoplasms / pathology. Soft Tissue Neoplasms / pathology
[MeSH-minor]
Adult. Aged. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Biomarkers,
Tumor
/ metabolism. Child. Female. Humans.
Male
. Middle Aged. S100 Proteins / metabolism. Vimentin / metabolism. Young Adult
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20471560.001).
[ISSN]
1532-8198
[Journal-full-title]
Annals of diagnostic pathology
[ISO-abbreviation]
Ann Diagn Pathol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / S100 Proteins; 0 / Vimentin
40.
Teo C, Broggi M:
Surgical outcome of patients considered to have "inoperable" tumors by specialized pediatric neuro-oncological multidisciplinary teams.
Childs Nerv Syst
; 2010 Sep;26(9):1219-25
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: A retrospective study was conducted on all pediatric brain and spinal cord
tumor
patients operated in a single center from 1999 to 2009.
Details of preoperative treatment,
diagnosis
and clinical status, postoperative
diagnosis
, early and late outcomes, progression-free survival and overall survival, and parental satisfaction were reviewed.
In ten cases, radical removal of the
tumor
resulted in a change in histological
diagnosis
, usually from a presumed
diagnosis of
malignancy to a more
benign
variety (n = 6).
[MeSH-minor]
Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans.
Male
. Retrospective Studies. Treatment Outcome
MedlinePlus Health Information.
consumer health - Brain Tumors
.
MedlinePlus Health Information.
consumer health - Childhood Brain Tumors
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Childs Nerv Syst. 2010 Sep;26(9):1227-8
[
20574741.001
]
[ErratumIn]
Childs Nerv Syst. 2010 Dec;26(12):1833. Charles, Teo [corrected to Teo, Charles]; Morgan, Broggi [corrected to Broggi, Morgan]
[Cites]
Curr Neurol Neurosci Rep. 2001 Mar;1(2):137-43
[
11898509.001
]
[Cites]
Breast J. 2004 Sep-Oct;10(5):469-72
[
15327510.001
]
[Cites]
BMJ. 1996 Jan 20;312(7024):145-8
[
8563532.001
]
[Cites]
J Neurooncol. 2009 May;92(3):275-82
[
19357955.001
]
[Cites]
Breast. 2006 Feb;15(1):119-22
[
16473745.001
]
[Cites]
Neuro Oncol. 2005 Jan;7(1):49-63
[
15701282.001
]
[Cites]
BMJ. 1996 May 4;312(7039):1155-6
[
8620140.001
]
[Cites]
Br J Cancer. 2006 Oct 23;95(8):979-85
[
17047646.001
]
[Cites]
Oncologist. 2007 Jul;12(7):884-98
[
17673619.001
]
[Cites]
Breast J. 2003 Jan-Feb;9(1):60-3
[
12558678.001
]
[Cites]
Med Pediatr Oncol. 2001 Feb;36(2):274-82
[
11452935.001
]
[Cites]
Curr Probl Pediatr Adolesc Health Care. 2005 Jul;35(6):230-45
[
15956960.001
]
[Cites]
Neurosurgery. 2004 Mar;54(3):553-63; discussion 563-5
[
15028128.001
]
[Cites]
Cancer. 1978 Jan;41(1):29-35
[
626937.001
]
[Cites]
Acta Neurochir (Wien). 2009 Feb;151(2):109-12
[
19194651.001
]
[Cites]
Oncology (Williston Park). 2004 Sep;18(10):1263-8; discussion 1268-70, 1275
[
15526830.001
]
[Cites]
Eur J Cancer. 2006 Oct;42(15):2480-91
[
16904313.001
]
[Cites]
Surg Clin North Am. 2000 Apr;80(2):505-33
[
10836005.001
]
[Cites]
Curr Opin Oncol. 2001 May;13(3):160-6
[
11307058.001
]
[Cites]
Pediatr Clin North Am. 1985 Jun;32(3):633-51
[
3889800.001
]
[Cites]
Semin Radiat Oncol. 2001 Apr;11(2):152-62
[
11285553.001
]
[Cites]
Oncology (Williston Park). 2004 Nov;18(13):1649-61; discussion 1662, 1665-6, 1668
[
15648297.001
]
(PMID = 20563727.001).
[ISSN]
1433-0350
[Journal-full-title]
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
[ISO-abbreviation]
Childs Nerv Syst
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
41.
Gu LQ, Li FY, Zhao L, Liu Y, Chu Q, Zang XX, Liu JM, Ning G, Zhao YJ:
Association of XIAP and P2X7 receptor expression with lymph node metastasis in papillary thyroid carcinoma.
Endocrine
; 2010 Oct;38(2):276-82
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In this cross-sectional study, a total of 62 cases were examined, including 43 patients with PTCs and 19 with
benign
nodular goiters.
In logistic regression analysis, P2X7 receptor expression,
tumor
size, and capsular infiltration were predictors for lymph node metastasis (P=0.001).
[MeSH-minor]
Adult. Biomarkers,
Tumor
/ metabolism. Female. Goiter, Nodular / metabolism. Goiter, Nodular / pathology. Humans. Lymphatic Metastasis / pathology.
Male
. Middle Aged. Predictive Value of Tests. Prognosis
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Pharmacol Rev. 2006 Mar;58(1):58-86
[
16507883.001
]
[Cites]
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
[
16916931.001
]
[Cites]
Endocr Rev. 2007 Dec;28(7):742-62
[
17940185.001
]
[Cites]
Purinergic Signal. 2009 Sep;5(3):351-68
[
19399640.001
]
[Cites]
Thyroid. 2009 Jan;19(1):21-5
[
19072670.001
]
[Cites]
Eur J Cancer. 2001 Jun;37(9):1104-10
[
11378340.001
]
[Cites]
J Endocrinol Invest. 2002 Dec;25(11):959-66
[
12553555.001
]
[Cites]
Cancer Lett. 2010 Sep 1;295(1):110-23
[
20236757.001
]
[Cites]
World J Surg. 2007 Nov;31(11):2085-91
[
17885787.001
]
[Cites]
Endocrinology. 2008 Jan;149(1):389-96
[
17947359.001
]
[Cites]
J Biol Chem. 2009 Apr 10;284(15):10120-8
[
19204004.001
]
[Cites]
J Immunol. 2006 Apr 1;176(7):3877-83
[
16547218.001
]
[Cites]
Histopathology. 2004 Mar;44(3):206-15
[
14987223.001
]
[Cites]
J Clin Endocrinol Metab. 2009 Feb;94(2):695-8
[
19017759.001
]
[Cites]
J Biol Chem. 2009 Dec 11;284(50):34553-60
[
19854829.001
]
[Cites]
JAMA. 2006 May 10;295(18):2164-7
[
16684987.001
]
[Cites]
Apoptosis. 2001 Aug;6(4):253-61
[
11445667.001
]
[Cites]
Endocrinology. 2005 Jul;146(7):3172-8
[
15790728.001
]
[Cites]
Cancer Res. 2001 Mar 1;61(5):1862-8
[
11280739.001
]
[Cites]
Nature. 2009 Aug 20;460(7258):1035-9
[
19626005.001
]
[Cites]
J Biol Chem. 2001 Apr 6;276(14):11135-42
[
11150303.001
]
[Cites]
Exp Cell Res. 2002 Oct 1;279(2):277-90
[
12243753.001
]
[Cites]
Ann Surg Oncol. 2008 May;15(5):1518-22
[
18324441.001
]
[Cites]
Biochem Pharmacol. 2009 Nov 1;78(9):1115-26
[
19540829.001
]
[Cites]
Ann Diagn Pathol. 2007 Aug;11(4):235-40
[
17630106.001
]
[Cites]
Hum Immunol. 2010 Aug;71(8):818-25
[
20493226.001
]
[Cites]
Cancer Immunol Immunother. 2004 Sep;53(9):770-6
[
15138717.001
]
[Cites]
Breast Cancer Res Treat. 2004 Jan;83(1):1-10
[
14997049.001
]
[Cites]
Mol Biol Rep. 2010 Apr;37(4):2037-42
[
19649722.001
]
[Cites]
Exp Mol Pathol. 2004 Jun;76(3):253-9
[
15126108.001
]
[Cites]
EMBO Rep. 2006 Oct;7(10):988-94
[
17016456.001
]
[Cites]
Curr Cancer Drug Targets. 2007 Dec;7(8):785-94
[
18220537.001
]
[Cites]
Purinergic Signal. 2009 Jun;5(2):251-6
[
19263244.001
]
[Cites]
Nephrol Dial Transplant. 2007 Feb;22(2):386-95
[
17040997.001
]
[Cites]
Cancer Res. 2006 Jan 15;66(2):907-14
[
16424024.001
]
[Cites]
Endocr Pathol. 2010 Sep;21(3):149-53
[
20506003.001
]
[Cites]
Science. 1996 May 3;272(5262):735-8
[
8614837.001
]
[Cites]
J Neurochem. 2000 Sep;75(3):965-72
[
10936177.001
]
[Cites]
Indian J Cancer. 2010 Apr-Jun;47(2):206-16
[
20448388.001
]
(PMID = 20972735.001).
[ISSN]
1559-0100
[Journal-full-title]
Endocrine
[ISO-abbreviation]
Endocrine
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Receptors, Purinergic P2X7; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
42.
Ohtsuka H:
Chondrolipoma of the popliteal fossa and Japanese reports.
J Dermatol
; 2006 Mar;33(3):202-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Six patients were
male
and five were female.
Two lesions each arose on the tongue, upper back and popliteal fossa, and one each on the buccal submucosa, shoulder,
breast
, lateral chest and sole.
The presented
tumor
was an early one because of the shortest duration and the smallest size in Japan.
Recent criteria for a
benign
mesenchymoma including a chondrolipoma were also described.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16620227.001).
[ISSN]
0385-2407
[Journal-full-title]
The Journal of dermatology
[ISO-abbreviation]
J. Dermatol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Japan
[Number-of-references]
18
43.
Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, Sanlioglu S:
Differential expression of TRAIL and its receptors in benign and malignant prostate tissues.
J Urol
; 2007 Jan;177(1):359-64
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Differential expression of TRAIL and its receptors in
benign
and malignant prostate tissues.
PURPOSE: Because TRAIL (
tumor
necrosis factor related apoptosis inducing ligand) selectively kills cancer cells without damaging normal cells, a gene therapy approach using TRAIL is feasible for treating patients with cancer.
Our recent studies suggest that TRAIL receptor composition is the major modulator of TRAIL sensitivity, as demonstrated using prostate,
breast
and lung cancer cells.
MATERIALS AND METHODS: Paraffin embedded prostate tissues of 44 patients with
benign
prostatic hyperplasia, 28 with organ confined prostate carcinoma and 26 with advanced prostate carcinoma were analyzed using immunohistochemical staining procedures.
RESULTS: Significant levels of TRAIL-R4 decoy receptor expression were detected in patients with
benign
prostatic hyperplasia, and organ confined and advanced prostate carcinoma.
All TRAIL markers tested appear to be valuable markers for separating patients with
benign
prostatic hyperplasia from patients with organ confined prostate carcinoma or advanced prostate carcinoma.
[MeSH-minor]
Humans. Immunohistochemistry.
Male
MedlinePlus Health Information.
consumer health - Enlarged Prostate (BPH)
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17162091.001).
[ISSN]
0022-5347
[Journal-full-title]
The Journal of urology
[ISO-abbreviation]
J. Urol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand
44.
Smarrito S, Salmon R:
[Desmoid tumor in a male breast in the context of Gardner's syndrome. Case report].
Ann Chir
; 2005 Jan;130(1):40-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Desmoid
tumor
in a
male breast
in the context of Gardner's syndrome. Case report].
[Transliterated title]
Tumeur
desmoïde
du sein chez l'homme
dans le cadre d'un syndrome
de
Gardner. A propos d'un cas.
Fibromatosis (Desmoid
tumor
) of the
male breast
is an exceptional location.
We present a case of such a
tumor
, in the context of Gardner's syndrome.
A palpable mass was discovered in the right
breast
of a 52 years old man, with a history of rectocolic adenomatous polyposis.
Mammography ant thoracic CT scan showed a stellar
tumor
, mimicking a
breast
cancer.
Treatment consisted of wide excision and histology revealed a desmoid
tumor
.
Desmoid tumors of the
breast
are
benign
lesions; they should be widely excised because of a high risk of recurrence.
Coloscopy is indicated in the presence of mammary fibromatosis, to look for associated multiple polyps, confirming
the diagnosis
of Gardner's syndrome.
[MeSH-major]
Breast
Neoplasms,
Male
/ pathology.
Breast
Neoplasms,
Male
/ surgery. Fibromatosis, Aggressive / pathology. Fibromatosis, Aggressive / surgery. Gardner Syndrome / complications
[MeSH-minor]
Colonoscopy. Humans.
Male
. Middle Aged. Risk Factors. Tomography, X-Ray Computed
Genetic Alliance.
consumer health - Desmoid Tumor
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15664376.001).
[ISSN]
0003-3944
[Journal-full-title]
Annales de chirurgie
[ISO-abbreviation]
Ann Chir
[Language]
fre
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
France
45.
Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T:
Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin.
Anal Quant Cytol Histol
; 2010 Apr;32(2):90-101
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the
breast
and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin.
RESULTS: HSP47 and fascin were localized to cytoplasm, and HSP47 and fascin IR were higher in IDC and PCa than
benign
groups (p < 0.05).
Fascin expression correlated with estrogen receptor and progesterone receptor negativity,
tumor
size and stage in IDC and surgical margin status in PCa.
Although there is no relationship with recurrence or metastatic status, fascin overexpression correlated with
tumor
size, which may prompt its use as a prognostic factor in IDC.
Genetic Alliance.
consumer health - invasive ductal carcinoma
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20701077.001).
[ISSN]
0884-6812
[Journal-full-title]
Analytical and quantitative cytology and histology
[ISO-abbreviation]
Anal. Quant. Cytol. Histol.
[Language]
ENG
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / FSCN1 protein, human; 0 / HSP47 Heat-Shock Proteins; 0 / Microfilament Proteins
46.
Ahmed HG, Ali AS, Almobarak AO:
Frequency of breast cancer among Sudanese patients with breast palpable lumps.
Indian J Cancer
; 2010 Jan-Mar;47(1):23-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Frequency of
breast
cancer among Sudanese patients with
breast
palpable lumps.
BACKGROUND:
Breast
cancer mortality is high in Sudan and most patients are detected at later stages of the disease due to the lack of awareness and absence of screening programs.
This study aimed to determine the pattern and frequency of
breast
cancer among patients presenting with palpable
breast
lumps within one year duration.
METHODS AND MATERIALS: We obtained information (patient's personal data) and Fine-Needle Aspiration (FNA) materials, for occurrence of 200
breast
lesions in patients.
RESULTS: The diagnoses of the 200
breast
lesions were as follows: 68 (34%) were malignant, 56 cases (28%) were fibroadenoma, 23 cases (11.5%) were fibrocystic change, 22 cases (11%) were inflammatory lesions (including mastitis and abscess formation), 12 cases (6%) were
benign
cysts and the remaining 19 patients (9.5%) were with lactation changes (8 cases), lipoma (6 cases), gynecomastia (3 cases) and phyllodes
tumor
(2 cases).
CONCLUSIONS: The frequency of advanced
breast
cancer among patients with
breast
lesions is high, in this subset of patients, which signals the urgency for implementation of
breast
screening programs.
[MeSH-major]
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms / epidemiology.
Breast
Neoplasms,
Male
/
diagnosis
.
Breast
Neoplasms,
Male
/ epidemiology
[MeSH-minor]
Adolescent. Adult. Age Distribution. Age Factors. Aged. Aged, 80 and over. Biopsy, Fine-Needle.
Breast
Diseases /
diagnosis
.
Breast
Diseases / epidemiology. Female. Humans.
Male
. Middle Aged. Sudan / epidemiology. Young Adult
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20071785.001).
[ISSN]
1998-4774
[Journal-full-title]
Indian journal of cancer
[ISO-abbreviation]
Indian J Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
47.
Nabarra B, Pontoux C, Godard C, Osborne-Pellegrin M, Ezine S:
Neoplastic transformation and angiogenesis in the thymus of transgenic mice expressing SV40 T and t antigen under an L-pyruvate kinase promoter (SV12 mice).
Int J Exp Pathol
; 2005 Dec;86(6):397-413
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We describe the development of a carcinoma originating from thymic hyperplasia and followed by the formation of a
benign
tumour composed chiefly of medullary epithelial cells expressing the transgene and of lymphocytes, a pathology very rarely reported in mice.
[MeSH-major]
Antigens, Polyomavirus Transforming / genetics. Antigens, Viral,
Tumor
/ genetics. Neovascularization, Pathologic. Promoter Regions, Genetic. Pyruvate Kinase / genetics. Thymus Neoplasms / pathology
[MeSH-minor]
Animals. Biomarkers,
Tumor
/ analysis. Cell Transformation, Neoplastic. Female. Immunohistochemistry / methods.
Male
. Mice. Mice, Inbred CBA. Mice, Transgenic. Microscopy, Immunoelectron. Thymus Gland / pathology
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Thymus. 1993 Aug;22(1):13-33
[
7508157.001
]
[Cites]
Br J Cancer. 1994 Mar;69(3):409-16
[
8123467.001
]
[Cites]
Mol Cell Biol. 1994 Apr;14(4):2686-98
[
8139568.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3979-83
[
8171023.001
]
[Cites]
Prog Growth Factor Res. 1994;5(1):89-97
[
7515293.001
]
[Cites]
Histopathology. 1994 Jul;25(1):21-9
[
7959642.001
]
[Cites]
Int Rev Cytol. 1995;159:113-60
[
7537724.001
]
[Cites]
Am J Pathol. 1995 May;146(5):1029-39
[
7538264.001
]
[Cites]
Breast Cancer Res Treat. 1995;36(2):127-37
[
8534862.001
]
[Cites]
Nat Med. 1995 Jan;1(1):27-31
[
7584949.001
]
[Cites]
J Pathol. 1995 Nov;177(3):309-15
[
8551394.001
]
[Cites]
Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5742-6
[
8650163.001
]
[Cites]
Cell. 1996 Aug 9;86(3):353-64
[
8756718.001
]
[Cites]
Cancer Metastasis Rev. 1995 Dec;14(4):263-77
[
8821090.001
]
[Cites]
Cancer Lett. 1996 Oct 22;107(2):293-300
[
8947527.001
]
[Cites]
Cell. 1997 Jun 13;89(6):981-90
[
9200616.001
]
[Cites]
Science. 1997 Jul 4;277(5322):48-50
[
9229772.001
]
[Cites]
Am J Pathol. 1997 Sep;151(3):671-7
[
9284815.001
]
[Cites]
Lab Invest. 1990 Jun;62(6):690-6
[
1694254.001
]
[Cites]
Lab Invest. 1990 Sep;63(3):298-306
[
1697637.001
]
[Cites]
Anticancer Res. 1990 Sep-Oct;10(5A):1335-9
[
1700664.001
]
[Cites]
Annu Rev Physiol. 1991;53:217-39
[
1710435.001
]
[Cites]
Exp Pathol. 1990;40(4):301-12
[
2098275.001
]
[Cites]
Eur J Cancer. 1991;27(6):781-5
[
1712608.001
]
[Cites]
Virchows Arch. 1998 Jan;432(1):33-42
[
9463585.001
]
[Cites]
Nat Med. 2000 Apr;6(4):389-95
[
10742145.001
]
[Cites]
Dev Comp Immunol. 2001 Apr;25(3):231-43
[
11164888.001
]
[Cites]
Nat Immunol. 2002 Jul;3(7):635-42
[
12068292.001
]
[Cites]
Immunity. 2002 Jun;16(6):803-14
[
12121662.001
]
[Cites]
J Immunol. 2002 Sep 15;169(6):2842-5
[
12218095.001
]
[Cites]
Mol Aspects Med. 2002 Dec;23(6S):S1-27
[
12537983.001
]
[Cites]
Dev Immunol. 2002 Dec;9(4):223-31
[
15144019.001
]
[Cites]
Cancer Res. 1975 Oct;35(10):2771-9
[
1157049.001
]
[Cites]
Nature. 1979 Mar 15;278(5701):261-3
[
218111.001
]
[Cites]
J Mol Biol. 1981 Dec 25;153(4):933-59
[
6177862.001
]
[Cites]
Am J Clin Pathol. 1982 Oct;78(4):500-7
[
6182789.001
]
[Cites]
Cell. 1982 Sep;30(2):361-72
[
6183000.001
]
[Cites]
Differentiation. 1983;23(3):256-69
[
6189757.001
]
[Cites]
Pathol Res Pract. 1982;175(2-3):256-65
[
6190148.001
]
[Cites]
Am J Pathol. 1984 Jan;114(1):121-30
[
6197886.001
]
[Cites]
J Pathol. 1983 Nov;141(3):385-413
[
6198502.001
]
[Cites]
Lab Invest. 1984 Jan;50(1):36-41
[
6198559.001
]
[Cites]
Cell. 1984 Jun;37(2):367-79
[
6327063.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11822-7
[
9751749.001
]
[Cites]
Am J Surg Pathol. 1998 Dec;22(12):1474-81
[
9850173.001
]
[Cites]
Semin Diagn Pathol. 1999 Feb;16(1):2-17
[
10355650.001
]
[Cites]
Pathology. 1998 May;30(2):111-22
[
9643488.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7533-7
[
8356051.001
]
[Cites]
Cancer Res. 1984 Dec;44(12 Pt 1):5797-804
[
6209004.001
]
[Cites]
Lab Invest. 1985 Jan;52(1):31-8
[
2578201.001
]
[Cites]
Lab Invest. 1985 Mar;52(3):243-56
[
2579289.001
]
[Cites]
Mol Cell Biol. 1985 Apr;5(4):642-8
[
2985963.001
]
[Cites]
J Natl Cancer Inst. 1985 Aug;75(2):369-79
[
3860689.001
]
[Cites]
Nature. 1985 Aug 1-7;316(6027):457-60
[
2991771.001
]
[Cites]
Lab Invest. 1986 Nov;55(5):521-30
[
2430138.001
]
[Cites]
Science. 1987 Jan 23;235(4787):442-7
[
2432664.001
]
[Cites]
J Virol. 1987 Jun;61(6):2029-32
[
3033329.001
]
[Cites]
Thymus. 1987;9(2):95-121
[
3296336.001
]
[Cites]
Mol Cell Biol. 1987 Sep;7(9):3178-84
[
3118193.001
]
[Cites]
EMBO J. 1987 Sep;6(9):2699-704
[
2824189.001
]
[Cites]
Proc Natl Acad Sci U S A. 1988 May;85(9):3135-9
[
2452444.001
]
[Cites]
J Comp Pathol. 1988 Aug;99(2):187-203
[
2846660.001
]
[Cites]
Toxicol Pathol. 1988;16(3):321-6
[
3194653.001
]
[Cites]
Cell Tissue Res. 1988 Oct;254(1):225-31
[
2461804.001
]
[Cites]
Oncogene Res. 1988;3(1):87-97
[
3060799.001
]
[Cites]
Annu Rev Genet. 1988;22:479-519
[
3071256.001
]
[Cites]
Nature. 1989 May 4;339(6219):58-61
[
2469964.001
]
[Cites]
Cell. 1989 Sep 8;58(5):803-5
[
2673531.001
]
[Cites]
Cancer Res. 1989 Nov 1;49(21):6108-17
[
2551499.001
]
[Cites]
Am J Pathol. 1989 Oct;135(4):679-95
[
2552813.001
]
[Cites]
J Clin Invest. 1989 Nov;84(5):1470-8
[
2478587.001
]
[Cites]
Science. 1989 Dec 8;246(4935):1306-9
[
2479986.001
]
[Cites]
Am J Surg Pathol. 1990 Feb;14(2):151-66
[
1689123.001
]
[Cites]
Blood. 1990 Jun 15;75(12):2417-26
[
1693532.001
]
[Cites]
Semin Immunol. 1990 Jan;2(1):13-24
[
1717051.001
]
[Cites]
Science. 1991 Nov 22;254(5035):1161-7
[
1957168.001
]
[Cites]
J Clin Invest. 1992 Jan;89(1):244-53
[
1729274.001
]
[Cites]
Mol Biol Cell. 1992 Feb;3(2):211-20
[
1550962.001
]
[Cites]
Development. 1992 Feb;114(2):521-32
[
1592003.001
]
[Cites]
Nature. 1992 Oct 29;359(6398):845-8
[
1279432.001
]
[Cites]
Oncogene. 1992 Nov;7(11):2175-87
[
1279498.001
]
[Cites]
Cancer. 1993 Jan 1;71(1):99-105
[
7677978.001
]
[Cites]
Cancer Treat Res. 1992;63:359-71
[
1284027.001
]
[Cites]
Cell. 1993 Mar 26;72(6):835-46
[
7681362.001
]
[Cites]
FASEB J. 1993 Jul;7(10):866-71
[
8344486.001
]
[Cites]
Toxicol Pathol. 1993;21(2):206-18
[
8210943.001
]
[Cites]
Immunol Today. 1993 Sep;14(9):445-59
[
8216723.001
]
[Cites]
Cancer Metastasis Rev. 1993 Sep;12(3-4):303-24
[
8281615.001
]
(PMID = 16309545.001).
[ISSN]
0959-9673
[Journal-full-title]
International journal of experimental pathology
[ISO-abbreviation]
Int J Exp Pathol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, Polyomavirus Transforming; 0 / Antigens, Viral, Tumor; 0 / Biomarkers, Tumor; EC 2.7.1.40 / Pyruvate Kinase
[Other-IDs]
NLM/ PMC2517450
48.
Meaney PM, Fanning MW, di Florio-Alexander RM, Kaufman PA, Geimer SD, Zhou T, Paulsen KD:
Microwave tomography in the context of complex breast cancer imaging.
Conf Proc IEEE Eng Med Biol Soc
; 2010;2010:3398-401
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Microwave tomography in the context of complex
breast
cancer imaging.
The notion of applying microwave imaging to
breast
cancer imaging has been studied at various levels by numerous scientists.
The earliest appeal of this concept related to the presumably high property contrast between
benign
and malignant tissue that was unique to the
breast
.
Subsequent published studies have shown that this assumption was overly simplistic and that the tissue property heterogeneity is considerable within the
breast
.
As we have expanded the clinical use of our microwave tomographic system, we are now using this approach to monitor
tumor
progressions during neoadjuvant chemotherapy.
In these cases, while we can still characterize and track the
tumor
progression, we have observed a new phenomenon.
Very often these cancer patients exhibit skin thickening near the
tumor
site.
Our images have reconstructed elevated dielectric properties along the
breast
surface associated with the accompanying edema.
These observations further add to the complex nature of
breast
dielectric properties and the challenges for imaging them using microwave interrogation.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
IEEE Trans Med Imaging. 2001 Feb;20(2):104-16
[
11321590.001
]
[Cites]
J Microw Power. 1981 Jun;16(2):107-19
[
7033539.001
]
[Cites]
Magn Reson Med. 1991 Apr;18(2):371-83
[
2046518.001
]
[Cites]
IEEE Trans Biomed Eng. 1995 Oct;42(10):1017-26
[
8582719.001
]
[Cites]
Breast Cancer Res. 2013;15(2):R35
[
23621959.001
]
[Cites]
Acad Radiol. 2007 Feb;14(2):207-18
[
17236994.001
]
[Cites]
Radiology. 2007 May;243(2):350-9
[
17400760.001
]
[Cites]
Med Phys. 2007 Jun;34(6):2014-23
[
17654905.001
]
[Cites]
Phys Med Biol. 2007 Oct 21;52(20):6093-115
[
17921574.001
]
[Cites]
IEEE Trans Med Imaging. 1999 Jun;18(6):496-507
[
10463128.001
]
(PMID = 21097245.001).
[ISSN]
1557-170X
[Journal-full-title]
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference
[ISO-abbreviation]
Conf Proc IEEE Eng Med Biol Soc
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P01 CA080139; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / P01-CA080139
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS512905; NLM/ PMC3757128
49.
Glazebrook KN, Reynolds CA:
Mammary fibromatosis.
AJR Am J Roentgenol
; 2009 Sep;193(3):856-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
CONCLUSION: Mammary fibromatosis is a rare,
benign
, nonmetastasizing stromal
tumor
.
It presents clinically and radiologically as a palpable, spiculated, and locally invasive
tumor
that is suspicious for malignancy.
Although histologically
benign
, the
tumor
is locally aggressive and has significant recurrence rates.
[MeSH-major]
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms,
Male
/
diagnosis
. Fibroma /
diagnosis
[MeSH-minor]
Adult.
Diagnosis
, Differential. Female. Humans. Magnetic Resonance Imaging.
Male
. Middle Aged. Retrospective Studies. Ultrasonography, Mammary
Genetic Alliance.
consumer health - Fibromatosis
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19696302.001).
[ISSN]
1546-3141
[Journal-full-title]
AJR. American journal of roentgenology
[ISO-abbreviation]
AJR Am J Roentgenol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
50.
Xu F, Liu B, Chen XY, Zhou EX, Fan DF, Ma Y, Tang ZH:
[Diagnosis and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases].
Zhongguo Dang Dai Er Ke Za Zhi
; 2009 Feb;11(2):120-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Diagnosis
and therapy of childhood thyroid carcinoma: clinical analysis of 12 cases].
OBJECTIVE: To explore the clinical characteristics,
diagnosis
and therapy of thyroid carcinoma in children.
RESULTS: A hard thyroid mass was observed in 10 out of 12 children with thyroid carcinoma, but only one out of 15 children with
benign
thyroid
tumor
(<0.05).
The rate of cervical lymph node metastasis in children with thyroid carcinoma was significantly higher than that in children with
benign
thyroid
tumor
(<0.05).
A combination of ultrasonography and CT is helpful to
the diagnosis
of childhood thyroid carcinoma.
[MeSH-major]
Thyroid Neoplasms /
diagnosis
. Thyroid Neoplasms / surgery
[MeSH-minor]
Adolescent. Child. Female. Follow-Up Studies. Humans. Iodine Radioisotopes / therapeutic use.
Male
. Postoperative Complications / etiology. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19222949.001).
[ISSN]
1008-8830
[Journal-full-title]
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
[ISO-abbreviation]
Zhongguo Dang Dai Er Ke Za Zhi
[Language]
chi
[Publication-type]
English Abstract; Journal Article
[Publication-country]
China
[Chemical-registry-number]
0 / Iodine Radioisotopes
51.
Paulino AC, Fowler BZ:
Secondary neoplasms after radiotherapy for a childhood solid tumor.
Pediatr Hematol Oncol
; 2005 Mar;22(2):89-101
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Secondary neoplasms after radiotherapy for a childhood solid
tumor
.
This study was conducted to determine the outcome of patients who develop a second
neoplasm
after radiotherapy (RT) for a childhood solid
tumor
.
From 1956 to 1998, 429 children with a malignant solid
tumor
were treated at a single radiation oncology facility.
The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary
neoplasm
after treatment for malignancy.
Twenty-three (5.4%) patients developed a secondary
neoplasm
.
There were 14 malignant neoplasms in 13 (3.0%) and 14
benign
neoplasms in 11 patients (2.6%).
The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms
tumor
in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
For the 14 malignant neoplasms, the median time interval from initial
tumor
to second malignancy was 10.1 years.
The 14 second malignant neoplasms (SMN) were osteosarcoma in 3,
breast
carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
The 5- and 10-year overall survival rate after
diagnosis of
an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
The 14
benign
neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial
neoplasia
in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell
tumor
in 1.
Only 5 (36%) of the 14
benign
tumors occurred in the RT field, with osteochondroma being the most common.
More than two-thirds of children with a radiation-induced malignancy are alive 10 years after
the diagnosis
of a SMN.
[MeSH-minor]
Adolescent. Adult. Cause of Death. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant.
Male
. Radiation Dosage. Retrospective Studies. Survival Rate
MedlinePlus Health Information.
consumer health - Cancer in Children
.
MedlinePlus Health Information.
consumer health - Radiation Therapy
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15804994.001).
[ISSN]
0888-0018
[Journal-full-title]
Pediatric hematology and oncology
[ISO-abbreviation]
Pediatr Hematol Oncol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
52.
Kornasiewicz O, Debski M, Stepnowska M, Szałas A, Bar-Andziak E, Krawczyk M:
The enzymatic activity of type 1 iodothyronine deiodinase (D1) is low in liver hemangioma: a preliminary study.
Arch Immunol Ther Exp (Warsz)
; 2010 Feb;58(1):77-80
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
There has been strong evidence that the metabolism of thyroid hormones is disturbed in some neoplastic tissues such as thyroid, renal, and
breast
cancer.
However, there are few available data about D1 enzyme activity in
benign
tumors such as hemangioma, which is the most common primary liver
tumor
.
These finding demonstrate a low enzymatic activity of D1 in liver hemangioma and suggest an as yet unknown role of thyroid hormones in this type of
benign
liver
tumor
.
[MeSH-minor]
Adult. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans.
Male
. Middle Aged
Genetic Alliance.
consumer health - Hemangioma
.
MedlinePlus Health Information.
consumer health - Birthmarks
.
MedlinePlus Health Information.
consumer health - Liver Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Endocr Rev. 2002 Feb;23(1):38-89
[
11844744.001
]
[Cites]
Eur J Endocrinol. 2002 Apr;146(4):559-66
[
11916626.001
]
[Cites]
Clin Endocrinol (Oxf). 2002 Jun;56(6):735-43
[
12072042.001
]
[Cites]
Eur J Endocrinol. 2002 Aug;147(2):263-8
[
12153750.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Mar;88(3):1384-8
[
12629133.001
]
[Cites]
Cancer Lett. 2003 Mar 31;192(2):121-32
[
12668276.001
]
[Cites]
Mol Cell Endocrinol. 2003 Mar 28;201(1-2):25-31
[
12706290.001
]
[Cites]
Monaldi Arch Chest Dis. 2003 Apr-Jun;59(2):140-5
[
14635503.001
]
[Cites]
Pediatrics. 2003 Dec;112(6 Pt 1):1424-6
[
14654623.001
]
[Cites]
J Clin Endocrinol Metab. 1994 Sep;79(3):791-8
[
8077363.001
]
[Cites]
Endocrinology. 1996 Aug;137(8):3308-15
[
8754756.001
]
[Cites]
Thyroid. 2005 Mar;15(3):210-21
[
15785240.001
]
[Cites]
J Pediatr Endocrinol Metab. 2005 May;18(5):511-4
[
15921182.001
]
[Cites]
Clin Endocrinol (Oxf). 2005 Jun;62(6):672-8
[
15943828.001
]
[Cites]
Thyroid. 2005 Aug;15(8):875-81
[
16131330.001
]
[Cites]
J Clin Invest. 2005 Sep;115(9):2524-33
[
16127464.001
]
[Cites]
Thyroid. 2005 Oct;15(10):1137-46
[
16279847.001
]
[Cites]
Mol Endocrinol. 2005 Dec;19(12):3126-36
[
16037131.001
]
[Cites]
J Vasc Res. 2006;43(6):522-32
[
17008795.001
]
[Cites]
Thyroid. 2007 Jan;17(1):3-10
[
17274741.001
]
[Cites]
J Endocrinol Invest. 2001 Apr;24(4):253-61
[
11383912.001
]
(PMID = 20049650.001).
[ISSN]
1661-4917
[Journal-full-title]
Archivum immunologiae et therapiae experimentalis
[ISO-abbreviation]
Arch. Immunol. Ther. Exp. (Warsz.)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
[Chemical-registry-number]
EC 1.11.1.- / iodothyronine deiodinase type I; EC 1.11.1.8 / Iodide Peroxidase
[Other-IDs]
NLM/ PMC2816262
53.
Blanco-Aparicio C, Cañamero M, Cecilia Y, Pequeño B, Renner O, Ferrer I, Carnero A:
Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.
PLoS One
; 2010;5(2):e9305
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Elevated expression of AKT has been noted in a significant percentage of primary human
breast
cancers, mainly as a consequence of the PTEN/PI3K pathway deregulation.
To investigate the mechanistic basis of the AKT gain of function-dependent mechanisms of
breast
tumorigenesis, we explored the phenotype induced by activated AKT transgenes in a quantitative manner.
Finally, we analyzed the impact that a possible senescent checkpoint might have in the
tumor
promotion inhibition observed, crossing these lines to mammary specific p53(R172H) mutant expression, and to p27 knock-out mice.
We analyzed the
benign
, premalignant and malignant lesions extensively by pathology and at molecular level analysing the expression of proteins involved in the PI3K/AKT pathway and in cellular senescence.
Finally, our work shows that levels of activated AKT are not essential in the induction of
benign
or premalignant tumors, or in the cooperation of AKT with other tumorigenic signal such as mutant p53, once AKT pathway is activated, the relative level of activity seems not to determine the phenotype.
[MeSH-minor]
Animals. Blotting, Western. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate.
Male
. Mice. Mice, Inbred C57BL. Mice, Knockout. Mice, Transgenic. Phosphorylation.
Tumor
Suppressor Protein p53 / genetics.
Tumor
Suppressor Protein p53 / metabolism
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Biol Chem. 2001 Mar 30;276(13):9817-24
[
11139588.001
]
[Cites]
Cancer Genet Cytogenet. 2001 Mar;125(2):131-8
[
11369056.001
]
[Cites]
Trends Endocrinol Metab. 2002 Mar;13(2):75-8
[
11854022.001
]
[Cites]
Mol Cell Biol. 2002 Jun;22(11):3842-51
[
11997518.001
]
[Cites]
Nat Rev Cancer. 2002 Jul;2(7):489-501
[
12094235.001
]
[Cites]
Nat Rev Cancer. 2002 Aug;2(8):594-604
[
12154352.001
]
[Cites]
Development. 2002 Sep;129(17):4159-70
[
12163417.001
]
[Cites]
N Engl J Med. 2002 Nov 14;347(20):1593-603
[
12432047.001
]
[Cites]
Methods Mol Biol. 2003;222:131-45
[
12710684.001
]
[Cites]
Cancer Res. 2003 Jun 15;63(12):3395-402
[
12810676.001
]
[Cites]
Oncogene. 2003 Sep 11;22(39):7998-8011
[
12970748.001
]
[Cites]
Clin Cancer Res. 2003 Nov 15;9(15):5582-8
[
14654539.001
]
[Cites]
Science. 2004 Apr 23;304(5670):554
[
15016963.001
]
[Cites]
Semin Cell Dev Biol. 2004 Apr;15(2):177-82
[
15209377.001
]
[Cites]
Cancer Res. 2004 Aug 1;64(15):5048-50
[
15289301.001
]
[Cites]
Electroencephalogr Clin Neurophysiol. 1981 Aug;52(2):107-15
[
6167420.001
]
[Cites]
Nat Med. 1996 Jul;2(7):811-4
[
8673929.001
]
[Cites]
Nat Genet. 1997 May;16(1):64-7
[
9140396.001
]
[Cites]
Hum Mol Genet. 1997 Aug;6(8):1383-7
[
9259288.001
]
[Cites]
Hum Pathol. 1998 Jan;29(1):47-53
[
9445133.001
]
[Cites]
Biochim Biophys Acta. 1998 Oct 14;1378(2):F115-77
[
9823374.001
]
[Cites]
Mol Med. 1998 Dec;4(12):807-22
[
9990866.001
]
[Cites]
Breast Cancer Res Treat. 1998;52(1-3):1-15
[
10066068.001
]
[Cites]
Hum Mol Genet. 1999 Aug;8(8):1461-72
[
10400993.001
]
[Cites]
Cancer Res. 2004 Nov 1;64(21):7678-81
[
15520168.001
]
[Cites]
Oncogene. 2004 Nov 11;23(53):8571-80
[
15467756.001
]
[Cites]
Cancer Biol Ther. 2004 Aug;3(8):772-5
[
15254419.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7
[
15647370.001
]
[Cites]
Br J Cancer. 2005 Jan 17;92(1):167-75
[
15597097.001
]
[Cites]
Int J Surg Pathol. 2005 Jan;13(1):9-18
[
15735850.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 May 10;102(19):6936-41
[
15860581.001
]
[Cites]
J Cell Biochem. 2005 Aug 1;95(5):979-89
[
15838873.001
]
[Cites]
Nature. 2005 Aug 4;436(7051):636-7
[
16079829.001
]
[Cites]
Nature. 2005 Aug 4;436(7051):642
[
16079833.001
]
[Cites]
Nature. 2005 Aug 4;436(7051):725-30
[
16079851.001
]
[Cites]
Nature. 2005 Aug 11;436(7052):792
[
16094359.001
]
[Cites]
J Pathol. 2005 Oct;207(2):139-46
[
16088978.001
]
[Cites]
Ann Oncol. 2005 Nov;16(11):1723-39
[
15980158.001
]
[Cites]
Cancer Genet Cytogenet. 2005 Nov;163(1):23-9
[
16271952.001
]
[Cites]
Cancer Res. 2005 Nov 15;65(22):10174-8
[
16288002.001
]
[Cites]
Cancer Res. 2005 Nov 15;65(22):10199-207
[
16288007.001
]
[Cites]
Oncogene. 2005 Nov 14;24(50):7435-42
[
16288290.001
]
[Cites]
Cancer Cell. 2006 Jan;9(1):13-22
[
16413468.001
]
[Cites]
Cancer Cell. 2006 Jan;9(1):23-32
[
16413469.001
]
[Cites]
Cancer Biol Ther. 2006 Jul;5(7):779-85
[
16721043.001
]
[Cites]
Cancer Cell. 2006 Sep;10(3):191-202
[
16959611.001
]
[Cites]
Clin Cancer Res. 2006 Sep 15;12(18):5305-11
[
17000663.001
]
[Cites]
Breast. 2006 Dec;15(6):718-27
[
16675218.001
]
[Cites]
Oncogene. 2007 Feb 26;26(9):1338-45
[
17322919.001
]
[Cites]
Carcinogenesis. 2007 Mar;28(3):584-94
[
17050554.001
]
[Cites]
Oncogene. 2007 Apr 2;26(15):2177-84
[
17401426.001
]
[Cites]
Oncogene. 2007 Apr 2;26(15):2212-9
[
17401430.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7438-43
[
17460049.001
]
[Cites]
Front Biosci. 2007;12:4011-9
[
17485354.001
]
[Cites]
Carcinogenesis. 2007 Jul;28(7):1379-86
[
17341655.001
]
[Cites]
Nature. 2007 Jul 26;448(7152):439-44
[
17611497.001
]
[Cites]
Endocr Relat Cancer. 2007 Dec;14(4):907-33
[
18045947.001
]
[Cites]
Cancer Cell. 2008 Aug 12;14(2):146-55
[
18691549.001
]
[Cites]
J Cell Physiol. 2008 Nov;217(2):468-77
[
18561256.001
]
[Cites]
PLoS One. 2008;3(9):e3230
[
18800172.001
]
[Cites]
Clin Transl Oncol. 2008 Oct;10(10):618-27
[
18940742.001
]
[Cites]
J Pathol. 2008 Dec;216(4):399-407
[
18810758.001
]
[Cites]
Cancer Res. 2008 Dec 1;68(23):9643-53
[
19047141.001
]
[Cites]
Cancer Res. 2009 Feb 1;69(3):1099-108
[
19176372.001
]
[Cites]
Eur J Surg Oncol. 2009 Jul;35(7):702-8
[
18490128.001
]
[Cites]
J Biol Chem. 2009 Jul 10;284(28):19018-26
[
19435886.001
]
[Cites]
In Vivo. 2009 Sep-Oct;23(5):653-60
[
19779097.001
]
[Cites]
J Cell Mol Med. 2010 Jun;14(6B):1468-75
[
19799643.001
]
[Cites]
Cancer Res. 2000 Apr 15;60(8):2155-62
[
10786679.001
]
[Cites]
Clin Cancer Res. 2000 Jul;6(7):2777-87
[
10914724.001
]
[Cites]
Oncogene. 2000 Dec 11;19(53):6102-14
[
11156523.001
]
[Cites]
Mol Cell Biol. 2001 Mar;21(6):2203-12
[
11238953.001
]
(PMID = 20174572.001).
[ISSN]
1932-6203
[Journal-full-title]
PloS one
[ISO-abbreviation]
PLoS ONE
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Tumor Suppressor Protein p53; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
[Other-IDs]
NLM/ PMC2824815
54.
Waldmann J, Feldmann G, Slater EP, Langer P, Buchholz M, Ramaswamy A, Saeger W, Rothmund M, Fendrich V:
Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival.
Br J Cancer
; 2008 Dec 2;99(11):1900-7
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Snail expression was neither detected in normal adrenocortical tissue, nor in
benign
adrenocortical adenomas.
[MeSH-major]
Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / metabolism. Biomarkers,
Tumor
/ analysis. Transcription Factors / biosynthesis
[MeSH-minor]
Adolescent. Adult. Aged. Cadherins / biosynthesis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Ki-67 Antigen / biosynthesis.
Male
. Middle Aged.
Neoplasm
Staging. Prognosis. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Adrenocortical Carcinoma
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Nature. 1998 Mar 12;392(6672):190-3
[
9515965.001
]
[Cites]
Horm Res. 1997;47(4-6):279-83
[
9167965.001
]
[Cites]
Physiol Rev. 1959 Jan;39(1):162-82
[
13623432.001
]
[Cites]
Br J Cancer. 2005 Jan 31;92(2):252-8
[
15668718.001
]
[Cites]
Dig Dis Sci. 2005 Jan;50(1):42-6
[
15712635.001
]
[Cites]
Cancer. 2005 Apr 15;103(8):1631-43
[
15742334.001
]
[Cites]
Cell Cycle. 2005 Jun;4(6):772-6
[
15917668.001
]
[Cites]
Cancer Res. 2005 Sep 1;65(17):7622-7
[
16140927.001
]
[Cites]
Curr Opin Cell Biol. 2005 Oct;17(5):548-58
[
16098727.001
]
[Cites]
Cancer Cell. 2005 Sep;8(3):197-209
[
16169465.001
]
[Cites]
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
[
16493418.001
]
[Cites]
Eur J Endocrinol. 2006 Apr;154(4):587-98
[
16556722.001
]
[Cites]
Oncol Rep. 2006 Jul;16(1):65-71
[
16786124.001
]
[Cites]
Jpn J Clin Oncol. 2006 Jun;36(6):357-63
[
16766568.001
]
[Cites]
Clin Cancer Res. 2006 Sep 15;12(18):5395-402
[
17000672.001
]
[Cites]
J Clin Endocrinol Metab. 2007 Jan;92(1):148-54
[
17062775.001
]
[Cites]
Breast Cancer Res. 2006;8(4):105
[
16834762.001
]
[Cites]
Endocr Pathol. 2006 Winter;17(4):345-54
[
17525483.001
]
[Cites]
Histopathology. 2007 Aug;51(2):239-45
[
17593212.001
]
[Cites]
Endocr Relat Cancer. 2007 Sep;14(3):865-74
[
17914115.001
]
[Cites]
Nat Cell Biol. 2000 Feb;2(2):76-83
[
10655586.001
]
[Cites]
Cancer. 2000 Feb 15;88(4):711-36
[
10679640.001
]
[Cites]
Mol Cell. 2001 Jun;7(6):1267-78
[
11430829.001
]
[Cites]
Eur J Endocrinol. 2001 Sep;145(3):335-41
[
11517015.001
]
[Cites]
Cancer. 2001 Sep 1;92(5):1113-21
[
11571723.001
]
[Cites]
World J Surg. 2001 Jul;25(7):891-7
[
11572030.001
]
[Cites]
Methods. 2001 Dec;25(4):402-8
[
11846609.001
]
[Cites]
Cancer Res. 2002 Mar 15;62(6):1613-8
[
11912130.001
]
[Cites]
Am J Pathol. 2003 Feb;162(2):521-31
[
12547710.001
]
[Cites]
Am J Clin Pathol. 2004 Jul;122(1):78-84
[
15272533.001
]
[Cites]
Development. 2004 Sep;131(17):4213-24
[
15280211.001
]
[Cites]
Nat Cell Biol. 2004 Oct;6(10):931-40
[
15448698.001
]
[Cites]
Am J Clin Pathol. 1979 Sep;72(3):390-9
[
474519.001
]
[Cites]
Cancer. 1985 Feb 15;55(4):766-73
[
3967172.001
]
[Cites]
Am J Surg Pathol. 1989 Mar;13(3):202-6
[
2919718.001
]
[Cites]
Endocrinology. 1990 Jun;126(6):3251-62
[
2161753.001
]
[Cites]
Anticancer Res. 1997 Mar-Apr;17(2B):1303-9
[
9137490.001
]
[Cites]
Horm Metab Res. 1998 Jun-Jul;30(6-7):421-5
[
9694573.001
]
(PMID = 19018264.001).
[ISSN]
1532-1827
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Ki-67 Antigen; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / snail family transcription factors
[Other-IDs]
NLM/ PMC2600683
55.
Brown B, Ram A, Clayton P, Humphrey G:
Conservative management of bilateral Sertoli cell tumors of the testicle in association with the Carney complex: a case report.
J Pediatr Surg
; 2007 Sep;42(9):E13-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Large cell calcifying Sertoli cell
tumor
of the testicle is a rare, hormonally active sex cord-stromal
tumor
seen in patients with Carney complex.
The availability of specific antiestrogen drugs means that bilateral orchiectomy for this
benign tumor
may no longer be warranted.
Approximately two thirds of teenaged boys will develop some degree of
breast
enlargement that spontaneously regresses as testosterone levels rise (Ill Med J 1938;73:113).
Disorders of the
breast
.
[MeSH-major]
Multiple Endocrine
Neoplasia
/
diagnosis
. Sertoli Cell
Tumor
/ therapy. Testicular Neoplasms / therapy
[MeSH-minor]
Child. Gynecomastia / complications. Gynecomastia / therapy. Humans.
Male
Genetic Alliance.
consumer health - Carney Complex
.
MedlinePlus Health Information.
consumer health - Testicular Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17848226.001).
[ISSN]
1531-5037
[Journal-full-title]
Journal of pediatric surgery
[ISO-abbreviation]
J. Pediatr. Surg.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
56.
Mohri Y, Mohri T, Wei W, Qi YJ, Martin A, Miki C, Kusunoki M, Ward DG, Johnson PJ:
Identification of macrophage migration inhibitory factor and human neutrophil peptides 1-3 as potential biomarkers for gastric cancer.
Br J Cancer
; 2009 Jul 21;101(2):295-302
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI) and antibody arrays were used to compare protein expression in 21 pairs of gastric cancer tissue and adjacent normal mucosa and serum from 51 gastric cancer patients and 29 patients with
benign
gastric diseases.
Macrophage migration inhibitory factor (MIF) was increased five-fold (P=1.84 x 10(-7)) in the serum of gastric cancer patients relative to individuals with
benign
gastric disease.
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Clin Gastroenterol. 2001 Jan;32(1):41-4
[
11154168.001
]
[Cites]
Scand J Gastroenterol. 2000 Sep;35(9):950-6
[
11063155.001
]
[Cites]
Eur J Clin Invest. 2001 Apr;31(4):337-43
[
11298781.001
]
[Cites]
Cancer Lett. 2001 Oct 10;171(2):125-32
[
11520595.001
]
[Cites]
Tumour Biol. 2001 Sep-Oct;22(5):318-22
[
11553862.001
]
[Cites]
Helicobacter. 2001 Sep;6(3):216-24
[
11683924.001
]
[Cites]
Nat Immunol. 2001 Nov;2(11):1061-6
[
11668338.001
]
[Cites]
Cancer. 2002 Mar 1;94(5):1449-56
[
11920501.001
]
[Cites]
J Clin Pathol. 2002 Apr;55(4):298-304
[
11919217.001
]
[Cites]
Am J Pathol. 2002 Apr;160(4):1311-24
[
11943716.001
]
[Cites]
Am J Gastroenterol. 2003 Apr;98(4):735-9
[
12738449.001
]
[Cites]
Ann Oncol. 2003;14 Suppl 2:ii31-6
[
12810455.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9354-9
[
12878730.001
]
[Cites]
Cancer Res. 2003 Oct 15;63(20):6971-83
[
14583499.001
]
[Cites]
Oral Oncol. 2004 Feb;40(2):139-44
[
14693236.001
]
[Cites]
Am J Clin Pathol. 2008 May;129(5):772-9
[
18426738.001
]
[Cites]
J Immunol. 2008 Jun 1;180(11):7338-48
[
18490733.001
]
[Cites]
Pathol Oncol Res. 2008 Mar;14(1):79-83
[
18347935.001
]
[Cites]
Breast Cancer Res. 2008;10(3):R48
[
18510725.001
]
[Cites]
Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:42-7
[
15335412.001
]
[Cites]
Oncology. 1999 Jul;57(1):55-62
[
10394126.001
]
[Cites]
Gastric Cancer. 2004;7(4):233-9
[
15616771.001
]
[Cites]
BMC Cancer. 2005 Jan 19;5:8
[
15656915.001
]
[Cites]
Clin Cancer Res. 2005 Feb 1;11(3):1110-8
[
15709178.001
]
[Cites]
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
[
15761078.001
]
[Cites]
Gastroenterology. 2005 Jul;129(1):66-73
[
16012935.001
]
[Cites]
Gastroenterology. 2005 Nov;129(5):1485-503
[
16285950.001
]
[Cites]
J Clin Invest. 2006 Jan;116(1):271-84
[
16395409.001
]
[Cites]
Gut. 2006 Jun;55(6):797-802
[
16488898.001
]
[Cites]
Clin Chem. 2006 Jun;52(6):1045-53
[
16574760.001
]
[Cites]
Br J Cancer. 2006 Jun 19;94(12):1898-905
[
16755300.001
]
[Cites]
Immunity. 2006 Oct;25(4):595-606
[
17045821.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
[Cites]
Cancer Lett. 2008 Mar 18;261(2):147-57
[
18171602.001
]
[Cites]
J Exp Med. 1999 Nov 15;190(10):1375-82
[
10562313.001
]
[Cites]
Am J Surg. 2001 Jan;181(1):16-9
[
11248169.001
]
(PMID = 19550422.001).
[ISSN]
1532-1827
[Journal-full-title]
British journal of cancer
[ISO-abbreviation]
Br. J. Cancer
[Language]
ENG
[Grant]
United Kingdom / Cancer Research UK / /
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Macrophage Migration-Inhibitory Factors; 0 / Neoplasm Proteins; 0 / alpha-Defensins; 0 / human neutrophil peptide 1; 0 / human neutrophil peptide 2; 0 / human neutrophil peptide 3
[Other-IDs]
NLM/ PMC2720195
57.
Meguerditchian AN, Malik DA, Hicks DG, Kulkarni S:
Solitary fibrous tumor of the breast and mammary myofibroblastoma: the same lesion?
Breast J
; 2008 May-Jun;14(3):287-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Solitary fibrous
tumor
of the
breast
and mammary myofibroblastoma: the same lesion?
Benign
stromal tumors of the
breast
are rare mesenchymal neoplasms that have significant clinical and morphologic overlap.
We report the case of a spindle cell
tumor
occurring in the mammary gland with mixed features of solitary fibrous
tumor
and mammary myofibroblastoma.
[MeSH-major]
Breast
Neoplasms,
Male
/ pathology. Neoplasms, Muscle Tissue / pathology. Solitary Fibrous Tumors / pathology
[MeSH-minor]
Aged. Humans.
Male
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18384484.001).
[ISSN]
1524-4741
[Journal-full-title]
The breast journal
[ISO-abbreviation]
Breast J
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
26
58.
Abdel Salam I, Gaballa HE, Abdel Wahab N:
Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation.
Med Oncol
; 2009;26(2):161-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
A total of 30 patients with pathologically proven NSCLC were enrolled in this study in addition to ten normal controls subjects and ten cases with
benign
pulmonary diseases as broncheicatsis, chronic obstructive pulmonary disease.
The levels were significantly higher in those with stages III, IV compared with I, II, and in those with higher grades of the
tumor
.
[MeSH-major]
Biomarkers,
Tumor
/ blood. Carcinoma, Non-Small-Cell Lung /
diagnosis
. Lung Neoplasms /
diagnosis
. Receptor, Epidermal Growth Factor / blood. Receptor, ErbB-2 / blood
[MeSH-minor]
Aged. Bronchoalveolar Lavage Fluid / chemistry. Female. Humans.
Male
. Middle Aged. Prognosis
Genetic Alliance.
consumer health - Lung Cancer
.
Genetic Alliance.
consumer health - Non-small cell lung cancer
.
MedlinePlus Health Information.
consumer health - Lung Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Thorax. 2006 Feb;61(2):140-5
[
16284218.001
]
[Cites]
Science. 1986 Jun 27;232(4758):1644-6
[
3012781.001
]
[Cites]
Oncology. 1995 Sep-Oct;52(5):392-6
[
7637957.001
]
[Cites]
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3645-52
[
14506153.001
]
[Cites]
Clin Cancer Res. 1997 Apr;3(4):515-22
[
9815714.001
]
[Cites]
Clin Cancer Res. 2000 Jun;6(6):2349-55
[
10873086.001
]
[Cites]
J Clin Oncol. 2001 Mar 15;19(6):1698-706
[
11250999.001
]
[Cites]
J Thorac Cardiovasc Surg. 1994 Feb;107(2):590-5
[
7905543.001
]
[Cites]
J Biol Chem. 1991 Jan 25;266(3):1716-20
[
1671042.001
]
[Cites]
Biochim Biophys Acta. 1994 Dec 30;1198(2-3):165-84
[
7819273.001
]
[Cites]
J Surg Oncol. 1992 Apr;49(4):209-12
[
1348293.001
]
[Cites]
Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):136-43
[
14734462.001
]
[Cites]
J Clin Oncol. 2003 Nov 1;21(21):3902-8
[
14507943.001
]
[Cites]
J Thorac Cardiovasc Surg. 1999 Apr;117(4):736-43
[
10096969.001
]
[Cites]
J Clin Oncol. 2003 Oct 15;21(20):3798-807
[
12953099.001
]
[Cites]
Oncogene. 1996 Jul 4;13(1):63-72
[
8700555.001
]
[Cites]
Cancer. 2005 May 1;103(9):1865-73
[
15770690.001
]
[Cites]
Br J Cancer. 1998 Feb;77(4):663-9
[
9484827.001
]
[Cites]
Crit Rev Oncog. 1994;5(2-3):313-29
[
7849090.001
]
[Cites]
Clin Cancer Res. 2002 Jan;8(1):54-60
[
11801540.001
]
[Cites]
Diagn Mol Pathol. 2003 Dec;12(4):201-11
[
14639106.001
]
[Cites]
Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1093-7
[
9563724.001
]
[Cites]
J Clin Oncol. 1999 Jul;17(7):1983-7
[
10561248.001
]
[Cites]
J Pathol. 1987 Aug;152(4):297-307
[
3668732.001
]
[Cites]
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
[
11252954.001
]
[Cites]
Oncol Rep. 2000 May-Jun;7(3):603-7
[
10767376.001
]
[Cites]
J Clin Oncol. 2005 Aug 1;23(22):5007-18
[
16051952.001
]
[Cites]
Clin Cancer Res. 1998 Jan;4(1):241-9
[
9516978.001
]
[Cites]
Clin Cancer Res. 2002 Mar;8(3):734-44
[
11895903.001
]
[Cites]
Anticancer Res. 1997 Mar-Apr;17(2A):1023-6
[
9137444.001
]
[Cites]
Clin Cancer Res. 2001 Oct;7(10):2958-70
[
11595683.001
]
[Cites]
J Thorac Oncol. 2007 May;2(5):423-9
[
17473658.001
]
[Cites]
Ann Oncol. 2004 Jan;15(1):19-27
[
14679114.001
]
[Cites]
Br J Cancer. 1991 Mar;63(3):439-43
[
1672254.001
]
[Cites]
Lancet Oncol. 2001 Sep;2(9):533-43
[
11905707.001
]
[Cites]
Int J Cancer. 1996 Oct 21;69(5):398-402
[
8900374.001
]
[Cites]
Clin Chem. 2002 Aug;48(8):1360-2
[
12142395.001
]
[Cites]
Cancer. 1993 Oct 1;72(7):2083-8
[
8397058.001
]
[Cites]
Breast Cancer Res Treat. 1998 Jun;49(3):261-70
[
9776510.001
]
(PMID = 19093231.001).
[ISSN]
1357-0560
[Journal-full-title]
Medical oncology (Northwood, London, England)
[ISO-abbreviation]
Med. Oncol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
59.
Ewan King L, Li X, Cheikh Saad Bouh K, Pedneault M, Chu CW:
Human kallikrein 10 ELISA development and validation in breast cancer sera.
Clin Biochem
; 2007 Sep;40(13-14):1057-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Human kallikrein 10 ELISA development and validation in
breast
cancer sera.
There is significant interest in measuring hK10 which may act as a
tumor
suppressor in some cancers.
We have developed an ELISA for hK10 and determined its analytical and clinical performance in normal and
breast
cancer sera.
The assay was analytically validated and used to determine serum levels of hK10 in a set of
breast
cancer,
benign breast
disease and normal samples.
Concentrations were not age related and were not significantly different from
benign
fibrocystic disease or
breast
cancer.
However, in a subset of
breast
cancer patients with both early and late stage disease, serum hK10 levels were elevated, at >1.55 ng/mL, above all normal female and
benign
disease samples.
CONCLUSIONS: We report in detail the analytical performance of a colorimetric hK10 ELISA validated in human serum and report for the first time the hK10 serum concentration in
benign
and
breast
cancer samples.
[MeSH-major]
Breast
Neoplasms / blood. Enzyme-Linked Immunosorbent Assay / methods. Kallikreins / blood
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans.
Male
. Middle Aged. Reproducibility of Results
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17585892.001).
[ISSN]
0009-9120
[Journal-full-title]
Clinical biochemistry
[ISO-abbreviation]
Clin. Biochem.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
EC 3.4.21.- / KLK10 protein, human; EC 3.4.21.- / Kallikreins
60.
Kammori M, Izumiyama N, Nakamura K, Kurabayashi R, Kashio M, Aida J, Poon SS, Kaminishi M:
Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing benign from malignant tissue by tissue quantitative fluorescence in situ hybridization.
Oncology
; 2006;71(5-6):430-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Telomere metabolism and diagnostic demonstration of telomere measurement in the human esophagus for distinguishing
benign
from malignant tissue by tissue quantitative fluorescence in situ hybridization.
In conclusion, our TCR method can be used to distinguish between
benign
and malignant tissue in esophageal lesions.
[MeSH-major]
Carcinoma, Squamous Cell /
diagnosis
. Esophageal Neoplasms /
diagnosis
. Esophagus / pathology. In Situ Hybridization, Fluorescence / methods. Telomere / genetics
[MeSH-minor]
Aged. Anaphase / genetics. Biomarkers,
Tumor
/ biosynthesis. Centromere / pathology. Chromosomal Instability / genetics. Humans.
Male
. Middle Aged. Stem Cells / pathology
MedlinePlus Health Information.
consumer health - Esophageal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2006 S. Karger AG, Basel.
(PMID = 17878747.001).
[ISSN]
1423-0232
[Journal-full-title]
Oncology
[ISO-abbreviation]
Oncology
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Biomarkers, Tumor
61.
Yang DM, Kim HC, Lim JW, Jin W, Ryu CW, Kim GY, Cho H:
Sonographic findings of groin masses.
J Ultrasound Med
; 2007 May;26(5):605-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The most common
benign tumor
of the inguinal region was a lipoma.
Other
benign
tumors of the groin included leiomyomas, dermoid cysts, epidermoid cysts, and lymphangiomas.
Secondary malignant tumors of the inguinal regions were metastatic lymphomas and metastatic carcinomas of the lung,
breast
, ovary, and gastrointestinal tract.
CONCLUSIONS: Although there was substantial overlap of sonographic findings in the various inguinal masses, clinical history and certain sonographic details can assist in making the correct
diagnosis
.
[MeSH-minor]
Female. Humans.
Male
MedlinePlus Health Information.
consumer health - Soft Tissue Sarcoma
.
MedlinePlus Health Information.
consumer health - Ultrasound
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17460003.001).
[ISSN]
0278-4297
[Journal-full-title]
Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
[ISO-abbreviation]
J Ultrasound Med
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
62.
Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M:
Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
Hum Pathol
; 2006 Aug;37(8):1000-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential
diagnosis
and targeted therapy.
Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of
benign
and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
L1 was absent in
breast
carcinoma, gastrointestinal tract carcinomas, gastrointestinal carcinoids, renal clear-cell carcinomas, prostate adenocarcinomas, and mesotheliomas.
Surprisingly, L1 expression in established
breast
and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential
diagnosis
and target for antibody-based therapy.
[MeSH-major]
Antigens,
Neoplasm
/ metabolism. Biomarkers,
Tumor
/ metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
[MeSH-minor]
Antibodies, Monoclonal / immunology. Cell Line,
Tumor
.
Diagnosis
, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques.
Male
. Neutrophils / metabolism
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16867862.001).
[ISSN]
0046-8177
[Journal-full-title]
Human pathology
[ISO-abbreviation]
Hum. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
63.
Pontes ER, Matos LC, da Silva EA, Xavier LS, Diaz BL, Small IA, Reis EM, Verjovski-Almeida S, Barcinski MA, Gimba ER:
Auto-antibodies in prostate cancer: humoral immune response to antigenic determinants coded by the differentially expressed transcripts FLJ23438 and VAMP3.
Prostate
; 2006 Oct 1;66(14):1463-73
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Here we evaluate auto-antibody response against two potential antigenic determinants of genes highly expressed in low Gleason Score prostate cancer (PC)
tumor
samples, namely FLJ23438 and VAMP3.
The auto-antibody response against FLJ23438 and VAMP3 recombinant proteins was tested by immunoblot assays using PC,
benign
prostate hyperplasia (BPH), healthy donors (HD), and other human cancers plasma samples.
[MeSH-major]
Adenocarcinoma / immunology. Autoantibodies / blood. Biomarkers,
Tumor
/ immunology. Prostatic Neoplasms / immunology. Vesicle-Associated Membrane Protein 3 / immunology
[MeSH-minor]
Aged. Antigens / genetics. Antigens / immunology.
Breast
Neoplasms. Carcinoma, Squamous Cell. Cell Line,
Tumor
. Colorectal Neoplasms. Esophageal Neoplasms. Gene Expression Regulation, Neoplastic. Humans. Lung Neoplasms.
Male
. Middle Aged. Open Reading Frames / genetics. Prostatic Hyperplasia / epidemiology. Prostatic Hyperplasia / immunology. Prostatic Hyperplasia / physiopathology. RNA, Messenger / genetics. RNA, Small Nuclear / genetics. RNA, Small Nuclear / immunology. Recombinant Proteins / genetics. Recombinant Proteins / immunology. Seroepidemiologic Studies
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2006 Wiley-Liss, Inc.
(PMID = 16897729.001).
[ISSN]
0270-4137
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Small Nuclear; 0 / Recombinant Proteins; 0 / U2 small nuclear RNA; 0 / VAMP3 protein, human; 0 / Vesicle-Associated Membrane Protein 3
64.
Dakin Haché K, Gray S, Barnes PJ, Dewar R, Younis T, Rayson D:
Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray.
Breast Cancer Res Treat
; 2007 Oct;105(2):169-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Clinical and pathological correlations in
male breast
cancer: intratumoral aromatase expression via tissue microarray.
BACKGROUND:
Male breast
cancer (MBC) commonly expresses hormone receptors and there is anecdotal evidence of disease responsivity to aromatase inhibitors in the metastatic setting.
Specimens were reviewed for standard pathologic characteristics and
tumor
blocks were incorporated into three TMA's (four 1 mm cores per
tumor
).
ITA staining intensity was compared to control,
benign
hepatic tissue and if greater than or equal to liver was scored positive and if less than liver was scored negative.
Median
tumor
size was 2.6 cm (0.3-8.0 cm) and 22(41%) had nodal metastases.
[MeSH-major]
Aromatase / metabolism.
Breast
Neoplasms,
Male
/ enzymology
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Disease Progression. Humans. Immunoenzyme Techniques. Lymphatic Metastasis / pathology.
Male
. Middle Aged.
Neoplasm
Invasiveness. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Retrospective Studies. Survival Rate. Tissue Array Analysis
Genetic Alliance.
consumer health - Breast Cancer
.
Genetic Alliance.
consumer health - Breast Cancer, Male
.
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17268818.001).
[ISSN]
0167-6806
[Journal-full-title]
Breast cancer research and treatment
[ISO-abbreviation]
Breast Cancer Res. Treat.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 1.14.14.1 / Aromatase
65.
Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM:
Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer.
Mod Pathol
; 2007 Mar;20(3):375-83
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Aberrant expression of human leukocyte antigen G (HLA-G) has been proposed to be involved in
tumor
escape mechanisms.
It has been also proposed that detection of HLA-G might service as a potential biomarker for
diagnosis
or prediction of the clinical outcomes in ovarian and
breast
cancers, carcinoma of the lung and endometrial cancer.
In this prospectively study, HLA-G protein expression was observed in 64.6% (130/201) of the primary site colorectal carcinomas, but not in the normal colorectal tissues or
benign
adenomas.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis
[MeSH-minor]
Female. HLA-G Antigens. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology.
Male
. Middle Aged.
Neoplasm
Staging. Prognosis
Genetic Alliance.
consumer health - Colorectal Cancer
.
MedlinePlus Health Information.
consumer health - Colorectal Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17277760.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
66.
Gratzinger D, Zhao S, West R, Rouse RV, Vogel H, Gil EC, Levy R, Lossos IS, Natkunam Y:
The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities.
Am J Clin Pathol
; 2009 Feb;131(2):264-78
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The transcription factor LMO2 is involved in vascular and hematopoietic development and hematolymphoid
neoplasia
.
LMO2 reactivity is otherwise virtually absent in nonhematolymphoid tissues except in
breast
myoepithelium, prostatic basal cells, and secretory phase endometrial glands.
LMO2 is uniformly expressed in
benign
vascular and lymphatic neoplasms and in most malignant vascular neoplasms with the exception of epithelioid vascular neoplasms of pleura and bone.
Among nonvascular neoplasms, LMO2 reactivity is present in giant cell
tumor
of tendon sheath, juvenile xanthogranuloma, a subset of gastrointestinal stromal tumors, small round blue cell tumors, and myoepithelial-derived neoplasms.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19141387.001).
[ISSN]
1943-7722
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P01 CA034233; United States / NCI NIH HHS / CA / CA34233; United States / NCI NIH HHS / CA / CA122105; United States / NCI NIH HHS / CA / CA33399; United States / NCI NIH HHS / CA / R37 CA033399; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105; United States / NCI NIH HHS / CA / CA109335; United States / NCI NIH HHS / CA / P30 CA124435
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / LIM Domain Proteins; 0 / LMO2 protein, human; 0 / Metalloproteins; 0 / Proto-Oncogene Proteins
[Other-IDs]
NLM/ NIHMS636776; NLM/ PMC4305438
67.
Zhou XD, Sens MA, Garrett SH, Somji S, Park S, Gurel V, Sens DA:
Enhanced expression of metallothionein isoform 3 protein in tumor heterotransplants derived from As+3- and Cd+2-transformed human urothelial cells.
Toxicol Sci
; 2006 Oct;93(2):322-30
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Enhanced expression of metallothionein isoform 3 protein in
tumor
heterotransplants derived from As+3- and Cd+2-transformed human urothelial cells.
Immunohistochemical staining of MT-3 on archival diagnostic specimens showed that only 2 of 63 (3.17%)
benign
bladder specimens had even weak reactivity for the MT-3 protein.
The gain in MT-3 expression when cells were grown as heterotransplants was also shown to occur for the MCF-7, T-47D, Hs 578t, MDA-MB-231
breast
cancer, and the PC-3 prostate cancer cell lines.
[MeSH-minor]
Animals. Biomarkers,
Tumor
.
Breast
Neoplasms / metabolism. Cells, Cultured. Female. Humans. Immunohistochemistry.
Male
. Mice.
Neoplasm
Transplantation. Prostatic Neoplasms / metabolism. Protein Isoforms. RNA, Messenger / analysis. Transplantation, Heterologous
MedlinePlus Health Information.
consumer health - Arsenic
.
MedlinePlus Health Information.
consumer health - Bladder Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ARSENIC, ELEMENTAL
.
Hazardous Substances Data Bank.
CADMIUM, ELEMENTAL
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16854967.001).
[ISSN]
1096-6080
[Journal-full-title]
Toxicological sciences : an official journal of the Society of Toxicology
[ISO-abbreviation]
Toxicol. Sci.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / R01 CA094997; United States / NCI NIH HHS / CA / R01 CA098832
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Protein Isoforms; 0 / RNA, Messenger; 00BH33GNGH / Cadmium; 9038-94-2 / Metallothionein; N712M78A8G / Arsenic
68.
Chen L, Madura K:
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
Cancer Res
; 2005 Jul 1;65(13):5599-606
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in
breast
cancer tissue.
The activation of this pathway in various cancers and malignancies has been described, and several genetic determinants of
breast
cancer, including BRCA1 and BRCA2, are linked to protein degradation.
To investigate the involvement of the Ub/proteasome system in
breast
cancer, we examined a collection of 25 patient-matched
breast
cancer and normal adjacent tissues and detected activation of numerous components of the Ub/proteasome pathway.
The activity of the proteasome, and levels of proteasome subunits and various targeting factors, were increased in >90% of primary
breast
cancer tissue specimens.
In contrast, no activation was observed in
benign
solid tumors, indicating that the response is specific to abnormal growth in neoplastic cells.
Additionally, the accumulation of high levels of certain Ub-conjugating enzymes (UbcH1, UbcH2, and UbcH5), was specific to
breast
cancer, as no change in abundance was detected in primary colon cancer tissue extracts.
Surprisingly, the Ub/proteasome system was not activated in a well-characterized cell culture-based
breast
cancer model system.
Collectively, these findings suggest that the analysis of primary
breast
cancer tissue samples will be indispensable for the biochemical characterization of neoplastic growth and for the development of therapeutics.
[MeSH-major]
Breast
Neoplasms / enzymology. Peptide Elongation Factor 1 / metabolism. Proteasome Endopeptidase Complex / metabolism. Ubiquitin-Conjugating Enzymes / metabolism
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans.
Male
. Middle Aged.
Tumor
Cells, Cultured. Ubiquitin / metabolism
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15994932.001).
[ISSN]
0008-5472
[Journal-full-title]
Cancer research
[ISO-abbreviation]
Cancer Res.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA83875
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Peptide Elongation Factor 1; 0 / Ubiquitin; EC 3.4.25.1 / Proteasome Endopeptidase Complex; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes
69.
Da Ines D, Petitcolin V, Lannareix V, Montoriol P, Joubert Zakeyh J, Boyer L, Garcier J:
[Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation].
J Radiol
; 2009 Sep;90(9 Pt 1):1067-74
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
Rétraction capsulaire hépatique en regard d'une lésion circonscrite: à propos
de
26 patients avec preuve histologique.
PURPOSE: To review the histological features of 26 circumscribed liver lesions associated with liver capsule retraction and discuss the differential
diagnosis
while evaluating for the presence of fibrous stromal reaction.
RESULTS: Twenty-one patients had
benign
or malignant liver tumors and 5 patients had confluent hepatic fibrosis.
Twenty of 21 liver tumors were malignant (95.2%): 3 intra-hepatic cholangiocarcinoma, 17 cases of metastatic disease including colorectal carcinoma (n=8), bronchogenic carcinoma (n=1), pancreatic carcinoma (n=4), esophageal carcinoma (n=1),
breast
carcinoma (n=1), gallbladder carcinoma (1) and endocrine
neoplasm of
the pancreas (n=1), and 1 case of liver sclerosing angioma (n=1).
In keeping with previous reports, metastases were frequently the cause and intrahepatic cholangiocarcinoma was the most frequent primary
tumor
.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans.
Male
. Middle Aged. Retrospective Studies
MedlinePlus Health Information.
consumer health - Liver Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
J Radiol. 2009 Sep;90(9 Pt 1):1019-20
[
19752803.001
]
(PMID = 19752810.001).
[ISSN]
0221-0363
[Journal-full-title]
Journal de radiologie
[ISO-abbreviation]
J Radiol
[Language]
fre
[Publication-type]
English Abstract; Journal Article
[Publication-country]
France
70.
Rae JM, Johnson MD, Cordero KE, Scheys JO, Larios JM, Gottardis MM, Pienta KJ, Lippman ME:
GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
Prostate
; 2006 Jun 1;66(8):886-94
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Gene regulated in
breast
cancer 1 (GREB1) is a novel estrogen-regulated gene shown to play a pivotal role in hormone-stimulated
breast
cancer growth.
RESULTS: Real-time PCR demonstrated high level GREB1 expression in
benign
prostatic hypertrophy (BPH), localized prostate cancer (L-PCa), and hormone refractory prostate cancer (HR-PCa).
[MeSH-major]
Androgens / pharmacology. Cell Proliferation.
Neoplasm
Proteins / genetics.
Neoplasm
Proteins / physiology. Prostatic Neoplasms / genetics. Prostatic Neoplasms / physiopathology
[MeSH-minor]
Cell Line,
Tumor
. Chromatin Immunoprecipitation. DNA,
Neoplasm
/ drug effects. DNA,
Neoplasm
/ genetics. Dose-Response Relationship, Drug. Estrogens / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Humans.
Male
. Neoplasms, Hormone-Dependent / chemistry. Neoplasms, Hormone-Dependent / genetics. Neoplasms, Hormone-Dependent / pathology. Neoplasms, Hormone-Dependent / physiopathology. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis. RNA, Messenger / genetics. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16496412.001).
[ISSN]
0270-4137
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA069568
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Androgens; 0 / DNA, Neoplasm; 0 / Estrogens; 0 / GREB1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
71.
Gerszten PC, Burton SA:
Clinical assessment of stereotactic IGRT: spinal radiosurgery.
Med Dosim
; 2008;33(2):107-16
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
At our institution, we have developed a successful multidisciplinary spinal radiosurgery program in which 542 spinal lesions (486 malignant and 56
benign
lesions) were treated with a single-fraction radiosurgery technique.
The most common metastatic tumors were renal cell (89 cases),
breast
(74 cases), and lung (71 cases).
The most common
benign
tumors were neurofibroma (24 cases), schwannoma (13 cases), and meningioma (7 cases).
Tumor
volume ranged from 0.16 to 298 mL (mean 47 mL).
The primary indication for radiosurgery was pain in 326 cases, as a primary treatment modality in 70 cases, for
tumor
radiographic
tumor
progression in 65 cases, for post-surgical treatment in 38 cases, for progressive neurological deficit in 35 cases, and as a radiation boost in 8 cases.
Long-term
tumor
control was demonstrated in 90% of lesions treated with radiosurgery as a primary treatment modality and in 88% of lesions treated for radiographic
tumor
progression.
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Equipment Design. Female. Humans.
Male
. Middle Aged. Stereotaxic Techniques. Tomography, X-Ray Computed. Treatment Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18456162.001).
[ISSN]
0958-3947
[Journal-full-title]
Medical dosimetry : official journal of the American Association of Medical Dosimetrists
[ISO-abbreviation]
Med Dosim
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
72.
Misra S, Toole BP, Ghatak S:
Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells.
J Biol Chem
; 2006 Nov 17;281(46):34936-41
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Hyaluronan (HA) is enriched in the pericellular matrices of many malignant human tumors, and manipulations of HA interactions have strong effects on
tumor
progression in animal models.
On the other hand, inhibition of constitutive HA-
tumor
cell interactions in malignant cells inhibits these properties.
IGF1R-beta, PDGFR-beta, EGFR and c-MET, in colon, prostate, and
breast
carcinoma cells.
On the other hand, we show that these RTKs are activated in phenotypically normal or relatively
benign tumor
cells by experimentally increasing HA production.
[MeSH-minor]
Breast
Neoplasms / metabolism. Cell Line,
Tumor
. Colonic Neoplasms / metabolism. Female. Humans.
Male
. Prostatic Neoplasms / metabolism. Signal Transduction
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
HYALURONIC ACID
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16959784.001).
[ISSN]
0021-9258
[Journal-full-title]
The Journal of biological chemistry
[ISO-abbreviation]
J. Biol. Chem.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA073839; United States / NCI NIH HHS / CA / CA082867; United States / NCRR NIH HHS / RR / P20 RR016434; United States / NCRR NIH HHS / RR / P20 RR017698
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
9004-61-9 / Hyaluronic Acid; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
73.
Nonn L, Ananthanarayanan V, Gann PH:
Evidence for field cancerization of the prostate.
Prostate
; 2009 Sep 15;69(13):1470-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
In addition to comparing cancer-adjacent
benign
tissue to more distant areas or to "supernormal" tissue from cancer-free organs, investigators can use a nested case-control design for negative biopsies that offers a number of unique advantages.
CONCLUSIONS: True carcinogenic field effects should be distinguished from secondary responses of the microenvironment to a developing
tumor
, although the latter may still lead to useful clinical prediction tools.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Cancer. 2002 Jun 1;99(4):549-54
[
11992544.001
]
[Cites]
BJU Int. 2008 Aug;102(3):364-70
[
18410440.001
]
[Cites]
Cancer Res. 2002 Nov 15;62(22):6405-9
[
12438224.001
]
[Cites]
Oncogene. 2003 Apr 3;22(13):1978-87
[
12673203.001
]
[Cites]
Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5401-6
[
12702759.001
]
[Cites]
J Cell Biochem. 2004 Feb 15;91(3):540-52
[
14755684.001
]
[Cites]
J Urol. 2004 Apr;171(4):1419-23
[
15017188.001
]
[Cites]
Clin Cancer Res. 2004 May 15;10(10):3465-73
[
15161703.001
]
[Cites]
J Clin Oncol. 2004 Jul 15;22(14):2790-9
[
15254046.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11428-31
[
15280533.001
]
[Cites]
Mol Cancer Res. 2004 Sep;2(9):489-94
[
15383627.001
]
[Cites]
Clin Cancer Res. 2004 Oct 1;10(19):6572-8
[
15475446.001
]
[Cites]
Cancer. 1995 May 15;75(10):2545-51
[
7537624.001
]
[Cites]
Hum Pathol. 1995 Aug;26(8):824-8
[
7635445.001
]
[Cites]
Tumour Biol. 1996;17(1):58-64
[
7501974.001
]
[Cites]
Eur Urol. 1996;30(2):191-200
[
8875200.001
]
[Cites]
Hum Pathol. 1997 Feb;28(2):143-8
[
9023393.001
]
[Cites]
J Pathol. 1997 Aug;182(4):442-9
[
9306966.001
]
[Cites]
J Clin Invest. 1997 Oct 15;100(8):2133-7
[
9329980.001
]
[Cites]
J Urol. 1998 Oct;160(4):1533-9
[
9751408.001
]
[Cites]
Cancer. 1998 Nov 1;83(9):1995-2002
[
9806659.001
]
[Cites]
Cancer Res. 1998 Dec 15;58(24):5835-41
[
9865743.001
]
[Cites]
Genes Chromosomes Cancer. 1999 Feb;24(2):127-34
[
9885979.001
]
[Cites]
Clin Cancer Res. 1999 Mar;5(3):569-76
[
10100708.001
]
[Cites]
Prostate. 1999 Sep 15;41(1):12-9
[
10440871.001
]
[Cites]
Cancer Res. 1999 Oct 1;59(19):4784-7
[
10519384.001
]
[Cites]
Cancer. 1953 Sep;6(5):963-8
[
13094644.001
]
[Cites]
J Pathol Bacteriol. 1954 Oct;68(2):617-21
[
14354565.001
]
[Cites]
Cancer Res. 2005 May 15;65(10):4097-100
[
15899799.001
]
[Cites]
J Mol Histol. 2005 Mar;36(3):159-65
[
15900405.001
]
[Cites]
Prostate. 2005 Jun 1;63(4):341-6
[
15602744.001
]
[Cites]
BMC Cancer. 2005;5:45
[
15892885.001
]
[Cites]
Am J Pathol. 1999 Dec;155(6):1985-92
[
10595928.001
]
[Cites]
Eur J Cancer. 2001 Jul;37(11):1372-80
[
11435067.001
]
[Cites]
Cancer Res. 2001 Dec 15;61(24):8617-23
[
11751373.001
]
[Cites]
J Urol. 2005 Aug;174(2):514-8
[
16006883.001
]
[Cites]
Science. 2005 Oct 28;310(5748):644-8
[
16254181.001
]
[Cites]
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19093-6
[
16361440.001
]
[Cites]
Mol Cancer Res. 2006 Jan;4(1):1-8
[
16446401.001
]
[Cites]
J Natl Cancer Inst. 2006 Feb 15;98(4):255-61
[
16478744.001
]
[Cites]
Diagn Cytopathol. 2006 May;34(5):317-22
[
16604550.001
]
[Cites]
BMC Cancer. 2006;6:73
[
16545117.001
]
[Cites]
Int J Cancer. 2006 Sep 1;119(5):1082-7
[
16557596.001
]
[Cites]
J Mol Diagn. 2006 Jul;8(3):312-9
[
16825503.001
]
[Cites]
Expert Rev Mol Diagn. 2006 Nov;6(6):803-9
[
17140367.001
]
[Cites]
Nat Rev Cancer. 2007 Apr;7(4):256-69
[
17384581.001
]
[Cites]
Prostate. 2007 May 1;67(6):638-44
[
17342751.001
]
[Cites]
J Urol. 2007 May;177(5):1736-40
[
17437801.001
]
[Cites]
Am J Clin Pathol. 2007 Oct;128(4):657-66
[
17875519.001
]
[Cites]
Breast Cancer Res Treat. 2007 Nov;106(1):75-84
[
17221152.001
]
[Cites]
Mod Pathol. 2007 Nov;20(11):1121-7
[
17873893.001
]
[Cites]
Prostate. 2008 Feb 1;68(2):152-60
[
18058812.001
]
[Cites]
Mod Pathol. 2008 Feb;21(2):67-75
[
18065961.001
]
[Cites]
BJU Int. 2008 Mar;101(6):765-74
[
18190638.001
]
[Cites]
Clin Cancer Res. 2008 Jun 1;14(11):3380-5
[
18519767.001
]
[Cites]
PLoS One. 2008;3(10):e3617
[
18974881.001
]
[Cites]
J Clin Oncol. 2010 Apr 1;28(10):1714-20
[
20177031.001
]
[Cites]
J Invest Dermatol. 2002 Aug;119(2):522-6
[
12190879.001
]
(PMID = 19462462.001).
[ISSN]
1097-0045
[Journal-full-title]
The Prostate
[ISO-abbreviation]
Prostate
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA090759; United States / NCI NIH HHS / CA / R03 CA131595; United States / NCI NIH HHS / CA / R01 CA90759
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Genetic Markers
[Number-of-references]
59
[Other-IDs]
NLM/ NIHMS482768; NLM/ PMC3690597
74.
Chou SH, Tseleni-Balafouta S, Moon HS, Chamberland JP, Liu X, Kavantzas N, Mantzoros CS:
Adiponectin receptor expression in human malignant tissues.
Horm Cancer
; 2010 Jun;1(3):136-45
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
There was no difference in the expression of adiponectin receptors or their mRNA between malignant and
benign
kidney tissue specimens.
Overall, there were no correlations between expression of adiponectin receptors or their mRNA and
tumor
prognostic factors.
[MeSH-minor]
Adult. Aged. Blotting, Western. Carcinoma, Renal Cell / metabolism. Female. Humans. Immunohistochemistry. Kidney Neoplasms / metabolism.
Male
. Middle Aged. Obesity / complications. Obesity / metabolism. RNA, Messenger / analysis. Real-Time Polymerase Chain Reaction
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Am J Clin Nutr. 2007 Sep;86(3):s858-66
[
18265479.001
]
[Cites]
J Clin Endocrinol Metab. 2003 Mar;88(3):993-7
[
12629074.001
]
[Cites]
Int J Colorectal Dis. 2009 Mar;24(3):275-81
[
18979105.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Feb 24;101(8):2476-81
[
14983034.001
]
[Cites]
Oncology. 2007;73(3-4):261-9
[
18424891.001
]
[Cites]
Biochem Biophys Res Commun. 1999 Apr 2;257(1):79-83
[
10092513.001
]
[Cites]
Int J Oncol. 2009 Feb;34(2):339-44
[
19148467.001
]
[Cites]
Dig Dis Sci. 2008 Mar;53(3):597-605
[
17763959.001
]
[Cites]
Cancer Lett. 2010 Feb 28;288(2):177-82
[
19646806.001
]
[Cites]
Genes Dev. 2004 Aug 15;18(16):1926-45
[
15314020.001
]
[Cites]
Endocrinology. 2010 Jan;151(1):115-22
[
19887569.001
]
[Cites]
J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94
[
16288122.001
]
[Cites]
Jpn J Clin Oncol. 2008 Feb;38(2):106-11
[
18245516.001
]
[Cites]
Biochem Biophys Res Commun. 2005 Jul 22;333(1):79-87
[
15936715.001
]
[Cites]
Breast Cancer Res Treat. 2008 Dec;112(3):405-10
[
18163210.001
]
[Cites]
Maturitas. 2009 Jul 20;63(3):253-6
[
19524379.001
]
[Cites]
Int J Cancer. 1993 Oct 21;55(4):555-61
[
8406981.001
]
[Cites]
Clin Sci (Lond). 2002 Aug;103(2):137-42
[
12149104.001
]
[Cites]
Cancer Metastasis Rev. 2003 Dec;22(4):395-403
[
12884914.001
]
[Cites]
Mol Cell Endocrinol. 2008 Mar 26;285(1-2):43-50
[
18313838.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):10983-5
[
11572954.001
]
[Cites]
Obstet Gynecol Surv. 2005 Oct;60(10):683-92
[
16186785.001
]
[Cites]
Oncogene. 2004 Aug 23;23(38):6365-78
[
15322511.001
]
[Cites]
Obesity (Silver Spring). 2006 Jan;14(1):28-35
[
16493120.001
]
[Cites]
J Clin Endocrinol Metab. 2007 Mar;92(3):1041-8
[
17192291.001
]
[Cites]
Trends Pharmacol Sci. 2005 Feb;26(2):69-76
[
15681023.001
]
[Cites]
Lancet. 2008 Feb 16;371(9612):569-78
[
18280327.001
]
[Cites]
Eur J Cancer. 2007 Jun;43(9):1430-6
[
17512191.001
]
[Cites]
Oncol Rep. 2008 Oct;20(4):971-7
[
18813842.001
]
[Cites]
J Biol Chem. 2005 May 6;280(18):18341-7
[
15734737.001
]
[Cites]
Int J Hematol. 2008 Nov;88(4):374-80
[
18818986.001
]
[Cites]
J Clin Pathol. 2009 Aug;62(8):705-9
[
19638541.001
]
[Cites]
Int J Cancer. 2007 Jan 1;120(1):140-6
[
17036323.001
]
[Cites]
Endocr Relat Cancer. 2008 Mar;15(1):289-99
[
18310295.001
]
[Cites]
BMJ. 2007 Dec 1;335(7630):1134
[
17986716.001
]
[Cites]
Eur Urol. 2008 Oct;54(4):866-73
[
18343565.001
]
[Cites]
Int J Obes (Lond). 2007 Dec;31(12):1843-8
[
17607322.001
]
[Cites]
Int J Cancer. 2007 Apr 1;120(7):1573-8
[
17205522.001
]
[Cites]
J Clin Endocrinol Metab. 2004 Mar;89(3):1160-3
[
15001602.001
]
[Cites]
Anticancer Res. 2009 Aug;29(8):3321-7
[
19661351.001
]
[Cites]
Int J Cancer. 1996 Feb 8;65(4):432-6
[
8621222.001
]
[Cites]
Cancer. 2003 Aug 15;98(4):814-21
[
12910527.001
]
[Cites]
Oncogene. 2000 May 15;19(21):2474-88
[
10851046.001
]
[Cites]
Gut. 2008 Nov;57(11):1531-8
[
18676419.001
]
[Cites]
Lung Cancer. 2008 Sep;61(3):391-7
[
18342391.001
]
[Cites]
Cancer Causes Control. 2009 Jul;20(5):625-33
[
19051043.001
]
[Cites]
Cancer Causes Control. 2006 Sep;17(7):901-9
[
16841257.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):308-13
[
17301264.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1214-21
[
18483344.001
]
[Cites]
Cancer Sci. 2007 Jul;98(7):1120-7
[
17459059.001
]
(PMID = 21761356.001).
[ISSN]
1868-8500
[Journal-full-title]
Hormones & cancer
[ISO-abbreviation]
Horm Cancer
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / RNA, Messenger; 0 / Receptors, Adiponectin
75.
Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E, Czerwenka K:
Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition.
Oncol Rep
; 2006 Feb;15(2):353-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Protein expression was, however, considerably less frequent in normal
breast
(18%), lung (16%) and ovarian (12%) tissues.
In contrast to their corresponding
benign
tissues, pCrkL expression was significantly more common in
breast
cancer samples (49%, p<0.0001; Fisher's exact test), lung carcinomas (55%, p=0.0002), lymphatic tissues (80% vs. 10%, p=0.012), skin cancer (67%, p=0.020), ovarian malignomas (50%, p<0.0001) and colon carcinomas (63%, p<0.03).
We hypothesize that pCrkL is selectively up-regulated in a number of malignant
tumor
entities and involved in malignant transformation.
[MeSH-major]
Adaptor Proteins, Signal Transducing / biosynthesis. Biomarkers,
Tumor
/ analysis. Neoplasms / drug therapy. Neoplasms / metabolism. Nuclear Proteins / biosynthesis. Protein Kinase Inhibitors / therapeutic use. Protein-Tyrosine Kinases / drug effects
[MeSH-minor]
Benzamides. Blotting, Western. Cell Line,
Tumor
. Enzyme Activation / drug effects. Female. Humans. Imatinib Mesylate. Immunohistochemistry.
Male
. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Up-Regulation
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
Hazardous Substances Data Bank.
IMATINIB MESYLATE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16391854.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Benzamides; 0 / Biomarkers, Tumor; 0 / CRKL protein; 0 / Nuclear Proteins; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases
76.
Brodie A, Njar V, Macedo LF, Vasaitis TS, Sabnis G:
The Coffey Lecture: steroidogenic enzyme inhibitors and hormone dependent cancer.
Urol Oncol
; 2009 Jan-Feb;27(1):53-63
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVES: To improve treatment for patients with
breast
and prostate cancer.
Aromatase (estrogen synthetase) inhibitors have now been extensively tested in clinical trials in
breast
cancer patients.
Inhibitors of aromatase (AIs) are showing greater benefit than antiestrogens in the treatment of
breast
cancer.
Although effective in other conditions in both women and men, AIs have not been useful in
benign
prostatic hypertrophy or prostate cancer.
Analysis of
breast
tumors from mice treated with letrozole revealed up-regulation of HER-2 and MAP Kinase signaling proteins and down-regulation of the estrogen receptor.
When mice bearing resistant tumors were treated with trastuzumab, the anti-HER-2 antibody (herceptin), HER-2 was decreased in the
tumor
but the estrogen receptor and aromatase were restored.
Tumor
growth was significantly inhibited by treatment with trastuzumab in addition to letrozole.
CONCLUSIONS: Aromatase inhibitors are proving to be an effective new class of agents for the treatment of
breast
cancer.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ANASTROZOLE
.
Hazardous Substances Data Bank.
Trastuzumab
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Steroids. 1987 Oct-Dec;50(4-6):523-36
[
3332939.001
]
[Cites]
Br J Cancer. 1999 Oct;81(4):622-30
[
10574247.001
]
[Cites]
J Clin Endocrinol Metab. 1989 Feb;68(2):461-8
[
2465302.001
]
[Cites]
N Engl J Med. 1989 Aug 17;321(7):419-24
[
2503724.001
]
[Cites]
Cancer Res. 1989 Dec 1;49(23):6551-5
[
2479464.001
]
[Cites]
Biol Reprod. 1989 Nov;41(5):889-98
[
2696557.001
]
[Cites]
Cancer Res. 1990 Nov 1;50(21):6949-54
[
2208160.001
]
[Cites]
J Clin Endocrinol Metab. 1991 Oct;73(4):717-26
[
1890148.001
]
[Cites]
Ann Med. 1991 Aug;23(3):201-3
[
1718322.001
]
[Cites]
Gynecol Endocrinol. 1992 Mar;6(1):13-7
[
1580162.001
]
[Cites]
J Clin Endocrinol Metab. 1992 Jun;74(6):1247-52
[
1592866.001
]
[Cites]
Cancer. 1993 Feb 1;71(3 Suppl):1059-67
[
8428328.001
]
[Cites]
J Steroid Biochem Mol Biol. 1993 Mar;44(4-6):321-30
[
8476746.001
]
[Cites]
J Steroid Biochem Mol Biol. 1993 Apr;45(4):217-25
[
8499330.001
]
[Cites]
J Natl Cancer Inst. 1994 Apr 6;86(7):527-37
[
8133536.001
]
[Cites]
Cancer Res. 1994 Jun 1;54(11):2861-4
[
8187068.001
]
[Cites]
N Engl J Med. 1995 May 25;332(21):1393-8
[
7723794.001
]
[Cites]
Nat Genet. 1995 Apr;9(4):401-6
[
7795646.001
]
[Cites]
Annu Rev Pharmacol Toxicol. 1995;35:195-211
[
7598491.001
]
[Cites]
Cancer Res. 1995 Jul 15;55(14):3073-7
[
7606729.001
]
[Cites]
Science. 1995 Dec 1;270(5241):1491-4
[
7491495.001
]
[Cites]
Endocrinology. 1996 Jul;137(7):3061-8
[
8770932.001
]
[Cites]
Prostate. 1996 Sep;29(3):153-8
[
8827083.001
]
[Cites]
J Urol. 1997 Apr;157(4):1204-7
[
9120902.001
]
[Cites]
Drugs Aging. 1997 Jan;10(1):50-8
[
9111707.001
]
[Cites]
J Med Chem. 1998 Mar 12;41(6):902-12
[
9526564.001
]
[Cites]
J Biol Chem. 1998 May 22;273(21):13317-23
[
9582378.001
]
[Cites]
Curr Pharm Des. 1999 Mar;5(3):163-80
[
10066888.001
]
[Cites]
Cancer Lett. 1999 Jun 1;140(1-2):27-35
[
10403538.001
]
[Cites]
Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):884s-8s
[
15701882.001
]
[Cites]
J Med Chem. 2005 Apr 21;48(8):2972-84
[
15828836.001
]
[Cites]
Cancer Res. 2005 Jun 15;65(12):5380-9
[
15958587.001
]
[Cites]
Curr Med Chem. 2005;12(14):1623-9
[
16022662.001
]
[Cites]
BJU Int. 2005 Dec;96(9):1241-6
[
16287438.001
]
[Cites]
Minerva Endocrinol. 2006 Mar;31(1):1-12
[
16498360.001
]
[Cites]
Cancer Res. 2006 Mar 1;66(5):2815-25
[
16510604.001
]
[Cites]
Pharmacol Ther. 2006 Jul;111(1):27-52
[
16426683.001
]
[Cites]
Cancer Res. 2007 May 15;67(10):5033-41
[
17510436.001
]
[Cites]
Prostate Cancer Prostatic Dis. 2007;10(3):301-6
[
17387321.001
]
[Cites]
Mol Cancer Ther. 2008 Aug;7(8):2348-57
[
18723482.001
]
[Cites]
Cancer Res. 2009 Feb 15;69(4):1416-28
[
19190349.001
]
[Cites]
Br J Cancer. 2010 Sep 28;103(7):1001-7
[
20842117.001
]
[Cites]
Cancer Res. 2000 Dec 1;60(23):6630-40
[
11118046.001
]
[Cites]
Cancer. 2001 Oct 15;92(8):2095-101
[
11596025.001
]
[Cites]
J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):41-7
[
11850206.001
]
[Cites]
Lancet. 2002 Jun 22;359(9324):2131-9
[
12090977.001
]
[Cites]
Arch Pharm (Weinheim). 2002 Apr;335(4):119-28
[
12112031.001
]
[Cites]
Clin Cancer Res. 2002 Jul;8(7):2378-88
[
12114443.001
]
[Cites]
Oncogene. 2002 Jul 25;21(32):4921-31
[
12118371.001
]
[Cites]
Cancer. 2002 Nov 1;95(9):1864-8
[
12404279.001
]
[Cites]
J Natl Cancer Inst. 2003 Jan 15;95(2):142-53
[
12529347.001
]
[Cites]
Mol Endocrinol. 2003 Mar;17(3):309-17
[
12554774.001
]
[Cites]
Urol Oncol. 2003 Jul-Aug;21(4):245-54
[
12954493.001
]
[Cites]
N Engl J Med. 2003 Nov 6;349(19):1793-802
[
14551341.001
]
[Cites]
N Engl J Med. 2004 Mar 11;350(11):1081-92
[
15014181.001
]
[Cites]
J Natl Cancer Inst. 2004 Mar 17;96(6):456-65
[
15026471.001
]
[Cites]
Br J Cancer. 2004 Jun 14;90(12):2317-25
[
15150570.001
]
[Cites]
J Clin Endocrinol Metab. 1973 Feb;36(2):207-14
[
4688315.001
]
[Cites]
Endocrinology. 1973 Mar;92(3):866-80
[
4267111.001
]
[Cites]
J Clin Endocrinol Metab. 1974 Mar;38(3):476-9
[
4815174.001
]
[Cites]
Endocrinology. 1977 Jun;100(6):1684-95
[
404132.001
]
[Cites]
J Clin Endocrinol Metab. 1978 Jan;46(1):146-52
[
752017.001
]
[Cites]
Cancer Res. 1982 Aug;42(8 Suppl):3365s-3368s
[
7083201.001
]
[Cites]
Cancer Res. 1982 Aug;42(8 Suppl):3369s-3372s
[
7083202.001
]
[Cites]
Eur J Cancer Clin Oncol. 1982 Apr;18(4):333-7
[
6889509.001
]
[Cites]
Prostate. 1982;3(5):433-8
[
6183651.001
]
[Cites]
J Urol. 1984 Jul;132(1):61-3
[
6328052.001
]
[Cites]
J Urol. 1984 Oct;132(4):693-6
[
6471215.001
]
[Cites]
Lancet. 1984 Dec 1;2(8414):1237-9
[
6150277.001
]
[Cites]
Br J Urol. 1986 Feb;58(1):45-51
[
3947856.001
]
[Cites]
Cancer Res. 1986 Sep;46(9):4823-6
[
2942241.001
]
[Cites]
Cancer. 1987 Feb 15;59(4):779-82
[
3802035.001
]
[Cites]
Prostate. 1987;11(4):313-26
[
2446299.001
]
[Cites]
Br Med J (Clin Res Ed). 1988 Mar 12;296(6624):741-3
[
3126957.001
]
[Cites]
Steroids. 1987 Jul-Sep;50(1-3):269-79
[
3509763.001
]
(PMID = 19111799.001).
[ISSN]
1078-1439
[Journal-full-title]
Urologic oncology
[ISO-abbreviation]
Urol. Oncol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA027440; United States / NCI NIH HHS / CA / R01 CA062483-28W1; United States / NCI NIH HHS / CA / R01 CA027440-23; United States / NCI NIH HHS / CA / CA-62483; United States / NCI NIH HHS / CA / CA062483-28W1; United States / NCI NIH HHS / CA / CA027440-23; United States / NCI NIH HHS / CA / R01 CA062483
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Aromatase Inhibitors; 0 / Enzyme Inhibitors; 0 / Nitriles; 0 / Receptors, Estrogen; 0 / Steroids; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; EC 1.14.14.1 / Aromatase; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
[Number-of-references]
80
[Other-IDs]
NLM/ NIHMS88209; NLM/ PMC3090255
77.
Czecior E, Namysłowski G, Misiołek M, Scierski W, Polok A, Lisowska G, Mrówka-Kata K, Orecka B, Pawlas P:
[Strategy of the sinonasal tumors treatment].
Otolaryngol Pol
; 2007;61(4):559-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
They state about 1% of all tumors (kidney, testum,
breast
, pulmonary).
RESULTS: In the histological examination in 4 patients the
benign
neoplasm
and in 22 patients malignant tumors were diagnosed.
On the basis of the CT and MRI examination as well as the description of the surgical procedure we stated that in 13 cases the primary localization
of neoplasm
was the maxillary sinus, in 5 cases ethmoidal cells, in 3 nasal cavity.
In one patient the estimation of primary
tumor
localization was not possible, because of the very large extension of the
neoplasm
.
The choice of the surgical procedure was depend on the
tumor
extension and localization.
[MeSH-major]
Nose Neoplasms /
diagnosis
. Nose Neoplasms / surgery. Paranasal Sinus Neoplasms /
diagnosis
. Paranasal Sinus Neoplasms / surgery
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Female. Humans.
Male
. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18260251.001).
[ISSN]
0030-6657
[Journal-full-title]
Otolaryngologia polska = The Polish otolaryngology
[ISO-abbreviation]
Otolaryngol Pol
[Language]
pol
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Poland
78.
Makkat S, Luypaert R, Sourbron S, Stadnik T, De Mey J:
Assessment of tumor blood flow in breast tumors with T1-dynamic contrast-enhanced MR imaging: impact of dose reduction and the use of a prebolus technique on diagnostic efficacy.
J Magn Reson Imaging
; 2010 Mar;31(3):556-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Assessment of
tumor
blood flow in
breast
tumors with T1-dynamic contrast-enhanced MR imaging: impact of dose reduction and the use of a prebolus technique on diagnostic efficacy.
PURPOSE: To prospectively evaluate whether dose reduction and the application of a prebolus technique can effectively alleviate signal saturation effects in T1 dynamic contrast enhanced (T1-DCE) magnetic resonance imaging (MRI) data in
breast
tumors and lead to increased diagnostic efficacy of the regional
tumor
blood flow (TBF) values obtained with deconvolution of T1-DCE MRI data.
MATERIALS AND METHODS: After obtaining informed consent, 23 women (32-80 years) with histologically proven
breast
tumors underwent MR mammography that included a whole-
breast
T1 DCE sequence.
In the slice where the
tumor
enhanced maximally, a prebolus protocol was applied.
The relative enhancement time course from the
tumor
region of interest was deconvolved with the reconstructed AIF to generate the impulse response function, the maximum of which yielded the TBF.
RESULTS: Reducing the contrast dose by a factor of 2 led to an increase in diagnostic contrast for the TBF values of malignant and
benign
tumors by a factor of slightly more than 2.
CONCLUSION: Using a prebolus approach provides an estimate of the unsaturated AIF, while reduction of the high-dose bolus minimizes possible saturation effects in the
tumor
time course.
[MeSH-major]
Breast
Neoplasms /
diagnosis
.
Breast
Neoplasms / physiopathology. Magnetic Resonance Imaging / methods. Neovascularization, Pathologic /
diagnosis
. Neovascularization, Pathologic / physiopathology
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Blood Flow Velocity. Humans.
Male
. Middle Aged. Radiation Dosage. Reproducibility of Results. Sensitivity and Specificity
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - MRI Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20187197.001).
[ISSN]
1522-2586
[Journal-full-title]
Journal of magnetic resonance imaging : JMRI
[ISO-abbreviation]
J Magn Reson Imaging
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
79.
Gratz S, Kempke B, Kaiser W, Behr TM, Pfestroff A, Höffken H:
Unexpected 99mTc-tetrofosmin findings during myocardial perfusion scintigraphy: intraindividual comparison with PET/computed tomography.
Nucl Med Commun
; 2008 Nov;29(11):963-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
We report six patients found with unexpected mediastinal and thoracic
tumor
uptake during Tc-tetrofosmin myocardial perfusion scintigraphy (MPS).
Subsequently, the patients underwent resection of a thymoma (n=2), nonsmall cell lung cancer (n=1) and
breast
cancer (n=3).
In the patients with
breast
cancer one was a
male
patient with ductal, invasive
breast
cancer.
Benign
thymomas showed high 99mTc-tetrofosmin ROI >4.0 and low F-FDG SUVmax <2.0, whereas low 99mTc-tetrofosmin ROI <2.0 were found in nonsmall cell lung cancer and
breast
cancer and high F-FDG SUVmax >2.5 in these malignant tumors.
[MeSH-minor]
Aged.
Breast
Neoplasms,
Male
/ complications.
Breast
Neoplasms,
Male
/ radiography.
Breast
Neoplasms,
Male
/ radionuclide imaging. Carcinoma, Non-Small-Cell Lung / complications. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Female. Humans. Lung Neoplasms / complications. Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging.
Male
. Middle Aged. Myocardial Perfusion Imaging / methods. Positron-Emission Tomography / methods. Thymoma / complications. Thymoma / radiography. Thymoma / radionuclide imaging. Thymus Neoplasms / complications. Thymus Neoplasms / radiography. Thymus Neoplasms / radionuclide imaging. Tomography, Emission-Computed. Tomography, Emission-Computed, Single-Photon
MedlinePlus Health Information.
consumer health - Coronary Artery Disease
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18836374.001).
[ISSN]
0143-3636
[Journal-full-title]
Nuclear medicine communications
[ISO-abbreviation]
Nucl Med Commun
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane; 0Z5B2CJX4D / Fluorodeoxyglucose F18
80.
Koh YW, Kim JW, Lee SW, Choi EC:
Endoscopic thyroidectomy via a unilateral axillo-breast approach without gas insufflation for unilateral benign thyroid lesions.
Surg Endosc
; 2009 Sep;23(9):2053-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Endoscopic thyroidectomy via a unilateral axillo-
breast
approach without gas insufflation for unilateral
benign
thyroid lesions.
Recently, the authors developed a unilateral axillo-
breast
approach for endoscopic hemithyroidectomy to minimize the visible scar in a natural position and to overcome the limitation of instrumentation.
METHODS: This study enrolled 52 consecutive patients undergoing endoscopic hemithyroidectomy via a unilateral axillo-
breast
approach without gas insufflation.
A second 1.0-cm skin incision was made along the upper margin of the mammary areola on the
tumor
side for insertion of a 12-mm trocar.
RESULTS: Postoperative pathology showed 11 follicular adenomas, 1 follicular carcinoma, and 40
benign
thyroid lesions.
CONCLUSION: Although the aspect of invasiveness could be improved, endoscopic hemithyroidectomy via a unilateral axillo-
breast
approach without gas insufflation is safe and effective and appears to provide better cosmetic results and a shorter operation time than other endoscopic methods for managing selective unilateral
benign
thyroid lesions.
[MeSH-minor]
Adenocarcinoma, Follicular / surgery. Adolescent. Adult. Axilla.
Breast
. Drainage. Feasibility Studies. Female. Hematoma / etiology. Humans. Length of Stay.
Male
. Middle Aged. Postoperative Complications / etiology. Seroma / etiology. Vocal Cord Paralysis / etiology. Young Adult
MedlinePlus Health Information.
consumer health - Endoscopy
.
MedlinePlus Health Information.
consumer health - Thyroid Cancer
.
MedlinePlus Health Information.
consumer health - Thyroid Diseases
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Surg Endosc. 2008 Jan;22(1):154-7
[
17440778.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2006 Aug;16(4):226-31
[
16921301.001
]
[Cites]
Surg Endosc. 2007 Dec;21(12):2166-71
[
17479328.001
]
[Cites]
Surg Endosc. 2002 Dec;16(12 ):1741-5
[
12140635.001
]
[Cites]
Am J Surg. 2002 Mar;183(3):286-9
[
11943128.001
]
[Cites]
Am J Surg. 2000 Aug;180(2):82-5
[
11044518.001
]
[Cites]
Surgery. 1997 Nov;122(5):893-901
[
9369889.001
]
[Cites]
Anesth Analg. 1997 May;84(5):1154-6
[
9141952.001
]
[Cites]
Eur J Cancer. 2007 Mar;43(5):891-900
[
17289376.001
]
[Cites]
World J Surg. 2007 Mar;31(3):601-6
[
17308853.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2003 Jun;13(3):196-201
[
12819505.001
]
[Cites]
Surg Endosc. 1997 Aug;11(8):877
[
9266657.001
]
[Cites]
Arch Surg. 2002 Mar;137(3):301-4; discussion 305
[
11888453.001
]
[Cites]
J Laparoendosc Adv Surg Tech A. 2007 Feb;17(1):21-5
[
17362173.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2003 Feb;13(1):20-5
[
12598753.001
]
[Cites]
J Surg Oncol. 1994 Dec;57(4):235-8
[
7990478.001
]
[Cites]
World J Surg. 2007 Dec;31(12):2302-6; discussion 2307-8
[
17566819.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2001 Aug;11(4):268-72
[
11525373.001
]
[Cites]
Surg Laparosc Endosc Percutan Tech. 2000 Feb;10(1):1-4
[
10872517.001
]
[Cites]
J Am Coll Surg. 1999 Jun;188(6):697-703
[
10359365.001
]
(PMID = 18528625.001).
[ISSN]
1432-2218
[Journal-full-title]
Surgical endoscopy
[ISO-abbreviation]
Surg Endosc
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article
[Publication-country]
Germany
81.
Chang X, Han J, Pang L, Zhao Y, Yang Y, Shen Z:
Increased PADI4 expression in blood and tissues of patients with malignant tumors.
BMC Cancer
; 2009;9:40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Expression of PADI4 was investigated in various tumors and non-
tumor
tissues (n = 1673) as well as in A549, SKOV3 and U937
tumor
cell lines by immunohistochemistry, real-time PCR, and western blot.
RESULTS: Immunohistochemistry detected significant PADI4 expression in various malignancies including
breast
carcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cancer cells, colorectal adenocarcinomas, renal cancer cells, ovarian adenocarcinomas, endometrial carcinomas, uterine adenocarcinomas, bladder carcinomas, chondromas, as well as other metastatic carcinomas.
However, PADI4 expression was not observed in
benign
leiomyomas of stomach, uterine myomas, endometrial hyperplasias, cervical polyps, teratomas, hydatidiform moles, trophoblastic cell hyperplasias, hyroid adenomas, hemangiomas, lymph hyperplasias, schwannomas, neurofibromas, lipomas, and cavernous hemangiomas of the liver.
Additionally, PADI4 expression was not detected in non-
tumor
tissues including cholecystitis, cervicitis and synovitis of osteoarthritis, except in certain acutely inflamed tissues such as in gastritis and appendicitis.
Quantitative PCR and western blot analysis showed higher PADI4 expression in gastric adenocarcinomas, lung adenocarcinomas, hepatocellular carcinomas, esophageal squamous cell cancers and
breast
cancers (n = 5 for each disease) than in the surrounding healthy tissues.
Furthermore, western blot analysis detected PADI4 expression in cultured
tumor
cell lines.
ELISA detected increased PADI4 and cAT levels in the blood of patients with various malignant tumors compared to those in patients with chronic inflammation and
benign
tumors.
Additionally, PADI4 and cAT levels were significantly associated with higher levels of known
tumor
markers.
[MeSH-major]
Hydrolases / metabolism.
Neoplasm
Proteins / metabolism. Neoplasms / metabolism
[MeSH-minor]
Antithrombins / metabolism. Blotting, Western. Cell Line,
Tumor
. Citrulline / metabolism. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Immunoprecipitation.
Male
. Polymerase Chain Reaction / methods
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Tumori. 1998 May-Jun;84(3):364-7
[
9678618.001
]
[Cites]
Pathologe. 1996 Nov;17(6):425-32
[
9082363.001
]
[Cites]
J Cell Mol Med. 2004 Oct-Dec;8(4):498-508
[
15601578.001
]
[Cites]
Folia Histochem Cytobiol. 2004;42(4):235-40
[
15704650.001
]
[Cites]
Rheumatology (Oxford). 2005 Mar;44(3):293-8
[
15561738.001
]
[Cites]
Semin Cancer Biol. 2005 Aug;15(4):309-18
[
15907383.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2936-42
[
16365013.001
]
[Cites]
Mol Carcinog. 2006 Mar;45(3):183-96
[
16355400.001
]
[Cites]
Mod Pathol. 2006 Sep;19(9):1261-9
[
16799479.001
]
[Cites]
Mol Endocrinol. 2007 Jul;21(7):1617-29
[
17456793.001
]
[Cites]
J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):76-80
[
17826626.001
]
[Cites]
World J Gastroenterol. 2008 Mar 21;14(11):1682-9
[
18350599.001
]
[Cites]
Histochem Cell Biol. 2008 Jun;129(6):705-33
[
18461349.001
]
[Cites]
Endocr Relat Cancer. 2008 Jun;15(2):475-83
[
18509000.001
]
[Cites]
J Biol Chem. 2008 Jul 18;283(29):20060-8
[
18499678.001
]
[Cites]
Mol Cell Biol. 2008 Aug;28(15):4745-58
[
18505818.001
]
[Cites]
Adv Exp Med Biol. 2008;630:112-32
[
18637488.001
]
[Cites]
Histopathology. 2001 Jan;38(1):62-7
[
11135048.001
]
[Cites]
Cell Death Differ. 2002 May;9(5):486-92
[
11973607.001
]
[Cites]
Biochem Soc Trans. 2002 Apr;30(2):173-7
[
12023846.001
]
[Cites]
Biochem Soc Trans. 2002 Apr;30(2):201-7
[
12023851.001
]
[Cites]
Nat Genet. 2003 Aug;34(4):395-402
[
12833157.001
]
[Cites]
Best Pract Res Clin Anaesthesiol. 2004 Sep;18(3):385-405
[
15212335.001
]
[Cites]
Cell. 2004 Sep 3;118(5):545-53
[
15339660.001
]
[Cites]
Anticancer Res. 1990 May-Jun;10(3):579-82
[
2114816.001
]
[Cites]
APMIS. 1991 Nov;99(11):981-8
[
1720319.001
]
[Cites]
Virchows Arch A Pathol Anat Histopathol. 1992;421(3):209-15
[
1384221.001
]
[Cites]
Int J Cancer. 1993 Jul 9;54(5):793-806
[
7686887.001
]
[Cites]
Thromb Haemost. 1998 Nov;80(5):767-72
[
9843169.001
]
(PMID = 19183436.001).
[ISSN]
1471-2407
[Journal-full-title]
BMC cancer
[ISO-abbreviation]
BMC Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antithrombins; 0 / Neoplasm Proteins; 29VT07BGDA / Citrulline; EC 3.- / Hydrolases; EC 3.5.3.15 / peptidylarginine deiminase type IV
[Other-IDs]
NLM/ PMC2637889
82.
Zhang J, Park SI, Artime MC, Summy JM, Shah AN, Bomser JA, Dorfleutner A, Flynn DC, Gallick GE:
AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.
J Clin Invest
; 2007 Oct;117(10):2962-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Using immunohistochemistry of human tissue arrays, we found that AFAP-110 was absent or expressed at very low levels in normal prostatic epithelium and
benign
prostatic hyperplasia but significantly increased in prostate carcinomas.
[MeSH-minor]
Animals. Cell Adhesion / genetics. Cell Line,
Tumor
. Cell Movement / genetics. Cell Proliferation. Down-Regulation. Extracellular Matrix / pathology. Humans. Integrins / metabolism.
Male
. Mice. Mice, Nude. Mutation. Protein-Tyrosine Kinases / metabolism. Up-Regulation
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Exp Cell Res. 2000 Feb 25;255(1):102-13
[
10666339.001
]
[Cites]
Clin Exp Metastasis. 1999;17(8):713-21
[
10919716.001
]
[Cites]
Lab Invest. 2000 Aug;80(8):1243-50
[
10950115.001
]
[Cites]
Clin Cancer Res. 2000 Aug;6(8):3177-82
[
10955801.001
]
[Cites]
EMBO J. 2000 Oct 16;19(20):5406-17
[
11032808.001
]
[Cites]
J Cell Sci. 2000 Dec;113 Pt 23:4139-40
[
11069756.001
]
[Cites]
EMBO J. 2001 Jun 1;20(11):2723-41
[
11387207.001
]
[Cites]
Oncogene. 2001 Oct 1;20(44):6435-47
[
11607843.001
]
[Cites]
Oncogene. 2001 Oct 4;20(45):6607-16
[
11641786.001
]
[Cites]
J Cell Sci. 2002 Jan 15;115(Pt 2):257-65
[
11839777.001
]
[Cites]
Nat Rev Cancer. 2001 Oct;1(1):34-45
[
11900250.001
]
[Cites]
J Mol Diagn. 2003 Feb;5(1):48-53
[
12552080.001
]
[Cites]
Am J Pathol. 2003 May;162(5):1529-37
[
12707036.001
]
[Cites]
Breast Cancer Res Treat. 2003 Apr;78(3):323-35
[
12755491.001
]
[Cites]
Cancer Res. 2003 Jun 1;63(11):2990-6
[
12782608.001
]
[Cites]
Cancer Metastasis Rev. 2003 Dec;22(4):337-58
[
12884910.001
]
[Cites]
Clin Cancer Res. 2003 Nov 1;9(14):5161-70
[
14613995.001
]
[Cites]
Oncol Rep. 2004 Feb;11(2):321-6
[
14719062.001
]
[Cites]
J Cell Biochem. 2004 Feb 15;91(3):602-20
[
14755689.001
]
[Cites]
Trends Cell Biol. 2004 May;14(5):241-9
[
15130580.001
]
[Cites]
Mol Cell Biol. 2004 Sep;24(17):7578-97
[
15314167.001
]
[Cites]
Proc Natl Acad Sci U S A. 1990 May;87(9):3328-32
[
2110361.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):5192-6
[
1594631.001
]
[Cites]
J Cancer Res Clin Oncol. 1993;119(11):637-44
[
7688749.001
]
[Cites]
Mol Cell Biol. 1993 Dec;13(12):7892-900
[
8247004.001
]
[Cites]
Mol Cell Biochem. 1997 Oct;175(1-2):243-52
[
9350057.001
]
[Cites]
Oncol Rep. 1998 Mar-Apr;5(2):305-9
[
9468546.001
]
[Cites]
Microsc Res Tech. 1999 Oct 1;47(1):67-78
[
10506763.001
]
[Cites]
Oncogene. 2005 Apr 7;24(15):2568-73
[
15735692.001
]
[Cites]
Cancer Res. 2005 Apr 15;65(8):3273-80
[
15833860.001
]
[Cites]
Oncogene. 2005 Apr 28;24(19):3110-20
[
15735682.001
]
[Cites]
Mol Cancer Ther. 2005 May;4(5):726-32
[
15897236.001
]
[Cites]
Pancreas. 2005 Oct;31(3):263-74
[
16163059.001
]
[Cites]
Cancer Metastasis Rev. 2005 Sep;24(3):403-11
[
16258728.001
]
[Cites]
Cancer Metastasis Rev. 2005 Sep;24(3):425-39
[
16258730.001
]
[Cites]
BJU Int. 2005 Dec;96(9):1219-23
[
16287434.001
]
[Cites]
Clin Exp Metastasis. 2005;22(7):565-73
[
16475027.001
]
[Cites]
J Nutr Biochem. 2006 Mar;17(3):204-10
[
16198100.001
]
[Cites]
Am J Pathol. 2006 Mar;168(3):962-72
[
16507911.001
]
[Cites]
Exp Cell Res. 2006 May 15;312(9):1658-70
[
16527272.001
]
[Cites]
Eur J Cancer. 2006 Jun;42(9):1213-8
[
16632344.001
]
[Cites]
Angiogenesis. 2006;9(2):101-10
[
16871430.001
]
[Cites]
Oncogene. 2007 Feb 1;26(5):745-56
[
16862179.001
]
[Cites]
J Cell Physiol. 2007 Dec;213(3):740-9
[
17520695.001
]
[Cites]
Clin Cancer Res. 2002 Jun;8(6):1904-14
[
12060635.001
]
[Cites]
Mol Biol Cell. 2002 Jul;13(7):2311-22
[
12134071.001
]
[Cites]
Biochem Soc Trans. 2003 Feb;31(Pt 1):90-3
[
12546661.001
]
(PMID = 17885682.001).
[ISSN]
0021-9738
[Journal-full-title]
The Journal of clinical investigation
[ISO-abbreviation]
J. Clin. Invest.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / AFAP 110; 0 / Integrins; 0 / Microfilament Proteins; 0 / Phosphoproteins; EC 2.7.10.1 / Protein-Tyrosine Kinases
[Other-IDs]
NLM/ PMC1978423
83.
Dragoumis D, Atmatzidis S, Chatzimavroudis G, Lakis S, Panagiotopoulou K, Atmatzidis K:
Benign spindle cell tumor not otherwise specified (NOS) in a male breast.
Int J Surg Pathol
; 2010 Dec;18(6):575-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Benign
spindle cell
tumor
not otherwise specified (
NOS
) in a
male breast
.
Breast
spindle cell tumors (BSCTs), although uncommon, constitute a heterogeneous group of
benign
and malignant lesions, often necessitating different therapeutic approaches.
This study describes the case of a 62-year-old man who displayed a gradually growing retroareolar
tumor
of the left
breast
.
Diverse histological results and immunohistochemical features established
the diagnosis
of
benign
BSCT, not otherwise specified.
This case report adds to the spectrum of the
benign
BSCTs and delineates the nature of different types of these lesions, in order to carefully select optimal therapeutic regimes.
[MeSH-major]
Breast
Neoplasms,
Male
/ pathology. Solitary Fibrous Tumors / pathology
[MeSH-minor]
Biomarkers,
Tumor
/ analysis. Humans. Immunohistochemistry.
Male
. Middle Aged
MedlinePlus Health Information.
consumer health - Male Breast Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19064588.001).
[ISSN]
1940-2465
[Journal-full-title]
International journal of surgical pathology
[ISO-abbreviation]
Int. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor
84.
Beatty JS, Williams HT, Aldridge BA, Hughes MP, Vasudeva VS, Gucwa AL, David GS, Lind DS, Kruse EJ, McLoughlin JM:
Incidental PET/CT findings in the cancer patient: how should they be managed?
Surgery
; 2009 Aug;146(2):274-81
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Of the 133 patients evaluated further, clinicians identified a second primary malignancy in 41 patients (31%),
benign
disease in 62 patients (47%), and metastatic disease from their known malignancy in 30 patients (23%).
The most common sites for a proven second primary malignancy were: lung (N = 10),
breast
(N = 7), and colon (N = 5).
In our data, approximately half of these findings were
benign
, a third were consistent with a second primary malignancy or a metastatic focus, and the remainder were never evaluated due to physician and patient decision.
Advanced primary tumors are unlikely to be impacted by a second primary
tumor
suggesting that this subset of patients will not benefit from further investigation.
The timing and route of investigation should be dictated by clinical judgment and the status of the primary
tumor
.
[MeSH-major]
Incidental Findings. Neoplasms, Second Primary /
diagnosis
. Positron-Emission Tomography. Tomography, X-Ray Computed
[MeSH-minor]
Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Fluorodeoxyglucose F18. Humans.
Male
. Middle Aged. Radiopharmaceuticals. Young Adult
MedlinePlus Health Information.
consumer health - CT Scans
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19628085.001).
[ISSN]
1532-7361
[Journal-full-title]
Surgery
[ISO-abbreviation]
Surgery
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
86.
Khalifeh I, Taraif S, Reed JA, Lazar AF, Diwan AH, Prieto VG:
A subgroup of melanocytic nevi on the distal lower extremity (ankle) shares features of acral nevi, dysplastic nevi, and melanoma in situ: a potential misdiagnosis of melanoma in situ.
Am J Surg Pathol
; 2007 Jul;31(7):1130-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Melanocytic lesions in certain locations (eg, genital,
breast
, acral) may have histologic and clinical features simulating melanoma.
One hundred fifteen melanocytic lesions from the ankle were retrieved from January 1990 to August 2006 from the files
of M
. D.
Anderson Cancer Center and were classified as
benign
melanocytic nevi (BN; n=17), DN (n=35), melanomas (MM; n=52), and melanocytic nevi of the ankle with atypical features (MNAAF; ie, cases that did not readily fit in any of the previous categories, n=11).
All MNAAF showed moderate-severe architectural
disorder
whereas 78% showed only mild-moderate cytologic atypia.
After complete excision, follow-up data indicate an apparently
benign
outcome.
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Ankle. Biomarkers,
Tumor
/ metabolism.
Diagnosis
, Differential. Female. Humans.
Male
. Melanins / metabolism. Middle Aged. Retrospective Studies
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17592281.001).
[ISSN]
0147-5185
[Journal-full-title]
The American journal of surgical pathology
[ISO-abbreviation]
Am. J. Surg. Pathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Melanins
87.
Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, Abati A:
Diagnostic effects of prolonged storage on fresh effusion samples.
Diagn Cytopathol
; 2007 Jan;35(1):6-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Specimens evaluated included four pleural (3
benign
, 1
breast
adenocarcinoma) and six peritoneal (2 ovarian adenocarcinomas, 1 malignant melanoma, 2 mesotheliomas, 1 atypical mesothelial) effusions.
[MeSH-major]
Artifacts. Ascitic Fluid / pathology. Cytodiagnosis / methods. Neoplasms /
diagnosis
. Pleural Effusion, Malignant /
diagnosis
. Specimen Handling / methods
[MeSH-minor]
Adult. Biomarkers,
Tumor
. DNA,
Neoplasm
/ analysis. Female. Humans.
Male
. Middle Aged. Polymerase Chain Reaction. Time Factors
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17173298.001).
[ISSN]
8755-1039
[Journal-full-title]
Diagnostic cytopathology
[ISO-abbreviation]
Diagn. Cytopathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
88.
Abdul M, Hoosein N:
N-methyl-D-aspartate receptor in human prostate cancer.
J Membr Biol
; 2005 Jun;205(3):125-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Of 18
benign
prostatic hyperplasia (BPH) specimens, none had stromal NMDAr staining, but 2 had low and 1 had high epithelial NMDAr immunoreactivity.
We have also examined the effects of the NMDAr antagonist memantine on the growth of ten human cancer cell lines: four prostate, two
breast
and four colon.
[MeSH-minor]
Breast
/ metabolism. Cell Line. Cell Line,
Tumor
. Cell Proliferation / drug effects. Colonic Neoplasms. Cysteine / analogs & derivatives. Cysteine / pharmacology. Dizocilpine Maleate / pharmacology. Humans. Immunohistochemistry.
Male
. Memantine / pharmacology. Prostate / physiology. Prostatic Hyperplasia / physiopathology
Genetic Alliance.
consumer health - Prostate cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
Hazardous Substances Data Bank.
MEMANTINE
.
Hazardous Substances Data Bank.
CYSTEINE
.
Hazardous Substances Data Bank.
DIZOCILPINE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
JAMA. 2004 Jan 21;291(3):317-24
[
14734594.001
]
[Cites]
Mol Chem Neuropathol. 1997 Jan-Feb;30(1-2):77-94
[
9138430.001
]
[Cites]
Neuropharmacology. 1999 Jun;38(6):735-67
[
10465680.001
]
[Cites]
Cancer Lett. 2002 Dec 1;186(1):99-105
[
12183081.001
]
[Cites]
J Neurosci Res. 1996 Oct 15;46(2):164-78
[
8915893.001
]
[Cites]
J Androl. 2000 Jul-Aug;21(4):566-78
[
10901443.001
]
[Cites]
Trends Pharmacol Sci. 2001 Apr;22(4):174-81
[
11282417.001
]
[Cites]
J Nutr. 2000 Apr;130(4S Suppl):1007S-15S
[
10736372.001
]
[Cites]
Biochem Pharmacol. 2002 Oct 15;64(8):1195-200
[
12234599.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 May 22;98(11):6372-7
[
11331750.001
]
[Cites]
Nat Med. 2001 Sep;7(9):1010-5
[
11533703.001
]
(PMID = 16362500.001).
[ISSN]
0022-2631
[Journal-full-title]
The Journal of membrane biology
[ISO-abbreviation]
J. Membr. Biol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Receptors, N-Methyl-D-Aspartate; 2381-08-0 / cysteine sulfinic acid; 6LR8C1B66Q / Dizocilpine Maleate; K848JZ4886 / Cysteine; W8O17SJF3T / Memantine
89.
Li JS, Sun GW, Wei XY, Tang WH:
Expression of periostin and its clinicopathological relevance in gastric cancer.
World J Gastroenterol
; 2007 Oct 21;13(39):5261-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Immunohistochemistry was performed to localize and quantify the expression of periostin in
benign
gastric diseases and gastric cancer, and immunostaining results were correlated with gastric cancer pathological stages.
Immunohistochemical staining revealed that periostin was overexpressed in primary gastric cancer, as well as in metastatic lymph nodes, but only faint staining was found in
benign
gastric ulcers.
By quantitative analysis of the immunostaining results, periostin expression was increased 2.5-4-fold in gastric cancer, compared to that in
benign
gastric disease, and there was a trend toward increasing periostin expression with
tumor
stage.
[MeSH-minor]
Aged. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Lymphatic Metastasis / pathology.
Male
. Middle Aged.
Neoplasm
Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Stomach / metabolism. Stomach / pathology
MedlinePlus Health Information.
consumer health - Stomach Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17876898.001).
[ISSN]
1007-9327
[Journal-full-title]
World journal of gastroenterology
[ISO-abbreviation]
World J. Gastroenterol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
China
[Chemical-registry-number]
0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / RNA, Messenger
[Other-IDs]
NLM/ PMC4171309
90.
Böttger T, Terzic A, Müller M:
[Laparoscopic pancreatic resection].
Zentralbl Chir
; 2006 Aug;131(4):309-14
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
RESULTS: In all four cases laparoscopic distal pancreatic resection was performed for
tumor
.
Histologic examination showed a neuroendocrine carcinoma, a serous-microcystic adenoma, a low differentiated ductal adenocarcinoma and an intraductal papillary-mucinous
tumor
of borderline type.
CONCLUSION: Laparoscopic resection of distal pancreas shows the common benefit of minimal invasive surgery for the early postoperative period and is an attractive alternative for treatment of
benign
and semimalign pancreatic tumors.
[MeSH-major]
Adenoma / surgery. Carcinoma, Ductal,
Breast
/ surgery. Carcinoma, Neuroendocrine / surgery. Cystadenoma, Mucinous / surgery. Laparoscopy. Pancreas / surgery. Pancreatic Neoplasms / surgery
[MeSH-minor]
Adult. Aged. Fundoplication. Gastroesophageal Reflux / surgery. Humans. Length of Stay. Liver Neoplasms / radiography. Liver Neoplasms / secondary.
Male
. Middle Aged. Minimally Invasive Surgical Procedures. Positron-Emission Tomography. Radiography, Abdominal. Spleen / surgery. Tomography, X-Ray Computed
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Pancreatic Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17004190.001).
[ISSN]
0044-409X
[Journal-full-title]
Zentralblatt für Chirurgie
[ISO-abbreviation]
Zentralbl Chir
[Language]
ger
[Publication-type]
Case Reports; Comparative Study; English Abstract; Journal Article
[Publication-country]
Germany
91.
Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS, Geradts J:
Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression.
Hum Pathol
; 2007 Nov;38(11):1628-38
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression characteristics of prostate-derived Ets factor support a role in
breast
and prostate cancer progression.
The purpose of this study was to understand the characteristics of prostate-derived Ets factor (PDEF) protein expression in
breast
and prostate cancer progression.
A polyclonal antibody specific to PDEF was raised and reacted with tissue microarrays consisting of
benign breast
, in situ ductal, invasive ductal, and invasive lobular
breast
carcinomas.
The antibody was also reacted with tissue microarrays, including
benign
prostate, prostate intraepithelial neoplasias (PINs), and prostate carcinomas.
Increased expression of PDEF was identified in 18%, 50%, 46%, and 51% of
benign breast
tissues, intraductal, invasive ductal, and invasive lobular carcinomas, respectively.
Importantly, in matched samples of
benign breast
vs
tumor
, 90% showed higher expression of PDEF in the
tumor
tissue.
Moreover, in invasive
breast
carcinomas, increased PDEF expression tended to correlate with Her2/neu overexpression.
Increased expression of PDEF was also found in 27%, 33%, and 40% of
benign
prostate tissues, PIN samples, and prostate adenocarcinomas, respectively.
Again, in matching samples of cancer vs
benign
and cancer vs PIN, 68% and 70%, respectively, showed increased expression in the malignant tissue.
In addition, R1881 treatment induced PDEF expression in the LNCaP prostate
tumor
cell line, suggesting regulation of PDEF by androgens in vivo.
Together, these results for the first time show frequent increased expression of PDEF protein in
breast
and prostate tumors and support a role for PDEF in
breast
and prostate cancer progression.
Genetic Alliance.
consumer health - Prostate cancer
.
Genetic Alliance.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Steroids. 2007 Jan;72(1):7-25
[
17169390.001
]
[Cites]
Ann Surg. 2006 Aug;244(2):176-84
[
16858179.001
]
[Cites]
Cancer Biol Ther. 2007 Jan;6(1):76-82
[
17172821.001
]
[Cites]
Breast Cancer Res Treat. 2007 Mar;102(1):19-30
[
16897429.001
]
[Cites]
J Biol Chem. 2000 Jan 14;275(2):1216-25
[
10625666.001
]
[Cites]
Cancer Res. 2000 Mar 1;60(5):1348-52
[
10728697.001
]
[Cites]
J Clin Pathol. 2000 Sep;53(9):688-96
[
11041059.001
]
[Cites]
Crit Rev Oncog. 2000;11(3-4):227-53
[
11358268.001
]
[Cites]
Clin Cancer Res. 2001 Sep;7(9):2731-8
[
11555586.001
]
[Cites]
Nat Rev Mol Cell Biol. 2001 Nov;2(11):827-37
[
11715049.001
]
[Cites]
Bioessays. 2002 Apr;24(4):362-70
[
11948622.001
]
[Cites]
Climacteric. 2002 Mar;5(1):15-25
[
11974555.001
]
[Cites]
Cancer Biother Radiopharm. 2002 Apr;17(2):137-49
[
12030108.001
]
[Cites]
Curr Cancer Drug Targets. 2001 May;1(1):49-57
[
12188891.001
]
[Cites]
Cancer Res. 2003 Aug 1;63(15):4626-31
[
12907642.001
]
[Cites]
J Biol Chem. 2004 Mar 19;279(12):11281-92
[
14662758.001
]
[Cites]
Endocr Relat Cancer. 2004 Sep;11(3):459-76
[
15369448.001
]
[Cites]
BMJ. 1997 Jun 28;314(7098):1843-4
[
9224112.001
]
[Cites]
Breast Cancer Res. 2004;6(6):229-39
[
15535852.001
]
[Cites]
Annu Rev Med. 2005;56:117-37
[
15660505.001
]
[Cites]
Curr Opin Urol. 2005 May;15(3):181-6
[
15815195.001
]
[Cites]
Curr Opin Urol. 2005 May;15(3):187-95
[
15815196.001
]
[Cites]
Curr Opin Oncol. 2005 May;17(3):257-60
[
15818171.001
]
[Cites]
J Endocrinol Invest. 2005;28(3 Suppl):8-13
[
16044581.001
]
[Cites]
Curr Pharm Des. 2005;11(22):2873-87
[
16101443.001
]
[Cites]
Am J Pharmacogenomics. 2005;5(5):327-38
[
16196502.001
]
[Cites]
N Engl J Med. 2005 Oct 20;353(16):1673-84
[
16236738.001
]
[Cites]
Cancer Res. 2005 Dec 15;65(24):11572-80
[
16357167.001
]
[Cites]
Curr Gene Ther. 2006 Feb;6(1):17-33
[
16475943.001
]
[Cites]
J Clin Pathol. 2007 Jan;60(1):1-7
[
16790693.001
]
(PMID = 17521701.001).
[ISSN]
0046-8177
[Journal-full-title]
Human pathology
[ISO-abbreviation]
Hum. Pathol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / CA 86164; United States / NCI NIH HHS / CA / CA086164-03; United States / NCI NIH HHS / CA / R41 CA086164-03; United States / NCI NIH HHS / CA / P30 CA 16056
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
[Chemical-registry-number]
0 / Proto-Oncogene Proteins c-ets; 0 / SPDEF protein, human; 2C323EGI97 / Metribolone
[Other-IDs]
NLM/ NIHMS33974; NLM/ PMC2121591
92.
Ferbeyre-Binelfa L, Ramírez-Bollas J, Bautista-Piña V, Espejo-Fonseca R, Ruvalcaba-Limón E, Serratos-Garduño E:
[Fibromatosis of the breast. Report of two cases and review of the literature].
Cir Cir
; 2009 Jul-Aug;77(4):313-8; 291-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Fibromatosis of the
breast
. Report of two cases and review of the literature].
BACKGROUND: Fibromatosis is a term used to describe a group of lesions characterized by well-differentiated fibroblast proliferation with an usually
benign
biological behavior but with an infiltrative pattern of growth, frequently recurrent and locally invasive.
The presence of this entity in
breast
tissue is an uncommon clinical situation, comprising approximately 0.2% of
breast
tumors and very often misdiagnosed as malignant disease or phyllodes
tumor
.
In this rare condition, immunohistochemistry is an important diagnostic tool in anatomopathological differential
diagnosis
with other spindle cell tumors of the
breast
.
CLINICAL CASES: We present two cases of
breast
fibromatosis confirmed immunohistochemically and also by biopsy.
One case had the clinical and imaging appearance of
breast
carcinoma with the classic irregular mass presentation and the other case was misdiagnosed as phyllodes
tumor
because of the size and density of the
tumor
and the cytology.
CONCLUSIONS: Approximately 83 cases of
breast
fibromatosis have been reported during the last 30 years, including one
male
patient.
We reviewed clinicopathological features of two cases of fibromatosis of the
breast
treated at our institute.
[MeSH-major]
Breast
Neoplasms /
diagnosis
. Fibroma /
diagnosis
Genetic Alliance.
consumer health - Fibromatosis
.
MedlinePlus Health Information.
consumer health - Breast Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19919794.001).
[ISSN]
0009-7411
[Journal-full-title]
Cirugía y cirujanos
[ISO-abbreviation]
Cir Cir
[Language]
eng; spa
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
Mexico
[Number-of-references]
44
93.
Landers KA, Samaratunga H, Teng L, Buck M, Burger MJ, Scells B, Lavin MF, Gardiner RA:
Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer.
Br J Cancer
; 2008 Aug 5;99(3):491-501
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Claudin-4, coding for an integral membrane cell-junction protein, was the most significantly (P<0.00001) upregulated marker in both primary and metastatic tumour specimens compared with
benign
prostatic hyperplasia at both RNA and protein levels.
[MeSH-major]
Biomarkers,
Tumor
/ metabolism. Membrane Proteins / metabolism. Prostatic Neoplasms / pathology. Prostatic Neoplasms / secondary
[MeSH-minor]
Base Sequence. Blotting, Western. Cell Line,
Tumor
. Claudin-4. DNA Primers. Humans. Immunohistochemistry.
Male
. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction
Genetic Alliance.
consumer health - Prostate cancer
.
Genetic Alliance.
consumer health - Metastatic cancer
.
MedlinePlus Health Information.
consumer health - Prostate Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Prostate Suppl. 2000;9:4-14
[
11056496.001
]
[Cites]
Hum Pathol. 2007 Apr;38(4):564-9
[
17306334.001
]
[Cites]
Gastroenterology. 2001 Feb;120(2):411-22
[
11159882.001
]
[Cites]
Gastroenterology. 2001 Sep;121(3):678-84
[
11522752.001
]
[Cites]
Histol Histopathol. 2001 Oct;16(4):1183-95
[
11642738.001
]
[Cites]
Am J Surg Pathol. 2001 Nov;25(11):1397-404
[
11684956.001
]
[Cites]
Cancer Res. 2001 Nov 1;61(21):7878-81
[
11691807.001
]
[Cites]
JAMA. 2002 Apr 3;287(13):1662-70
[
11926890.001
]
[Cites]
Ann N Y Acad Sci. 2002 Jun;963:169-84
[
12095942.001
]
[Cites]
Int J Cancer. 2002 Jul 10;100(2):228-37
[
12115574.001
]
[Cites]
Urology. 2003 Apr;61(4):736-41
[
12670557.001
]
[Cites]
Clin Cancer Res. 2003 Jul;9(7):2567-75
[
12855632.001
]
[Cites]
Cancer Res. 2003 Oct 1;63(19):6265-71
[
14559813.001
]
[Cites]
J Urol. 2004 Jan;171(1):187-91
[
14665873.001
]
[Cites]
Clin Cancer Res. 2003 Dec 15;9(17):6357-62
[
14695135.001
]
[Cites]
Am J Pathol. 2004 Mar;164(3):903-14
[
14982844.001
]
[Cites]
Am J Clin Pathol. 2004 Feb;121(2):226-30
[
14983936.001
]
[Cites]
Am J Pathol. 2004 May;164(5):1627-33
[
15111309.001
]
[Cites]
Eur Urol. 2004 Aug;46(2):271-2
[
15245824.001
]
[Cites]
Tumori. 2004 Nov-Dec;90(6):535-46
[
15762353.001
]
[Cites]
Int J Cancer. 2005 May 10;114(6):950-6
[
15609297.001
]
[Cites]
Cancer Res. 2005 May 15;65(10):4334-42
[
15899825.001
]
[Cites]
Cell. 2000 Jan 7;100(1):57-70
[
10647931.001
]
[Cites]
Hum Pathol. 2000 May;31(5):578-83
[
10836297.001
]
[Cites]
J Urol. 2000 Aug;164(2):411-5
[
10893598.001
]
[Cites]
Cell. 2000 Oct 13;103(2):295-309
[
11057902.001
]
[Cites]
Br J Dermatol. 2004 Aug;151(2):328-34
[